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treatment based on accepted clinical practices.
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Foreword
Benzodiazepines have a chequered clinical history and continue to produce polar opinions in the medical 
community. Benzodiazepines have been associated with both benefits and harms for patients, and a clear 
guide for accountable prescribing has been requested from multiple agencies.
Drug therapies will only ever have a partial role in managing complex bio-psychosocial issues that 
characterise mental health care. In the modern health environment, we have to explore and use non-drug 
therapies, and redefine the place of existing medications.
This guide represents a synthesis of the best available evidence for benzodiazepine use in the primary 
care setting. Consistent with all medications, prescribing benzodiazepines requires clear patient selection 
and ongoing clinical monitoring to optimise outcomes. The risk–benefit ratio of benzodiazepines changes 
considerably with concomitant psychoactive drugs, or comorbid alcohol or substance abuse or misuse.
In completing this guide, we acknowledge the work of the key advisers and reviewers, and the many people 
who have provided constructive feedback.
The Royal Australian College of General Practitioners (RACGP) welcomes feedback on this guide to 
continually improve services at the general practice level. Please use the feedback section on our website 
to help co-create this guide.
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Summary of recommendations
Drugs of dependence have important therapeutic uses, but there is a need to ensure the supply of these 
medicines is clinically appropriate. A key measure is accountable prescribing that can be supported by 
a range of strategies at the practice level. Please refer to RACGP’s Prescribing drugs of dependence in 
general practice, Part A – Clinical governance framework for information about these strategies. 
Since 2002, approximately 7 million prescriptions for benzodiazepines have been dispensed in Australia 
each year, for conditions such as anxiety and insomnia. There is concern a portion of these prescriptions 
is causing or contributing to patient harm. This is a practical guide general practitioners (GPs) can use to 
minimise harm and maximise benefits to patients.
Evidence-based recommendations are collated here and there is further information in the body of the guide. 
Wording of key principles and recommendations
Within the key principles and recommendations, the term ‘should’ refers to a recommended action, ‘must’ 
refers to an obligation, ‘must not’ to a prohibition, and ‘may’ refers to a discretionary action.
Recommendations denoted with ‘Rec’ and a number are those taken from existing evidence-based 
guidelines and are accompanied by a link to the original source and grading. Each ‘Rec’ has a hyperlink 
allowing you to click through to the references. Other links are provided to sections in the body of the 
document. Recommendations without a ‘Rec’ are practice points. 
For definitions of key terms, refer to Appendix A.
Key principles
Incorporating key principles of accountable prescribing, practice systems of care and patient-focused care: 
1. Prescription of benzodiazepines, as with any treatment, should be based on a comprehensive medical 
assessment; a diagnosis; thoughtful consideration of the likely risks and benefits of any medication, as 
well as alternative interventions; and a management plan derived through shared decision making and 
continual clinical monitoring.
2. GPs should be aware of the common concerns associated with benzodiazepines, such as potential 
dependence, withdrawal, problematic drug use (including diversion and misuse) and known harmful 
effects, including falls, potential cognitive decline and motor vehicle accidents. These risks should be 
discussed with patients.
3. Treatment seeks to maximise outcomes for the health and social functioning of the patient while 
minimising risks. To minimise risks, benzodiazepines should be prescribed at the lowest effective dose 
for the shortest clinical timeframe.
4. Avoid prescribing benzodiazepines to patients with comorbid alcohol or substance use disorders or 
polydrug use. GPs should consider seeking specialist opinion in the management of these patients. 
Patients who use two or more psychoactive drugs in combination (polydrug use) and those with a 
history of substance misuse may be more vulnerable to major harms.
5. Benzodiazepines are generally regarded by clinical practice guidelines as a short-term therapeutic 
option. Long-term use, beyond 4 weeks, should be uncommon, made with caution and based on 
thoughtful consideration of the likely risks and benefits of benzodiazepines. 
 – If alternatives to benzodiazepine treatment fail, have limited benefit or are inappropriate (either 
psychologically or pharmacologically), supervised benzodiazepine treatment may remain an 
acceptable long-term therapeutic option. 
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 – Long-term benzodiazepine prescriptions should be at the lowest effective dose, preferably given 
intermittently, and regular attempts at reduction should be scheduled. Continued professional 
monitoring of health outcomes is required.
 – Benzodiazepines should be prescribed from one practice and preferably one GP and dispensed from 
one pharmacy. 
6. GPs may wish to use the diagnosis of substance use disorder (SUD) rather than dependence, addiction 
or abuse; this is based on the Diagnostic and Statistical Manual of Mental Disorders, 5th edition’s, 
(DSM-5’s) sedative, hypnotic or anxiolytic use disorder criteria. This is a more neutral term that may reduce 
stigmatisation of patients with problematic use of benzodiazepines and other drugs or alcohol.
7. GPs should develop strategies to manage inappropriate requests for benzodiazepines by patients.
8. All patients, including those who use benzodiazepines and other drugs or alcohol problematically, have 
the right to respectful care that promotes their dignity, privacy and safety. 
Treatment of insomnia
Insomnia is a common problem that can cause significant distress and reduced functioning. Chronic 
insomnia can be more challenging to manage, as it may be associated with an underlying cause, or be 
an independent disorder that can precipitate or worsen other comorbid conditions (eg depression). The 
understanding of chronic insomnia is still evolving.
The first step is comprehensive medical assessment, including identification of any underlying issues, and 
diagnosis.
Where treatment is indicated:
• First-line therapy should be non-drug interventions. Cognitive behavioural therapy (CBT), which may 
include stimulus control, sleep restriction, relaxation techniques and sleep hygiene education is well 
supported by evidence. It should therefore be offered to patients, including older adults. (Level A 
Evidence) Rec 1.
• Decisions to prescribe pharmacological treatment should be made on an individual basis, after serious 
consideration of all risks and possible benefits. 
• Effective pharmacological therapies include benzodiazepines and Z drugs (benzodiazepine receptor 
agonists), and both should be treated with the same cautions. (Level A Evidence) Rec 2, Rec 3.
• Short-term or intermittent dosing of benzodiazepines should be used to reduce the risk of tolerance and 
dependence. (Level B Evidence) Rec 4, Rec 5.
• Pharmacological treatment should be accompanied by specific patient education, regular review and 
continued efforts to employ the lowest effective dosage of medication, and to taper medication when 
conditions allow.
Note: When access to CBT is an issue, GPs and practice nurses may consider offering brief behavioural 
therapy to patients (refer to www.racgp.org.au/your-practice/guidelines/handi/interventions/mental-health/
brief-behavioural-therapy-for-insomnia-in-adults).
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Treatment of anxiety disorders
Anxiety disorders are common and exist as a spectrum of conditions that vary from mild to severe. 
Comprehensive clinical assessment is the first step in management. Effective management requires 
obtaining a diagnosis and recognising that patients may not present with a single disorder (eg patients may 
experience generalised anxiety, panic disorder as well as depression).
Where treatment is indicated:
• First-line therapy for generalised anxiety disorder (GAD), panic disorder, and panic attacks should include 
CBT due to its effectiveness at reducing the symptoms of anxiety in the short and long term. (Level A 
Evidence) Rec 6.
• Selective serotonin reuptake inhibitor (SSRI) and serotonin-norepinephrine reuptake inhibitor (SNRI) 
medications are effective across the range of anxiety disorders and are generally suitable for first-line 
pharmacological treatment of anxiety. (Level A Evidence) Rec 7.
• Benzodiazepine use in anxiety disorders is mostly limited to severe or treatment-resistant cases. 
• Benzodiazepines have proven benefit for GAD, social anxiety disorder and panic disorder. 
Benzodiazepines have not shown benefit for obsessive compulsive disorder (OCD) or post-traumatic 
stress disorder (PTSD). (Level A Evidence) Rec 8.
• Short-term benzodiazepine use as occasional adjunctive therapy may be effective at reducing worsening 
of symptoms that can occur in the first few days to weeks of initiating antidepressant medication.
Note: When access to CBT is an issue, internet-based or computerised CBT programs have been shown 
to be effective (visit www.racgp.org.au/your-practice/guidelines/handi/interventions/mental-health/internet-
based-or-computerised-cbt-for-depression-and-anxiety). 
Treatment for alcohol withdrawal
Benzodiazepines are an effective component of an alcohol withdrawal program. However, not every 
patient withdrawing from alcohol will require medication. Comprehensive medical assessment (including 
assessment of social support and the use of formal assessment tools) is required to determine the most 
appropriate approach for alcohol withdrawal (ie in the primary care or specialist alcohol services setting).
Where assisted withdrawal from alcohol is indicated:
• Benzodiazepines (eg diazepam, oxazepam) are the drugs of choice for treatment of acute alcohol 
withdrawal (including alcohol withdrawal delirium), but should be limited to a maximum of 7 days. (Level 
A Evidence) Rec 9.
Discontinuing benzodiazepines
When discontinuing benzodiazepines, consider using a stepped approach, starting with minimal 
interventions and moving to more intensive measures.
• Minimal interventions such as advisory letters or GP’s advice should be considered as an initial step in 
benzodiazepine discontinuation.
• The strength of the GP–patient therapeutic alliance is an important positive factor that assists the 
successful withdrawal of benzodiazepines.
• If benzodiazepine use disorder has become moderate or severe, it can become a long-term and 
distressing problem. However, gradual dose reduction interventions are possible for many patients 
titrating the dose reduction against the level of withdrawal symptoms experienced. Additional 
psychological therapies increase the effectiveness of gradual dose reduction.
• Switching from a short half-life benzodiazepine to a long half-life benzodiazepine before gradual taper 
may assist patients with problematic withdrawal symptoms on reduction.
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1. Introduction
The arrival of benzodiazepines into clinical practice in the 1960s was met with enthusiasm. It allowed 
doctors to offer patients a class of medication with a range of properties (eg sedative/hypnotic, anxiolytic, 
anticonvulsant, muscle relaxation) at a time when there were few effective therapeutic alternatives. 
Benzodiazepines were effective and appeared safe in comparison to barbiturates, chloral hydrate and other 
drugs, which were problematic due to toxicity and overdose.1
Due to the seeming paucity of side effects, rapid onset of effect and a pressing mental health need, 
benzodiazepines were quickly used and prescribed short- and long-term for anxiety, depression, insomnia, 
mental illness and neuromuscular conditions. By the 1970s, they were the most commonly prescribed 
drugs in the world.2 In 1978, more than 2.3 billion doses of diazepam were sold in the US alone.3
In the 1980s, evidence of the addictive nature of benzodiazepines grew and it became generally accepted 
that benzodiazepines brought their own problems. In 1988, the Committee on Safety of Medicines (UK) 
published the first guideline for benzodiazepine use and recommended limiting the length of treatment 
to 2–4 weeks.4 Since then, many international guidelines have advocated for the reduction in prescribing 
benzodiazepines, particularly short-acting benzodiazepines for long-term disorders such as anxiety. 
However, there has been – and still is – a wide divergence between recommendations and clinical practice. 
In Australia, nearly 7 million benzodiazepine prescriptions are currently recorded through the Pharmaceutical 
Benefits Scheme (PBS), Repatriation PBS and private scripts each year.5 Benzodiazepines have remained a 
major anxiolytic therapy, and given the trend towards larger quantity scripts, not just for short-term use.5
There is growing apprehension in Australia regarding the harms associated with the sanctioned and 
unsanctioned use of benzodiazepines.6 The misuse of alprazolam is particularly problematic. It appears to 
be disproportionately associated with misuse, fatal and non-fatal overdoses, paradoxical excitation, and 
withdrawal and rage responses, as well as traffic accidents and crime-related harms.7
The conditions where benzodiazepines are most commonly prescribed (ie anxiety and insomnia) remain 
sources of debate in medical circles. General practitioners (GPs) must consider multiple factors when 
prescribing benzodiazepines, including potential prescription abuse. Good clinical governance and an 
evidence-based approach remain key to safe and appropriate prescribing (refer to RACGP’s Prescribing 
drugs of dependence in general practice, Part A – Clinical governance framework).
1.1 Aims
This guide aims to provide assistance to GPs in the appropriate prescribing of benzodiazepines in the 
context of general practice. 
It is designed to discourage inappropriate use and reduce harms by providing GPs with: 
• evidence of the advantages and disadvantages associated with the use of benzodiazepines
• support for appropriate prescribing of benzodiazepines within regulatory frameworks
• support for safer prescribing within their practices
• alternatives to benzodiazepines, including non-drug options
• tools for managing patients who are prescribed benzodiazepines such as objective goals and time 
limited prescribing
• tools for recognising and managing higher risk situations.
Implementing principles from this guide should reduce the risk that GPs will be involved in an adverse 
event associated with prescribing benzodiazepines.
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1.2 How to use this guide
This guide is a reference to assist the management of benzodiazepine prescribing. It is part of a 
reference series on drugs of dependence. It is not a set of mandatory rules. Recommendations should 
be considered and implemented as required, and where appropriate to the individual practice and 
patient.
The appendices contain examples of some practice policies. These examples are not individually 
approved or endorsed by the RACGP Council, or by the RACGP Standards for general practices 
(4th edition) (the Standards). They are based on policies and practices from national and international 
sources. If practices wish to adopt any of these policies, they should be modified for relevance and 
applicability to the local context. 
1.3 Why do we need this guide?
Drugs of dependence have important therapeutic uses and are highly beneficial to many individuals. The 
clinically appropriate supply of these medicines needs to be maintained.8
This guide is a resource to assist with the appropriate and accountable prescribing of benzodiazepines 
to prevent and reduce harms to patients, and to prevent medico-legal issues for GPs.
GPs need to be aware of the broad issues around benzodiazepine use in society, as well as specific 
problems at a patient level, and how to address these issues with practice-based interventions.
1.3.1 Issues surrounding benzodiazepines
1.3.1.1 Variations in prescribing
Benzodiazepine prescribing rates vary between clinicians and practices. GPs vary in the extent 
to which they are willing to prescribe benzodiazepines. Some consider benzodiazepines to be 
extremely useful drugs for multiple situations, while others feel they have no place in general 
practice. Richard Balon wrote, ‘… benzodiazepines have been hesitantly lauded and frequently 
enthusiastically vilified ... ’9
The range of approaches to prescribing benzodiazepines may be explained by the variation in 
attitudes to the drugs, the changing context of prescribing, differing perceptions of the role and 
responsibility of the GP (and the personal responsibility of the patient), issues around alternative 
treatment options, perceptions of patient expectations, non-clinical considerations (eg race, 
gender) and the doctor–patient relationship.8 
1.3.1.2 Questions about over prescribing
Comparing the prevalence of conditions for which benzodiazepines are indicated and the number 
of prescriptions dispensed, the evidence suggests that they may be over-prescribed and/or 
prescribed outside published guidelines.10 
In 1991, there were an estimated 9.2 million benzodiazepine prescriptions dispensed from 
Australian retail pharmacies – enough to provide a daily dose for 3% of the adult population.5 
Since then there has been a modest declining trend in prescription numbers, although there are 
still approximately 7 million prescriptions for benzodiazepines written each year. Nearly 5 million 
prescriptions are subsidised through the PBS, and the rest are private or under co-payment 
prescriptions.11 Since 2000, there has been a shift away from the PBS to private scripts.5
The modest decline can be partly explained by the use of selective serotonin reuptake inhibitors 
(SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs). The use of SSRIs doubled 
between 2000–11, and have become the primary pharmacological treatments for anxiety 
disorders.5
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Figure 1. Year-wise total dispensing of benzodiazepine derivatives in Australia between 
1992 – 2011 
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Despite a decrease in the prevalence of benzodiazepine prescriptions overall, diazepam and 
alprazolam prescribing increased.5
Figure 2. Dispensing trend of major benzodiazepines in Australia between 1992 – 2011
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1.3.1.3 Questions about safety of prescribing
Coronial data reported in the Australian media have raised public concern about the safety of 
prescription medications. Based on Victorian drug-related death data,12 prescription drugs are 
associated with 77% of all drug-related deaths. 
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Approximately half (48.8%) of all drug-related deaths are associated with benzodiazepines, which 
were identified as causal or contributory.
The number of deaths associated with benzodiazepines as a single drug is uncommon, and less 
than that from alcohol.
The most serious adverse events with benzodiazepines occur in the context of polydrug use (the 
use of more than one psychoactive substance in combination). The Coroner’s Court of Victoria’s 
figures suggest benzodiazepines, when used in conjunction with prescription or illicit opioids, are 
associated with a significant number of drug-related deaths.12 Similar findings occur when used 
in conjunction with antidepressants and antipsychotic drugs.
In many of the benzodiazepine-related deaths (57%), there was a positive history of substance abuse.12
State coroners have called on the RACGP to address benzodiazepine prescribing by GPs 
following these benzodiazepine-related deaths.
Regulatory bodies are also reviewing benzodiazepines and how they are prescribed. As of February 
2014, alprazolam has been rescheduled by the Therapeutic Goods Administration (TGA) to a 
Schedule 8 (S8) drug, due to concerns about misuse and harms. This followed a dramatic increase 
in the prescriptions for alprazolam (especially private prescriptions) – rising from 4.1% of the 
population in 1998 to 27.9% in 2010 – and a trend towards higher dose formulations.13–15 
Table 1. Drug related deaths in Victoria 201012 
1A. Drugs contributing to drug-related deaths
Number 
of deaths
Percentage of all drug-related 
deaths
Prescription drugs (alone or in combination with 
other drugs)
261 77.2%
Multiple drugs 215 63.6%
Single drug alone 123 36.4%
Prescription drugs alone 137 40.5%
Illicit drugs (alone or in combination with other drugs) 152 45%
Illicit drugs alone 50 14.8%
Alcohol (alone or in combination with other drugs) 82 24.3%
Alcohol alone 21 6.2%
Total deaths* 338
1B. Drug-related deaths associated with benzodiazepines
Number of deaths
Number 
of deaths
Percentage 
of all drug 
related deaths
Percentage of 
benzodiazepine-
related deaths
Total (causal or contributory)* 165 48.8% 100%
Combined with illicit or prescription opioids 136 40.2% 82.4%
Combined with substance abuse history 94 27.8% 57%
Combined with antidepressants 69 20.4% 41.8%
Combined with antipsychotics 47 13.9% 28.5%
Combined with alcohol 42 12.4% 25.5%
Benzodiazepines alone 5 1.5% 3%
*Where an overdose involves more than one drug type, the death is counted under all contributing drug types. Therefore, 
individual data does not sum to the total.
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1.3.1.4 Increasing awareness of problematic use, including misuse
Problematic use has been identified in men and women of all ages. According to the National Drug 
Strategy Household Survey, in 2010:16
• tranquillisers/sleeping pills (including benzodiazepines) were used for non-medical purposes by 3.2% 
of the Australian population aged 14 years and older at some stage in their lifetime
• benzodiazepines were used for non-medical purposes by 1.4% of Australians in the 12 months 
before the survey
• non-medical use of benzodiazepines is highest in people aged 20–29 (2.9%).
Awareness of diversion is relatively high, with benzodiazepines acknowledged as being among the most 
commonly diverted prescription medications (along with opioids) for illicit use.17 However, unintentional 
misuse is less known. Australia is likely to have a large, but relatively hidden, population who 
unintentionally misuse benzodiazepines and who have developed an iatrogenic dependence.18 Patients 
may also intentionally take medications outside of recommended use (eg larger doses) for what they 
consider to be a legitimate medical purpose (eg chronic insomnia).
Deliberate misuse of benzodiazepines for non-medical purposes occurs for a variety of reasons. People 
use benzodiazepines to:6,7
• enjoy the effects (especially taking large intermittent doses in a binge pattern)
• enhance an opiate effect 
• help come down from stimulants 
• combat opiate withdrawal symptoms 
• substitute for their drug of choice.
The benzodiazepine, flunitrazepam, has been used to facilitate sexual assault.
The true prevalence of benzodiazepine misuse is unknown. However, the harms associated with non-
medical prescription drug use, notably dependence and overdose, are well documented.17 
1.3.2 The factors involved
1.3.2.1 Source of benzodiazepine misuse
In contrast to other drugs used for non-medical reasons, medical practitioners are the main source for 
benzodiazepine misuse.19
Individuals may obtain prescription medicines for non-medical purpose through a variety of means including: 
• multiple doctors (doctor shopping or prescription shopping)
• drug theft (including from pharmacies)
• forgery of prescriptions
• inappropriate prescribing
• illicit market purchases
• procuring medicines from family, friends or acquaintances20
• bartering for sex or other services
• the internet.
In a survey of recent users of tranquilisers and sleeping pills for non-medical purposes, 71% thought these 
drugs were easy to obtain.16 Patients are often highly skilled at obtaining prescriptions. They may present 
with a range of plausible and compelling reasons for why they should receive benzodiazepines. The most 
common is that they are benzodiazepine dependent and at risk of seizures if not prescribed the drug.21 
Patients often describe medical reasons for needing to take the medicine (eg epilepsy and anxiety).
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1.3.2.2 Benzodiazepines are often combined with other drugs 
Benzodiazepines are often used in combination with other drugs, including alcohol (polydrug use). 
This can dramatically increase the risk of harm (eg road traffic accidents and overdose). This also 
presents a medico-legal risk for prescribers (eg if the patient was not warned, concurrent drug or 
alcohol use was not assessed, or the risk or presence of substance use disorder [SUD] was not 
assessed). 
A Melbourne study of adolescents who died of a drug overdose found a pattern of escalating 
attendance at general practices in the 6 months before death. The main reason for attendance 
was to obtain prescriptions for benzodiazepines.21 Another study found 55% of heroin-related 
deaths and 88% of methadone deaths in Victoria involved benzodiazepines.22 More than 90% 
of a cohort of heroin users in Sydney reported using benzodiazepines; 35% of the sample had 
injected benzodiazepines and 26% of those who had ever used benzodiazepines were diagnosed 
as dependent.23 The 2011 Victorian Illicit Drug Reporting System (IDRS) – a sentinel survey of 
people who inject drugs – reported 92% of lifetime and 71% recent benzodiazepine use.24 
1.4 Clinical pharmacology of benzodiazepines
Numerous benzodiazepines are available. They can be classified according to their main use, speed of 
onset, duration of action and drug half-life.
While benzodiazepines differ in their pharmacokinetics (absorption, distribution, metabolism, excretion), 
they all have similar pharmacodynamic properties and clinical actions.
1.4.1 Properties 
Benzodiazepines have four basic properties that give rise to their clinical use:
• anxiolytic 
• sedative/hypnotic
• anticonvulsant
• muscle relaxant.
Benzodiazepines can also produce anterograde and retrograde amnesia. This effect is used peri-
procedurally.
These properties are the result of enhancement of activity of the major inhibitory neurotransmitter 
in the central nervous system (CNS), gamma-aminobutyric acid (GABA). Benzodiazepines bind 
to receptors on the GABA-A receptor complex causing inhibitory effects throughout the brain, 
including drowsiness and cognitive impairment (cerebral cortex), dampening of emotions such as 
fear and anxiety (mesolimbic dopamine system), memory impairment and anticonvulsant actions 
(hippocampus), and impairment of balance, motor control, muscle tone and coordination (cerebellum 
and other motor areas). These effects are non-selective.
Newer Z drugs (eg zolpidem and zopiclone) enhance the activity of GABA by binding at the same 
location as benzodiazepines. While these drugs have similar actions to benzodiazepines, they are 
marketed for insomnia due to their kinetic profile. High doses are required to produce the other 
actions such as decreased anxiety.25 There is evidence Z drugs, which are now the most commonly 
prescribed hypnotic agents, share similar risks to benzodiazepines.26–29
1.4.2 Speed of onset
Benzodiazepines are rapidly absorbed orally. After ingestion, peak effects will occur within 30 minutes 
to 2 hours (refer to Table 2). The more fat-soluble drugs (eg diazepam) enter the CNS more rapidly. 
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1.4.3 Metabolism and duration of activity
Benzodiazepines vary greatly in the speed at which they are metabolised and several different 
mechanisms are involved. Depending on their metabolic structure, benzodiazepines are short, 
medium or long acting (refer to Table 2).
For the majority of benzodiazepines, the elimination half-life is significantly longer than the duration of 
clinical action. As they are rapidly redistributed into fatty tissue after absorption, the noticeable clinical 
effects wear off after a few hours. However, the drugs may continue to exert subtle effects and, with 
repeated dosing, accumulation within the fatty tissue occurs and a steady state of blood concentration 
can be reached in approximately five half-lives. Due to slow leaching from fatty tissue, benzodiazepines 
may be detected in urine tests weeks to months after cessation of benzodiazepine use.
Benzodiazepines are metabolised by the liver and excreted renally. Metabolism may be impaired in 
patients with liver and/or kidney disease. Lorazepam, oxazepam and temazepam are metabolised 
by glucuronidation and therefore do not produce active metabolites. These are rarely susceptible 
to medication interactions, although their sedative effects remain synergistic. Some other 
benzodiazepines undergo metabolism by the cytochrome P450 (CYP450) 3A4 hepatic enzyme 
system and many are weak inhibitors of the CYP enzymes. Therefore, these benzodiazepines may 
have significant interactions with other drugs that are metabolised by these enzyme pathways. 
Refer to Resource B for common drug–drug interactions.
1.4.4 Tolerance
Tolerance to all drugs of dependence develops with repeated use.31 Steady state plasma 
concentrations of benzodiazepines and their metabolites are reached after about five elimination 
half-lives, usually a few days to 2 weeks after starting therapy. Within a few days of reaching 
a steady state of plasma concentration, patients may start to experience a loss of effect from 
benzodiazepines,32 due to a range of neuroadaptive and physiological mechanisms.
Tolerance to the different benzodiazepine effects develops at different speeds and to different 
degrees, and may never be complete.2,32–34 The degree of tolerance differs between patients:35 
• A high proportion of patients with epilepsy develop tolerance to the anticonvulsant effects within a 
few weeks. This is similar to patients with spasticity disorders and the muscular relaxant effects.2
• Tolerance to the hypnotic effects is less clear. Some of the literature claims it develops rapidly,2 while 
other authors claim it is slower.25 The evidence is limited by the length of trials.32 Sleep studies have 
shown that tolerance develops to the hypnotic effects of some rapidly eliminated benzodiazepines 
(eg triazolam) by 2 weeks, whereas for others (eg midazolam) tolerance emerges slowly and 
minimally.32,36 Tolerance also appears to develop with the Z drugs, however to a low degree.3,32,36 
• Tolerance to the anxiolytic and amnesic effects of benzodiazepines probably does not occur at 
all.32 Although, there is some evidence that a slow (years) tolerance may develop.2,37
Long-term use of benzodiazepines may produce chronic changes in benzodiazepine-receptor 
functioning, which are thought not to fully return to their pre-addicted state after withdrawal and 
abstinence.38
There is a high degree of cross-tolerance between benzodiazepines and other sedative/hypnotic 
medications and alcohol.39
The development of tolerance is associated with escalation in dose, binge dosing and is one of the 
criteria for dependence31 and SUD40 (refer to Table 3). However, it is unusual for patients to steadily 
increase their dosage, even with long-term use, as might be expected with the development of 
tolerance.25,41 Patients who are prescribed benzodiazepines for anxiety or sleep problems usually 
do not escalate their doses even over a lengthy period of use. However, high-dose benzodiazepine 
mono-dependence has been reported.3
Tolerance also makes it difficult to calculate equivalence.
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1.4.5 Equivalent dosages
Equivalent doses are primarily used when making a transfer between drugs. Comparative oral doses of 
benzodiazepines are described in various sources, such as the Therapeutic Guidelines.35 However, the 
clinical potency of different drugs varies among individuals and it is difficult to demonstrate equivalence 
with drugs having very different half-lives (refer to Table 2). Due to this and variations in metabolism 
among people, these equivalence tables should be used with caution. 
1.5 Adverse effects of benzodiazepines
1.5.1 Adverse effects on mental health and functioning
While used commonly for mental illness, benzodiazepines are associated with a range of adverse 
effects on mental health and function. 
1.5.1.1 Cognitive impairment
Cognitive impairment is a broad term that encompasses several symptoms of benzodiazepine-
induced CNS effects.42
Acute administration may induce dose-related sedation, drowsiness, learning impairment, 
psychomotor slowing and anterograde amnesia.33,43–48
Chronic cognitive effects are modified by tolerance to some, but not all of the acute effects.3 A range 
of cognitive and psychomotor effects may persist after withdrawal.49
Long-term use of benzodiazepines has been associated with significant long-term cognitive 
impairment and increased risk of dementia in various studies.50–52 The difficulty with these studies is 
symptoms that may naturally precede dementia for 10 years or more (eg anxiety, sleep disorders) 
are the very indications for which benzodiazepines are commonly prescribed.53
Other prospective trials show no association between benzodiazepines and accelerated cognitive 
decline.54
One aspect of psychomotor functioning that has received a lot of attention is driving ability. 
Benzodiazepines are associated with a 60–80% increase in the risk of traffic accidents, and taking 
alcohol and benzodiazepines together increases accident risk more than seven times.55
1.5.1.2 Anxiety
Patients may experience new or worsened anxiety while taking benzodiazepines long term or after 
stopping long-term use (rebound anxiety).37,56
1.5.1.3 Depression 
Patients taking benzodiazepines may experience aggravated depression or depression that first 
appears during benzodiazepine use.37,57 Benzodiazepines may cause and aggravate depression, 
possibly by reducing the output of neurotransmitters such as serotonin and noradrenaline.
1.5.1.4 Paradoxical stimulation and disinhibition
Benzodiazepines may have a disinhibitory effect (especially at high doses), leading patients to behave 
out of character and potentially placing themselves in dangerous situations because of an impaired 
perception of inherent risk. Common scenarios involve high-risk sexual behaviour and reckless driving.42 
So called ‘benzo binges’ have been associated with shoplifting and other crimes.30
Patients may also experience paradoxical excitement with increased anxiety, insomnia, talkativeness, 
restlessness, mania, and occasionally rage and violent behaviour (known as the ‘Rambo effect’).7
Refer to Precautions in special groups interventions for further precautions and adverse effects.
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1.5.2 Dependence, withdrawal syndrome and problematic use
1.5.2.1 Dependence – A contemporary understanding
Despite its familiarity and ubiquitous use, the concept of dependence is complex. 
Historically, dependence has been defined in pharmacological terms. That is a state that develops 
during chronic drug treatment in which cessation elicits an abstinence reaction (withdrawal). This is 
time limited and reversible by renewed administration of the drug.
As awareness of problematic use grew, the definition of benzodiazepine dependence changed 
to include benzodiazepine addiction and abuse. Various definitions evolved with Diagnostic 
and Statistical Manual of Mental Disorders, 4th edition (DSM-IV), International Classification of 
Disorders, 10th edition (ICD-10), World Health Organization (WHO) and leading authors describing 
it as a cluster of behavioural, cognitive and physiological phenomena that may develop after 
repeated substance use. This definition acknowledged that dependence is a complex condition 
that involves variable combinations of interacting patient and drug factors (eg reinforcement, 
tolerance, withdrawal).
This has created difficulties in determining incidence and prevalence of benzodiazepine 
dependence, caused inadvertent changes in reporting levels of adverse drug events58 and 
difficulties in comparing dependence and withdrawal reactions in benzodiazepine alternative (eg 
SSRIs).
The DSM-5 criteria combine the former DSM-IV categories of substance abuse and substance 
dependence into a single condition of SUD, measured on a continuum from mild to severe. The 
essential feature of SUD is a cluster of cognitive, behavioral and physiological symptoms indicating 
the individual continues using the substance despite significant substance-related problems. 
1.5.2.2 Withdrawal syndrome
Benzodiazepine withdrawal syndrome is highly variable. It remains unclear why some long-term 
users can withdraw without difficulty, even after years of continuous use, while others undergo 
protracted agonies.59
The symptoms of withdrawal usually appear within 2–3 half-lives of the benzodiazepines being 
withdrawn.60 They usually lessen and then disappear within a few weeks.60 Sudden withdrawal of 
benzodiazepines can be associated with seizures. 
The mildest form of withdrawal is rebound.3 Rebound comprises of the original symptoms 
recurring transiently at a greater intensity.3 Discontinuation of benzodiazepines is frequently 
associated with rebound anxiety and insomnia.36,61–66 Withdrawal symptoms include irritability, 
paraesthesia, tinnitus, headaches, dizziness, poor memory, poor concentration, perceptual 
distortions, menstrual disturbances and sensory hypersensitivity.38,59,65,67 Withdrawal symptoms 
can usually be minimised by gradual reduction.68,69 There is evidence that some patients suffer 
protracted withdrawal symptoms that can continue for months to years after cessation.59 There is 
debate about whether these persistent symptoms are withdrawal reactions, or simply features of 
an underlying disorder or worsening of that condition, which is triggered by treatment withdrawal.25 
Short- and intermediate-acting benzodiazepines carry a greater risk of rebound and withdrawal 
than long-acting benzodiazepines. Withdrawal syndrome can appear while the patient is still 
taking medication. This may be because the patient avoids increasing the dose to cover increased 
tolerance,59 or the patient is taking short-acting formulations and experiencing withdrawal as blood 
levels drop.
1.5.2.3 Incidence of withdrawal symptoms
The occurrence of withdrawal syndrome is related to high dosage and long-term use.3
Authors argue that based on the incidence of withdrawal symptoms, evidence of benzodiazepine 
dependence can be quite high. Withdrawal symptoms from benzodiazepines prescribed for 
insomnia can ensue after 4–6 weeks of use in approximately 15–30% of patients.70 Others suggest 
12 Prescribing drugs of dependence in general practice, Part BBenzodiazepines
much higher incidences of withdrawal: in the order of 30–45% of patients who have used regular 
therapeutic doses of benzodiazepines for more than a few months.71
It has been debated whether this is a clinical problem.72 For example, it has been suggested that 
in the absence of SUDs, the risk of addiction to benzodiazepines during long-term treatment 
of anxiety and related disorders has been exaggerated. In addition, the pharmacological 
dependence that develops when benzodiazepines are used long-term does not denote an 
all-encompassing preoccupation with and craving for benzodiazepines, nor does it create 
compulsive or uncontrollable benzodiazepine-seeking behaviour and adverse health and/or social 
consequences.73
1.5.2.4 Cravings and reinforcement
The reinforcement potential of a drug is its ability to maintain or increase the frequency of drug-
taking or drug-seeking behaviour. Drugs may have positive reinforcement potential by creating 
a reward (or ‘high’) or negative reinforcement potential by alleviating some form of distress (eg 
anxiety or withdrawal symptoms).57 
Benzodiazepines predominantly demonstrate negative reinforcement effects.71 By alleviating 
anxiety and withdrawal symptoms, it can encourage continued use. Used alone, and at 
therapeutic doses, they have not been associated with significant positive reinforcement for 
most patients (ie the drug itself does not encourage further use or dose escalation). Patients 
with a history of alcohol abuse, or even those with moderate alcohol consumption, appear to 
experience greater reinforcement effects with benzodiazepines. High doses may have positive 
reinforcing effects in some patients, particularly polydrug users.71
1.5.2.5 The spectrum of problematic use
Problematic use rarely develops in patients taking a normal, therapeutic dose for short periods. 
However, particular patient populations may be more vulnerable to developing problematic use.
An original US report focusing specifically on the development of physiological dependence, 
especially at therapeutic doses, notes that benzodiazepines do not strongly reinforce their own 
use and are not widely abused drugs. When abuse does occur, it is almost always among 
individuals who are also actively abusing alcohol, opiates or other sedative hypnotics.74
1.5.2.6 Low-dose or therapeutic-dose dependence
In cases of low-dose dependence, benzodiazepines were usually initiated for their anxiolytic or 
hypnotic effects. Doses may escalate slightly over years, however, prescriptions usually remain 
within therapeutically recommended limits.57
While high-dose dependence may be easier to recognise through drug-seeking behaviours, GPs 
should be aware of the more subtle behaviours of patients with low-dose dependence. 
Patients with low-dose dependence tend to return at regular intervals to obtain repeat 
prescriptions, often before the previous supply has run out. They often carry their tablets around, 
and it is not uncommon for them take an extra dose before an anticipated stressful event or a 
night in a strange bed. They have difficulty stopping the medication or reducing the dosage due 
to withdrawal symptoms.57
In contrast with patients with high-dose dependence (prescribed or recreational), patients with 
low-dose dependence tend not to abuse other drugs or alcohol.57
1.5.2.7 Problematic benzodiazepine use
Based on the available epidemiological data, the prevalence of benzodiazepine abuse is generally 
low in the therapeutic setting (ie where the drug is correctly medically prescribed). The American 
Psychiatric Publishing Textbook of Psychopharmacology quotes prevalence of 0.6% for abuse 
and 0.5% for dependence among therapeutic users.75 However, the incidences are much higher 
in people who abuse alcohol and other drugs.75
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Supporting this, a 2013 study found most patients used benzodiazepines according to 
guidelines, and only 0.9% ended up as excessive users after 3 years.76 Again, problematic use 
occurred mostly in individuals with alcohol and drug histories.
If benzodiazepine use disorder has become moderate or severe, it can become a long-term and 
distressing problem. There are several behaviours that indicate a patient may have problematic 
benzodiazepine use (eg escalating use patterns, drug-seeking behaviour and doctor or 
prescription shopping).77
GPs need to maintain vigilance in identifying SUDs, assist patients in recognising disordered use 
where it exists, set goals for recovery and assist patients to seek appropriate treatment.
1.5.3 Morbidity and mortality
Epidemiological studies have demonstrated an excess of consultations for accidents among persons 
taking benzodiazepines.78
In Victoria alone, benzodiazepines were involved in 3135 ambulance attendances in 2010–11 and 
3440 in 2011–12. In terms of all alcohol and drug related attendances, they were the second most 
common only to alcohol. There was a disproportionate increase in the involvement of alprazolam 
compared to all benzodiazepines in ambulance attendances.79,80
In older patients, benzodiazepines are associated with higher risk of falls and subsequent injuries.81–83
The harmful effects of benzodiazepines, other than the risk of dependence with long-term use, have 
been associated (ie not proven cause and effect) with a 4–6-fold increased risk of death from all 
causes.84 
Research has found patients prescribed hypnotic drugs (including benzodiazepines, Z drugs, 
barbiturates and sedative antihistamines) have an elevated risk of dying compared to those 
prescribed with no hypnotics.84 There is a dose-dependent relationship, but even patients prescribed 
fewer than 18 hypnotic doses per year experienced increased mortality.84 Note that this research 
did not find that hypnotic drugs were the cause of premature death – at best, it found a potential 
association. 
Large cohort studies refute the relationship between benzodiazepine therapy and premature death. 
Emerging evidence suggests underlying psychiatric disorders are the principal determinant driving 
the association between hypnotics and mortality risk.85
1.6 Clinical governance 
Please refer to RACGP’s Prescribing drugs of dependence in general practice, Part A – Clinical 
governance framework for further information on clinical governance and its role in improving safety and 
quality for the use of drugs of dependence in general practice. 
1.6.1 Laws and regulations
Most benzodiazepines are Schedule 4 (S4) ‘prescription only’ medicines. The exceptions are 
flunitrazepam and alprazolam, which are classed as S8 drugs.
Each state and territory has laws regulating the prescription of these medicines. Generally, there 
are tighter controls around the prescribing of S8 drugs and for prescribing to patients with known 
addiction. For example, GPs must seek a permit or an authority from the relevant state or territory 
health department when prescribing an S8 drug to persons who are drug dependent. 
Some states have subsets of S4 drugs that involve prescribing restrictions or additional 
requirements; benzodiazepines often fall into this category.
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GPs must be familiar with the relevant legislative requirements associated with writing prescriptions 
for S4 and S8 drugs. 
State and territory departments and government-funded drugs of dependence units (or equivalent) 
can provide information regarding prescribing. Refer to Resource C.
1.6.2 General practice systems of care
The quality and safety of patient care is no longer confined to the individual practitioner. General 
practices have responsibilities to work collaboratively with practitioners to address the safety and 
quality of health services provided in their facilities.
Practice systems of care around benzodiazepines can be put in place to maximise health outcomes 
and social functioning for patients while minimising drug and alcohol misuse, abuse, diversion and 
crime. Systems of care also provide the necessary infrastructure and support for GPs to perform 
their job efficiently and effectively.
1.6.2.1 Staff education and competency
Practices should ensure they have the level of knowledge among team members and practice 
capacity to address the issues associated with benzodiazepine prescribing (eg identification of 
patients with more complex needs and those at higher risk). Prescriber education is particularly 
important. The risk of benzodiazepine misuse and dependence is lower when the first-time 
prescriber is a specialist in general practice compared to a prescriber without specialty training.76 
GPs who are regularly involved in managing patients with problematic use of benzodiazepine 
or other drugs and alcohol should consider further training and developing good working 
relationships with addiction specialists.
Practices should promote the development of competency in prescribing benzodiazepines. 
Where potentially inappropriate and suboptimal prescribing is identified, practices and GPs have 
an opportunity to engage in education and support, and improve patient outcomes. 
Dependence programs
Access to relevant programs is limited in some areas of Australia. Practices may wish to consider 
supporting GP-based benzodiazepine detoxification programs in-house. Benzodiazepine 
detoxification typically requires significant and frequent communication with patients, more 
regular visits with the GP and other clinical staff, on-call mechanisms and management of 
patients who are often highly anxious.86 Suitably qualified staff, organised support and ongoing 
quality assurance arrangements may be required. GPs involved in this type of program should 
feel comfortable prescribing adjunct medications.86
1.6.2.2 Balancing patients’ needs with practice capacity (risk 
stratification)
Patients should be appropriately evaluated to determine the complexity of services required.
One of the goals in the initial assessment of a patient is to obtain a reasonable assessment of 
clinical complexity/risk in the context of concurrent SUD or psychopathology. In this context, 
patients can be stratified into three basic groups. The following will offer a practical framework 
to help determine which patients may be safely managed in the primary care setting, should be 
co-managed with specialist support and should be referred on for management in a specialist 
setting.
GPs with advanced training in addiction medicine and/or mental health management are suited 
to taking on higher responsibilities under this model.
• Group I – Managed in primary care: Patients with no evidence of past or current history of 
SUD or mental illness, apart from the presenting problem.
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• Group II – Managed in primary care with specialist support: Patients may have a past 
history of a treated SUD or a significant family history of problematic drug use. They may also 
have a past or concurrent psychiatric or chronic pain disorder. While not actively addicted, 
patients are at increased risk, which may be managed in consultation with appropriate 
specialist support.
• Group III – Managed by specialist services: This group of patients represents the most 
complex cases to manage because of an active SUD or major, untreated psychopathology. 
These patients are either actively misusing prescription drugs or pose significant risk to both 
themselves and to the practitioners, who may lack the resources or experience to manage 
them.
It is important to remember that all groups can be dynamic. Group II can become Group III 
with relapse to active addiction, while Group III patients can move to Group II with appropriate 
treatment. In some cases, as more information becomes available to the practitioner, the patient 
who was originally thought to be low risk (Group I) may be reclassified as Group II or even Group 
III. It is important to continually reassess risk over time.87 
1.6.2.3 Care coordination 
A key message from inter-professional dialogue is that all health professionals (eg psychiatrists, 
pharmacists, GPs, nurses) have difficulties when dealing with high-risk patients and prescribing 
benzodiazepines.88 There should be an agreed set of professional standards regarding 
communication and transfer of care. In particular, the responsibility of ongoing prescribing duties 
should be explicit.
Prescribing may be initiated and recommended by other specialists, or during hospital in-patient 
care. When prescribing is transferred from secondary to primary care, the following information 
should be relayed to the GP:
• indication for use
• expected length of treatment 
• when the treatment will be reviewed and by whom
• advice about withdrawal if indicated
• clear indications of the GP’s role 
• clear agreement on roles of all clinicians between GP and secondary care
• clear indications of support and referral pathways to the secondary service.
GPs should take care when patients on high doses of benzodiazepines are transferred from 
secondary care without a therapeutic rationale for clinical benefits or planned withdrawal 
schedule. GPs are not required to continue prescriptions commenced elsewhere if they are not 
comfortable doing so. However, GPs should not undermine the professional advice of colleagues, 
and should attempt immediate contact by telephone to clarify the management plan when there 
are concerns.
With continued monitoring of care, issues may arise which should prompt specialist review or 
immediate transfer to hospital (refer to RACGP’s Prescribing drugs of dependence in general 
practice, Part A – Clinical governance framework). The following should prompt consideration for 
referral to specialist mental health services:89
• insufficient experience to manage the patient’s condition requiring benzodiazepine therapy, or 
insufficient practice infrastructure to provide ongoing recall and review
• multiple attempts at treatment have not resulted in sustained improvement
• severe coexisting depressive symptoms or a risk of suicide
• evidence of problematic drug use 
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• comorbid physical illness and concomitantly prescribed treatments which could interact with 
prescribed psychotropic medication
• proposed interventions are not available within primary care services.
1.6.2.4 Practice policies and standards
General practices should have agreed clinical policies regarding prescribing benzodiazepines to 
improve the quality and consistency of prescribing, and improve safety for patients and practice 
staff.
Practices should consider having policies regarding:
• the management of patients according to mental illness and use of drugs of dependence to 
provide the appropriate level of service internally and externally
• repeat scripts for benzodiazepines (refer to Resource E.1)
• limitations for registrar prescribing of benzodiazepines (refer to RACGP’s Prescribing drugs of 
dependence in general practice, Part A – Clinical governance framework).
Simple, practice-based interventions can be quite effective. Practice-based letters sent to a 
general practice population have repeated proven effectiveness in reducing benzodiazepine use 
in older patients.90 A 10-year follow-up in the Netherlands after such an intervention revealed 
60% of these patients remained abstinent of benzodiazepine use.91 Those who returned to 
benzodiazepine therapy often did so at lower doses. Simple educational interventions may also 
reduce inappropriate benzodiazepine use.90,92
Benzodiazepine misuse might not be a highly visible problem in every practice, however all 
practices should be involved in supporting steps to reduce inappropriate benzodiazepine use in 
their practice and community. Each general practice should assess their own needs and develop 
policies that suit their circumstances.
1.6.2.5 Using and managing information
To help GPs manage prescribing risks, practices should have infrastructure (computer based or 
other) that provides:
• standardised patient information on benzodiazepines, including the effects on driving and 
operating machinery (refer to Resource D.1)
• a treatment plan when there is a clinical decision to continue benzodiazepines. The plan 
should clearly outline the responsibilities of the patient and the practice, and include an 
agreement to review and monitor clinical progress against therapeutic goals
• access to high-quality information systems and/or prescription shopping hotlines to assist in 
curtailing prescription abuse
• mechanisms/processes within the practice to share information regarding benzodiazepine 
abuse/misuse
• formalised benzodiazepine withdrawal guidelines within the practice (refer to Resource D.2B)
• standardised patient information on sleep hygiene methods (refer to Resource D.4).
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1.6.2.6 Quality improvement
Quality improvement measures around benzodiazepine prescribing include developing policies or 
an audit, communicating with patients and managing risks.
Further information about quality improvement can be found in the RACGP’s Prescribing drugs of 
dependence in general practice, Part A – Clinical governance framework.
1.6.3 Accountable prescribing of benzodiazepines
 Key points
• Prescribing benzodiazepines, as with any treatment, should be based on a comprehensive 
medical assessment, a diagnosis, thoughtful consideration of the likely risks and benefits of 
any medication as well as alternative interventions, and a management plan derived through 
shared decision making and continual clinical monitoring. 
• GPs should be aware of the concerns associated with benzodiazepines such as potential 
dependence, withdrawal, problematic drug use (including diversion and misuse), and known 
harmful effects, including falls, potential cognitive decline and motor vehicle accidents. 
These risks should be discussed with patients. 
• GPs may wish to use the diagnosis of SUD rather than dependence, addiction or abuse. 
This is based on the DSM-5 sedative, hypnotic or anxiolytic use disorder criteria. This is 
a more neutral term that may reduce stigmatisation of patients with problematic use of 
benzodiazepines and other drugs/alcohol.
• Treatment seeks to maximise outcomes for the health and social functioning of the patient 
while minimising risks. To minimise risks, benzodiazepines should be prescribed at the 
lowest effective dose, for the shortest clinical time frame. 
• Once started, some patients find it hard to stop benzodiazepines. Therefore, prescription 
should be accompanied with a plan to reduce and cease benzodiazepines.
• Patients who use two or more psychoactive drugs in combination (polydrug use), and those 
with a history of substance misuse may be more vulnerable to major harms. Significant 
caution should be taken if prescribing benzodiazepines to patients with comorbid alcohol/
substance abuse or polydrug use. GPs should consider seeking specialist opinion in 
management of these patients. 
• Benzodiazepines are generally regarded by clinical practice guidelines as a short-term 
therapeutic option. Long-term use, beyond 4 weeks, should be uncommon, made 
with caution and based on thoughtful consideration of the likely risks and benefits of 
benzodiazepines. 
 – If alternatives to benzodiazepine treatment fail, have limited benefit or are inappropriate 
(either psychologically or pharmacologically), supervised benzodiazepine treatment may 
remain an acceptable long-term therapeutic option. 
 – Long-term benzodiazepine prescriptions should be at the lowest effective dose, 
preferably given intermittently, and regular attempts at reduction should be scheduled. 
Continued professional monitoring of health outcomes is required.
 – Benzodiazepines should be prescribed from one practice and preferably one GP, with 
prescriptions dispensed from one pharmacy. 
• GPs should develop strategies to manage inappropriate requests for benzodiazepines by 
patients.
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1.6.3.1 Evidence-based prescribing of benzodiazepines
The evidence base for benzodiazepine use continues to evolve, but despite the length of time 
they have been used in clinical practice, the evidence remains incomplete in many areas.93 The 
clinical recommendations and practice points presented in this guide are based on the best 
available evidence. 
With respect to benzodiazepine therapy, recommendations based on these randomised 
controlled studies do not always reflect clinical reality. It is recognised that randomised controlled 
trials are generally a maximum of 12 weeks and performed in restricted patient groups with little 
comorbidity or other features resembling conventional clinical samples.94
1.6.3.2 Practical prescribing decisions
Good prescribing practice involves careful and considered diagnosis; clear therapeutic goals; 
the use of non-drug therapies where suitable; prescribing appropriate types, formulations and 
amounts of medication; explaining the effects of medications and any risk of dependence; and 
implementing regular medication reviews.
The risks of problematic use and diversion make prescribing benzodiazepines more challenging. 
The short-term use of benzodiazepines can be helpful for symptomatic relief across a wide range 
of clinical conditions. Given the potential for harm with benzodiazepine use, clinical discipline is 
required. The immediate relief with benzodiazepines is tempting, yet the best outcomes are often 
achieved with non-drug treatment. However, these interventions take time, may not be available 
in a timely fashion, and involve engagement and effort from patients. 
While the thrust of this guide is that benzodiazepines should generally be prescribed less, care 
should be exercised when changing from one psychoactive substance to another or when 
using combination therapies. All psychoactive drugs have risks and benefits. Some non-
benzodiazepine drugs also have problems with dependence and problematic use (eg quetiapine). 
There is consensus that although benzodiazepines have been problematic, when prescribing is 
placed in the broader historical context and the types of patients prescribed benzodiazepines are 
considered, it is apparent that other psychotropic drugs have raised similar problems.58,95–99
1.6.3.3 Assessing risk
Patients who previously misused drugs (eg opioids, anti-alcohol or smoke cessation treatments) 
have a higher risk of becoming excessive users compared to patients who have not previously 
misused drugs.76 Greater challenges exist for patients already prescribed benzodiazepines for 
some time. Once a benzodiazepine prescription has been started, it may be harder to stop.
To minimise harms associated with prescription drug misuse, GPs need to maintain vigilance 
in identifying SUDs, assist patients in recognising disordered use where it exists, set goals for 
recovery and assist patients to seek appropriate treatment.
Recognising patients with problematic benzodiazepine use
There are several behaviours that indicate a patient may have problematic benzodiazepine use, 
such as escalating use patterns, drug-seeking behaviour and doctor or prescription shopping.77
Drug-seeking behaviours that indicate risk, but are less predictive of problematic use include: 
• attending early for prescription renewal
• complaining aggressively about the need for higher doses
• hoarding drugs during periods of reduced symptoms
• requesting specific drugs 
• acquiring similar drugs from other medical sources
• escalating unsanctioned doses 1–2 times
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• using the drug to treat other symptoms
• selling prescription drugs.
Drug-seeking behaviours that are highly predicative of problematic use include: 
• forging prescriptions
• stealing or borrowing another patient’s drugs
• injecting oral formulations
• obtaining prescription drugs from non-medical sources
• abusing illicit drugs concurrently
• escalating unsanctioned doses multiple times
• losing prescriptions repeatedly.
Patients may be extremely convincing, using plausible stories and even manipulating a GP’s 
discomfort with confrontation to obtain medication.77
For ways to manage patient who may be drug seeking, refer to patient scripts in Resource A.
Patients with previous substance use problems, or those who use antipsychotic medication, 
are at increased risk of disordered benzodiazepine use.76 However, any patient can develop 
problematic use, and so universal precautions are important when considering prescribing. 
Assessment of substance use disorder
The DSM-5 criteria combine the old DSM-IV categories of substance abuse and substance 
dependence into a single condition of SUD, measured on a continuum from mild to severe.40 
The essential feature of SUD is a cluster of cognitive, behavioral and physiological symptoms 
indicating the individual continues using the substance despite significant substance-related 
problems.40
Using the term SUD should:
• reduce confusion associated with the terms dependence, addiction and abuse (which have 
been inconsistently and often incorrectly used to describe points on a spectrum of disordered 
use)
• be more acceptable to patients and their carers – a diagnosis of being ‘drug dependent’ may 
be confronting and create stigma.
Diagnosis of SUD requires the presence of at least two of 11 criteria, across four categories: 
impaired control, social impairment, risky use and pharmacology. Based on the total number of 
criteria the patient has, the substance use disorder can be classified as mild (2–3 symptoms), 
moderate (4–5 symptoms) or severe (6 or more symptoms). It is hoped these severity classifiers 
may help to clarify treatment options (refer to Table 3).
Although the term SUD is a helpful addition, the term dependence will necessarily be used when 
discussing any ‘drug of dependence’.
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Table 3. DSM-5 criteria for diagnosing a sedative, hypnotic or anxiolytic use disorder
A problematic pattern of sedative, hypnotic or anxiolytic use leading to clinically significant impairment or 
distress, as manifested by at least two of the following 11 criteria, occurring within a 12-month period:
Impaired control 
criteria
1. Sedatives, hypnotics or anxiolytics are often taken in larger amounts or over a longer 
period than was intended
2. There is a persistent desire or unsuccessful efforts to cut down or control sedative, 
hypnotic or anxiolytic use
3. A great deal of time is spent in activities necessary to obtain the sedative, hypnotic or 
anxiolytic; use the sedative, hypnotic or anxiolytic; or recover from its effects
4. Craving or strong desire or urge to use the sedative, hypnotic or anxiolytic
Social 
impairment 
criteria
5. Recurrent sedative, hypnotic or anxiolytic use resulting in a failure to fulfil major role 
obligations at work, school or home (eg repeated absences from work or poor work 
performance related to sedative, hypnotic or anxiolytic use; sedative-, hypnotic- or anxiolytic-
related absences, suspensions or expulsions from school; neglect of children or household)
6. Continued sedative, hypnotic or anxiolytic use despite having persistent or recurrent social or 
interpersonal problems caused by or exacerbated by the effects of sedatives, hypnotics or 
anxiolytics (eg arguments with a spouse about consequences of intoxication; physical fights)
7. Important social, occupational or recreational activities are given up or reduced because of 
sedative, hypnotic or anxiolytic use
Risky use criteria 8. Recurrent sedative, hypnotic or anxiolytic use in situations in which it is physically 
hazardous (eg driving an automobile or operating a machine when impaired by sedative, 
hypnotic or anxiolytic use)
9. Sedative, hypnotic or anxiolytic use is continued despite knowledge of having persistent 
or recurrent physical or psychological problem that is likely to have been caused or 
exacerbated by the sedative, hypnotic or anxiolytic
Pharmacological 
criteria
10. Tolerance, as defined by either of the following:
a. A need for markedly increasing amounts of the sedative, hypnotic or anxiolytic to 
achieve intoxication or desired effect
b. A markedly diminished effect with continued use of the same amount of the sedative, 
hypnotic or anxiolytic
Note: This criterion is not considered to be met for individuals taking sedatives, 
hypnotics or anxiolytics under medical supervision
11. Withdrawal, as manifested by either one of the following:
a. The characteristic withdrawal syndrome for sedatives, hypnotics or anxiolytics (refer 
to Criteria A and B of the criteria set for sedative, hypnotic or anxiolytic withdrawal in 
DSM-5 pp 557–558)
b. Sedatives, hypnotics or anxiolytics (or a closely related substance, such as alcohol) 
are taken to relieve or avoid withdrawal symptoms
Specifiers:
In early remission: After full criteria for sedative, hypnotic or anxiolytic use disorder were previously met, none of 
the criteria for sedative, hypnotic or anxiolytic use disorder have been met for at least 3 months but for less than 
12 months (with the exception that criterion 4 may be met)
In sustained remission: After full criteria for sedative, hypnotic or anxiolytic use disorder were previously met, 
none of the criteria for sedative, hypnotic or anxiolytic use disorder have been met at any time during a period of 
12 months or longer (with the exception that criterion 4 may be met)
In a controlled environment: This additional specifier is used if the individual is in an environment where access 
to sedatives, hypnotics or anxiolytics is restricted
Current severity:
Mild: Presence of 2–3 symptoms
Moderate: Presence of 4–5 symptoms
Severe: Presence of 6 or more symptoms
Reprinted with permission from the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (Copyright 2013). 
American Psychiatric Association. All Rights Reserved.
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1.6.4 Patient focus
 Key points
• All patients, including those who use benzodiazepines and other drugs and alcohol 
problematically, have the right to respectful care that promotes their dignity, privacy and safety.
1.6.4.1 Sharing prescribing decisions
Treatment and care of patients should take into consideration their needs and preferences. 
Clinical options and patient information should be culturally appropriate. It should be accessible 
to people with individual needs including those with physical, sensory or learning disabilities, and 
those who do not speak or read English.
Fully informing patients about the benefits and drawbacks of benzodiazepines may improve 
shared decision making between the patient and doctor. While there are time constraints in a 
consultation, this approach may reduce GPs’ workload with fewer patients returning for repeat 
prescriptions.8
Non face-to-face methods of communication can also be useful. For example, a study involving 
direct delivery of an educational tool on benzodiazepines to older patients increased their risk 
perception of inappropriate prescriptions.100
Exploring patient preferences, ideas and expectations during a consultation may lead to fewer 
benzodiazepine prescriptions. Evidence suggests doctors sometimes assume patients want 
drug treatment and/or would be resistant to withdrawal, whereas some patients prefer not to use 
medication or wish to discontinue drugs.8
Patients need good information and access to alternative treatments including CBT for insomnia 
and anxiety. These interventions may be made available in the practice or through local services. 
There are many resources available on the internet (eg computer-based anxiety therapies). 
1.6.4.2 Clinical responsibility in shared decision making
While most patients’ involvement with drugs of dependence is clinically driven, there 
can be elements of manipulation (and rarely criminal intent) behind patients’ requests for 
benzodiazepines.
The important caveat when prescribing drugs of dependence relates to healthcare benefits. 
Some patients with drug dependency may request higher doses on the basis that they are 
making a choice as an informed patient, or as harm minimisation.
Patients have a right to good healthcare, but not a right to drugs of dependence. Patients need 
to be informed of this at the beginning of any trial using drugs of dependence. If the clinician feels 
further therapy is detrimental to a patient’s health, then clinical withdrawal of medication should 
begin.
Doctors typically have a strong desire to alleviate a patient’s distress and suffering. The 
psychological phenomenon of transference in addiction, pain and mental illness can result in 
doctors having difficulty in these clinical areas. Some GPs may find it difficult to set boundaries for 
patients, and are therefore at risk of being pressured to prescribe inappropriately. Other GPs may 
have difficulty saying ‘no’ or believe they are ‘helping’ or taking a harm minimisation approach by 
giving in to a patient’s requests for drugs. 
All practitioners express difficulty responding to patients who use manipulative behaviour (eg 
threatening to self-harm if they do not receive medication). GPs should educate themselves 
about appropriate responses to common manipulative behaviours used to access drugs of 
dependence. To aid GPs’ negotiation skills, scripted replies have been developed to help with 
appropriate responses in difficult situations (refer to Resource A).
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1.6.4.3 Aboriginal and Torres Strait Islander peoples
There is very little literature on benzodiazepine use in Aboriginal and Torres Strait Islander 
peoples. While the clinical recommendations in this guide are the same for all patients, there is a 
need to understand the complex cultural context of Aboriginal and Torres Strait Islander peoples 
to build an effective therapeutic alliance. Working with local, respected Aboriginal Health Workers 
and/or drug and alcohol workers is crucial for comprehensive bio-psychosocial care.
Resources
The Working Together book is relevant in understanding and providing mental health care to 
Aboriginal and Torres Strait Islander peoples. This is available at http://aboriginal.telethonkids.org.
au/media/699863/Working-Together-Book.pdf
The Handbook for Aboriginal Alcohol and Drug Work includes useful information on 
benzodiazepines. This is available at http://ses.library.usyd.edu.au/bitstream/2123/8339/6/2012-
handbook_online-version3.pdf 
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2. Evidence-based guidance for 
benzodiazepines
2.1 Overview
The evidence base for benzodiazepine use continues to evolve, but despite the length of time they 
have been used in clinical practice, the evidence remains incomplete in many areas.93 The clinical 
recommendations and practice points presented in this guide are based on the best available evidence. 
Benzodiazepines are used for a broad range of conditions including:
• insomnia
• anxiety disorders 
• alcohol withdrawal
• mania/hypomania
• epilepsy
• acute seizures 
• arousal/agitation in the in-patient setting
• palliative care
• musculoskeletal disorders.
Insomnia and anxiety disorders are commonly managed in general practice and are the main focus of 
this chapter. Alcohol withdrawal may be managed in general practice and is covered briefly. However, 
GPs wishing to manage patients withdrawing from alcohol will need to consult other resources.
The following sections demonstrate how benzodiazepines fit into the context of treatment for a range of 
conditions, but do not represent comprehensive guidance. Additional resources are provided for each 
condition.
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2.2 Insomnia 
 Key points
• Insomnia is a common problem seen in general practice. The understanding of chronic 
insomnia is still evolving.
• In acute insomnia, sleep often returns to normal once the precipitating factor has resolved.
• In chronic insomnia, treatment is focused on addressing underlying comorbid precipitants 
(where present), and psychological and behavioural management.
• Pharmacotherapy for acute and chronic insomnia may be necessary for severe or resistant 
cases of insomnia. The decision to prescribe should be on an individual basis and involve 
serious consideration of all risks and possible benefits.
• Benzodiazepines and Z drugs have been shown to be effective treatments and may be 
prescribed for short-term or intermittent use. Harm, such as dependence and adverse events, 
may occur with both drug groups.
• Dose reduction and cessation should be discussed with the patient on first prescription and 
commenced once sleep patterns return to normal.
• Pharmacological treatment should be accompanied by specific patient education and regular review.
Evidence statements Grade
Rec 1 Cognitive behavioural therapy (CBT) based treatment packages for chronic insomnia, 
including sleep restriction and stimulus control, are effective and therefore should be 
offered to patients as first-line treatment.101
A
Rec 2  Z drugs and short-acting benzodiazepines are efficacious for insomnia.101 A
Rec 3 Prescription of zolpidem and zopiclone should be treated with the same caution as 
benzodiazepines.102
A
Rec 4 Intermittent dosing may reduce the risk of tolerance and dependence.101 B
Rec 5 If hypnotics are to be used for treating insomnia, it is recommended that treatment is 
short term (not more than 4 weeks) and at the lowest possible dose.103
B
To see the original source of the recommendations and grading, as well as supporting sources, click on the 
recommendation number in the left column.
2.2.1 Background
Sleep disturbance is the third most common psychological reason for patient encounters in general 
practice. Population surveys found 13–33% of adult Australians have regular difficulties getting to 
sleep or staying asleep.104 
Insomnia is defined in DSM-5 as a difficulty in getting to sleep, staying asleep or having non-
restorative sleep despite having adequate opportunity for sleep, together with associated impairment 
of daytime functioning, with symptoms being present for at least 4 weeks.40
Acute insomnia meets the DSM-5 definition of insomnia, but with symptoms occurring for less than 
4 weeks.40 It is experienced by up to 80% of the population at some stage, generally due to one or 
more precipitating factors.105 
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Factors that can precipitate acute insomnia include:104
• physiological – hyperarousal due to stress, being ‘on-call’, caring for a sick child/relative, being in 
a strange situation (eg in hospital)
• pharmacological – prescribed drugs (eg newly prescribed diuretic causing nocturia) and non-
prescribed drugs
• physical – coughing, environment (eg noise, temperature)
• disruption of circadian rhythm (eg jet lag).
Provided patients adhere to good sleep habits, most will return to normal sleep once the 
precipitating factor has resolved or diminished.106
Chronic insomnia was previously viewed as a sleep disturbance that was secondary to a medical 
condition, psychiatric illness, sleep disorder or medication, and would improve with treatment of the 
underlying disorder.107,108 However, evidence over the last 20 years indicates this view is incorrect. It is 
now recognised that insomnia may be an independent disorder.108–110 The understanding of chronic 
insomnia continues to evolve. Insomnia may have some similarities with depression in that they both 
represent long-term disorders for which many patients require maintenance treatment.
Chronic insomnia may occur in the absence of coexisting conditions. When coexisting conditions exist, 
insomnia may persist despite successful treatment of the coexisting condition. Treatment directed 
at the insomnia, rather than the comorbidity, may be necessary. Since insomnia can precipitate, 
exacerbate or prolong comorbid conditions, treatment of insomnia may in turn improve comorbidities. 
Chronic insomnia is unlikely to resolve spontaneously.111 
2.2.2 Management of insomnia in general practice
When patients present with insomnia to GPs in Australia, few (0.8%) receive a referral for 
specific non-drug therapy.112 All guidelines strongly recommend psychological and behavioural 
management.68,102,108,113
2.2.2.1 Assessment and diagnosis
Assessment and diagnosis of insomnia requires:111
• understanding the patient’s typical sleep pattern over an extended time frame (weeks to 
months) – a sleep diary can help assessment
• identifying contributing lifestyle factors (eg caffeine, nicotine, pets in the bedroom)
• understanding the patient’s beliefs and concerns about sleep
• determining the effects of poor sleep on the patient (eg poor memory, fatigue, work absence, 
accidents)
• identifying comorbid conditions – this may be aided by the Auckland Sleep Questionnaire, 
which is a validated screening tool.114
2.2.2.2 Acute insomnia
Treatment is focused on avoiding or withdrawing the precipitant, if possible. All patients should 
receive basic behavioural counselling on sleep hygiene and stimulus control. 
Drug treatment may be indicated as an adjuvant to non-drug therapies for acute insomnia that is 
severe, disabling and causing distress. Benzodiazepines and Z drugs are the most effective drugs.25 
The short-term use of benzodiazepines as hypnotic agents should only be one aspect of general 
management,25 with a clear endpoint of drug cessation once sleep patterns return to normal. 
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2.2.2.3 Chronic insomnia
Management of chronic insomnia starts with addressing any relevant, underlying problems that 
are present, such as: 
• pharmacological – prescribed drugs (eg some antidepressants, withdrawal of sedatives) and 
non-prescribed drugs (eg caffeine, alcohol)
• physical (eg pain, respiratory and cardiovascular disorders, neurological disorders, movement 
disorders, restless leg syndrome and other sleep disorders)
• psychiatric disorders (eg depression, anxiety, dementia and substance misuse)
• disruption of circadian rhythm (eg shift work). 
2.2.2.4 Non-drug interventions
First-line therapy for chronic insomnia should be non-drug interventions that are supported by 
evidence in achieving sustained improvements in sleep parameters.115,116 Interventions include:
• CBTs18,117 (eg stimulus control, sleep restriction therapy, relaxation techniques, cognitive 
therapy and sleep hygiene education)111
• brief behavioural therapy (ie modification of waking behaviours that affect the physiological 
systems regulating sleep)118–121
• exercise.122
Psychological and behavioural treatments administered weekly over a 4–8– week period have 
shown robust and stable improvements in sleep continuity for up to 2 years.123 These therapies 
are now available online, which has vastly improved access. 
Refer to Resource G for a GP guide to behavioural therapies for insomnia.
2.2.2.5 Drug therapy
For patients who continue to have insomnia that is sufficiently burdensome to warrant other 
interventions, reasonable approaches include continued behavioural therapies, medication or 
both.108 
Recommendations in guideline on the use of medication for chronic insomnia vary. This is 
primarily due to the lack of evidence from extended trials that adequately compare long-term 
risks and harms of these medications. Some guidelines suggest avoidance of hypnotic drugs as 
far as possible,102 while others make a considered judgement on the risks and benefits.68,108,113
The decision to treat chronic insomnia must weigh any potential serious side effects associated 
with pharmacologic therapy against potential health risks of not providing treatment. This 
includes decreased quality of life, increased risk for psychiatric comorbidities and SUD, and 
decreased performance. The approach should be individualised according to the patient’s values 
and preferences, the availability of advanced behavioural therapies, the severity and impact of the 
insomnia, and the potential benefits versus the risks, costs and inconveniences.108
Pharmacological treatment should be accompanied by specific patient education, regular review 
and continued effort to employ the lowest effective maintenance dosage of medication, and to 
taper medication when conditions allow.113
• Benzodiazepines – May have a place in the treatment of severe acute insomnia or 
treatment-resistant chronic insomnia. For patients with sleep onset insomnia, a short-acting 
medication is a reasonable choice for an initial trial of pharmacologic therapy. This may 
improve the insomnia with less residual somnolence the following morning. For patients with 
sleep maintenance insomnia, a longer-acting medication is preferable for an initial trial of 
pharmacological therapy.108 
• Z drugs – Have been shown to be effective in the treatment of insomnia in the short term. 
However, there is very limited evidence that they retain their efficacy during long-term 
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treatment.123 Z drugs are associated with issues relating to adverse events, rebound insomnia, 
development of tolerance and SUD, and need to be carefully monitored in individual patients.123 
Zolpidem’s black box warning states, ‘Zolpidem may be associated with potentially dangerous 
complex sleep-related behaviours which may include sleep walking, sleep driving and other 
bizarre behaviours. Zolpidem is not to be taken with alcohol. Caution is needed with other CNS 
depressant drugs. Limit use to four weeks maximum under close medical supervision’.124
Psychological and behavioural treatments produce comparable outcomes to Z drugs during 
active treatment and have better durability beyond the active administration of treatment.123
Prescription of zolpidem and zopiclone should be treated with the same precautions and 
patient management as benzodiazepines.102
• Melatonin – An endogenous hormone associated with the control of circadian rhythms and 
sleep regulation. Melatonin levels may be reduced in middle-aged and elderly patients with 
insomnia. Supplementation with melatonin has been shown to improve limited aspects of 
sleep in 30–50% of patients over 55 years of age.106,125,126 Data from clinical trials are variable. 
Some showed that some patients gain clinically significant improvements in quality of sleep 
and morning alertness with prolonged-release melatonin, but many patients in the clinical trials 
did not respond to treatment.35 Melatonin does not appear to be addictive or cause withdrawal 
effects when stopped.125 There are a lack of long-term study data.
At the time of writing, melatonin is available in Australia as a prolonged-release formulation for 
short-term treatment of primary insomnia, characterised by poor sleep quality in patients aged 
55 years or older.35 The recommended dose is 2 mg orally at bedtime, and at present, there is 
insufficient evidence to support treatment beyond 3 weeks.35
In a European campaign to reduce benzodiazepine and Z drug usage, the availability of 
prolonged-release melatonin was shown to positively contribute to success.127
• Other prescription medications – Includes antipsychotics (eg quetiapine, olanzepine). 
Studies demonstrating the usefulness of these medications for either short- or long-term 
management of insomnia are lacking. Furthermore, these agents have significant risks and 
therefore, their use in the treatment of chronic insomnia (without a relevant comorbid condition) 
cannot be recommended.107 Numerous other medications have a sedating effect, but are 
not recommended for routine use in patients with insomnia. These include antidepressants, 
diphenhydramine and antipsychotics.108
• Over-the-counter (OTC) medications – Such as antihistamines or antihistamine/analgesic 
type drugs, and herbal and nutritional substances (eg valerian) are not recommended in the 
treatment of chronic insomnia due to the relative lack of efficacy and safety data.
2.2.3 Resources
• Medical Journal of Australia supplement, Sleep Disorders: A practical guide for Australian health 
care practitioners, available at www.sleephealthfoundation.org.au/files/MJA%20Supplement/
MJA_Supplement_final.pdf
• Australasian Sleep Association, Insomnia, available at www.sleep.org.au/documents/item/355 
• Australian Prescriber, Cognitive behaviour therapy in medical practice, available at www.
australianprescriber.com/magazine/24/2/33/7
• Australian Psychological Society, Managing insomnia: What we’ve learnt in the last 10 years, 
available at www.psychology.org.au/inpsych/2014/april/bartlett
• RACGP Handbook of non-drug interventions (HANDI), Brief behavioural therapy for insomnia in 
adults, available at www.racgp.org.au/your-practice/guidelines/handi/interventions/mental-health/
brief-behavioural-therapy-for-insomnia-in-adults 
• South Australian kit – Insomnia management kit, available at www.sahealth.sa.gov.au/
wps/wcm/connect/public+content/sa+health+internet/clinical+resources/clinical+topics/
substance+misuse+and+dependence/sleep+problems+-+insomnia+management+kit
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2.3 Anxiety disorders
 Key points
• Anxiety disorders are common and exist as a spectrum of conditions that vary from mild to 
severe. 
• Comprehensive clinical assessment is the first step in management. Effective management 
requires obtaining a diagnosis, and recognising that patients may not present with a single 
disorder (eg patients may experience generalised anxiety, panic disorder as well as depression). 
• Where treatment is indicated:
 – First-line therapy for generalised anxiety disorder (GAD), panic disorder, and panic attacks 
should include CBT (due to its effectiveness at reducing the symptoms of anxiety in the short 
and long term. 
 – SSRI and SNRI medications are effective across the range of anxiety disorders and generally 
suitable for first-line pharmacological treatment of anxiety.
 – Short-term benzodiazepines as occasional adjunctive therapy may be effective at reducing 
worsening of symptoms that can occur in the first days to weeks of initiating antidepressant 
medication, and therefore aid adherence
 – Benzodiazepine use in anxiety disorders is mostly limited to severe or treatment-resistant cases. 
 – Patients who use two or more psychoactive drugs in combination (polydrug use) may be 
more vulnerable to major harms.
Evidence statements Grade
Rec 6 Cognitive behavioural therapy is recommended as one of the treatments of 
choice for generalised anxiety disorder, panic disorder, and panic attacks due to 
its effectiveness at reducing the symptoms of anxiety in the short and long term, 
although patient preference must be taken into consideration.64
A
Rec 7 Consider an selective serotonin reuptake inhibitor (SSRI) for first-line drug treatment, 
as SSRIs are effective across the anxiety and related disorders, in short and long 
term, and are generally well tolerated.128
A
Rec 8 Benzodiazepines have evidence of benefit in generalised anxiety disorder, social 
anxiety disorder and panic disorder, but not obsessive compulsive disorder or post-
traumatic stress disorder.94
A/B
To see the original source of the recommendations and grading, as well as supporting sources, click on the 
recommendation number in the left column.
2.3.1 Background
Anxiety disorders include GAD, panic disorder, OCD, PTSD, phobias and SAD.
In 2007, anxiety disorders were the most common self-reported mental disorder in Australia, 
affecting 14% of people aged 16–85 years.129 Anxiety disorders may be prominent in depressive 
conditions and other chronic health diseases. Anxiety and related disorders often become chronic.
Not all patients with anxiety symptoms require treatment. Anxiety symptoms exist on a continuum 
and many people with milder degrees of anxiety, particularly recent onset and association with 
stressful situations will recover without intervention.89 The need for treatment is determined by the 
severity and persistence of symptoms, the presence of comorbid mental or physical illness, the level 
of disability and the impact on social functioning. Treatment should aim to achieve full remission of 
symptoms and return of function, rather than just symptom improvement and distress reduction.130
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Randomised controlled trials across a range of anxiety disorders often demonstrate a high placebo 
response, which indicates that non-specific effects can play a large part in improvement.128
Approaching anxiety disorders systematically involves identifying and treating any comorbidities, 
providing patient education and appropriate psychological and pharmacological interventions. These 
should be evidence-based and patients should receive ongoing monitoring to determine whether 
treatment aims are being achieved.130
2.3.2 Management of anxiety in general practice
For a comprehensive review of management of anxiety disorders, GPs are advised to review 
individual clinical guidelines.
Benzodiazepine use in anxiety disorders is mostly limited to severe, or treatment-resistant, cases. 
Patients with a history of significant mental illness who use two or more psychoactive drugs 
(polydrug use) may be more vulnerable to major harms. Significant caution should be taken if 
prescribing benzodiazepines to patients with comorbid alcohol or SUDs, or polydrug use. GPs 
should consider seeking specialist opinion in the management of these patients.
2.3.2.1 Assessment and diagnosis
Comprehensive clinical assessment is the first step to developing a diagnosis and determining 
the patient’s level of disability. In milder, recent onset anxiety disorders, consider ‘watchful waiting’ 
(support, addressing social factors and monitoring).89
It is important to detect comorbid depression. Depression should be treated if depressive 
symptoms are moderate or severe. 
Most guidelines recommend CBT as first-line non-drug therapy, while SSRIs and SNRIs are 
the drugs of first choice. Benzodiazepine recommendations are generally limited to severe 
or treatment-resistant cases. However, the efficacy of psychological and pharmacological 
approaches is similar in the acute treatment of mild to moderate anxiety disorders.89,94,131
The selection of an initial treatment modality should be guided by considerations including 
the patient’s needs and preferences, the risks and benefits for the patient, the patient’s past 
treatment history, the presence of comorbid general medical and other psychiatric conditions, 
cost and the local availability of evidence-based psychological interventions. 
Where appropriate and available, patients should be offered a choice of evidence-based 
treatment approaches.
2.3.2.2 Cognitive behavioural therapy
All major guidelines recommend CBT as the first-line intervention for anxiety disorders.64,89,94,130
CBT is a multimodal intervention. Specific techniques used in the therapy include education, 
self-monitoring, relaxation training, cognitive restructuring, exposure to imagery and anxiety-
producing situations, and relapse prevention. CBT has been shown to be an effective stand-
alone treatment for GAD.132 Comorbidity does not decrease the treatment effects of CBT. 
CBT for most anxiety, and related disorders, can be delivered effectively in individual or group 
therapy formats.130 There are also an increasing number of self-directed formats that require 
minimal or no therapist contact, which have been shown to be effective.130 These include 
bibliotherapy (self-help books) and internet or computer-based programs.133,134
A combination of medication and cognitive behaviour or exposure therapy has been shown 
to be a clinically desired treatment strategy.94 However, combination therapy results have 
been conflicting,135,136 and results vary for different anxiety disorders. While current evidence 
does not support the routine combination of CBT and pharmacotherapy as initial treatment 
for all anxiety disorders, there is support for combined use in panic disorders, with or without 
agoraphobia.137,138
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Benzodiazepines are generally avoided in patients with anxiety disorders who are undergoing 
CBT. This is due to their potential interference with motivation and learning, which are required 
for CBT to be effective. Some authors are now challenging this,73 however there is sparse trial 
evidence to support a conclusion. More research is needed to ascertain if these treatment 
modalities can be combined effectively.
CBT protocols for anxiety usually involve 10–14 weekly sessions, but briefer strategies of 6–7 
sessions have been shown to be as effective. Unfortunately, a lack of access to trained clinicians 
may be an issue in some areas and therefore lead to the majority of patients with anxiety being 
treated with medications.139 Online CBT programs have shown efficacy, and may be suitable for 
patients who cannot access face-to-face therapy, or who prefer treatment in their own homes, in 
their own time.
2.3.2.3 Antidepressants
Note that anxiety disorders show a strong placebo response, especially at mild to moderate levels of 
symptom severity.89 If pharmacotherapy is indicated, the SSRIs and SNRIs are preferred agents.140 
Tricylic antidepressants (TCAs) and monoamine oxidase inhibitors (MOAI) are other alternatives.
Although preferred over benzodiazepines, there are limited studies comparing head-to-head 
effectiveness with antidepressants. Reviews of the studies performed suggest comparative 
effectiveness of benzodiazepines to older and new antidepressants.141–142
In trials of benzodiazepines and newer antidepressants, benzodiazepines have demonstrated 
comparable or greater improvements with fewer adverse events in patients suffering from GAD or 
panic disorder.141 Efficacy of benzodiazepines for panic disorder is comparable to SSRIs, SNRIs 
and TCAs.143 Similarly, the incidence of withdrawal symptoms from antidepressants seems to 
occur at similar levels to benzodiazepines.96
Reviewers have suggested the major change in prescribing pattern from benzodiazepines to 
newer antidepressants in anxiety disorders has occurred in the absence of comparative data of 
high-level of proof.141,144
However, SSRIs and SNRIs remain recommended first-line treatments by international guidelines 
for anxiety disorders.143
Short-term benzodiazepines as occasional adjunctive therapy may be effective at reducing 
worsening of symptoms that can occur in the first days to weeks of initiating antidepressant 
medication.
2.3.2.4 Benzodiazepines
Benzodiazepines are not indicated for ‘mild’ anxiety. 
Benzodiazepines may be used (as monotherapy or in combination with antidepressants) for 
patients with very distressing or impairing symptoms whom rapid symptom control is critical.143 
Benzodiazepines have evidence of benefit for GAD, social anxiety disorder and panic disorder, 
but not for OCD or PTSD.64,94 Trials have been conducted with clonazepam, diazepam and 
lorazepam, which have demonstrated the efficacy of these compounds in managing panic 
disorder clonazepam for SAD, diazepam and bromazepam for GAD.3
The benefit of a more rapid response to benzodiazepines must be balanced against the 
possibilities of troublesome side effects (eg sedation) and physiological dependence that may 
lead to difficulty discontinuing the medication.143 Note that:
• Due to its rapid onset and offset of action, alprazolam is the benzodiazepine most commonly 
prescribed for panic disorders. However, in a meta-analysis, it has not been shown to have 
better efficacy than other benzodiazepines for panic disorders, and it does have a greater risk 
of dependence, problematic use and withdrawal.145
• Although tolerance is less of an issue with anxiety, patients are at risk of dependence and 
other harms (eg depression, increased anxiety, accidents).
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When benzodiazepines are prescribed short term for severe anxiety, they are generally used in 
conjunction with other interventions including counselling or antidepressants (where appropriate), 
to reduce the risk of symptom recurrence89 or to alleviate and prevent the worsening of anxiety130 
that may occur at the start of antidepressant therapy.146 
Rarely, ongoing therapy with benzodiazepines may be necessary in patients with severe, 
treatment-resistant anxiety. Although concerns have surrounded the risks of tolerance and SUD 
with long-term use of benzodiazepines, there is little evidence of tolerance to their anxiolytic 
effects.35 Problematic use is a risk in those with a history of SUD, but is otherwise uncommon.147 
The decision to treat chronic anxiety with benzodiazepines must weigh the risks and benefits of 
benzodiazepine therapy. Concerns about potential problems in long-term use should not prevent 
their use in patients with persistent, severe, distressing and impairing anxiety symptoms,147 
or in patients who are resistant to, or cannot tolerate, multiple first-line therapies.130 Ongoing 
supervision is required.
2.3.3 Resources
• Australian Prescriber, Cognitive behaviour therapy in medical practice, available at www.
australianprescriber.com/magazine/24/2/33/7
• RACGP Handbook of non-drug interventions (HANDI), Depression and anxiety: internet based or 
computerised CBT (iCBT or CCBT), includes relevant website links, available at www.racgp.org.
au/your-practice/guidelines/handi/interventions/mental-health/internet-based-or-computerised-
cbt-for-depression-and-anxiety
2.4 Alcohol withdrawal
 Key points
• Benzodiazepines are an important component of alcohol withdrawal programs, but not every 
patient requires medication.
• Benzodiazepines are generally only used as first-line options for acute treatment in a controlled 
environment for alcohol withdrawal.
Evidence statements Grade
Rec 9 Benzodiazepines (eg diazepam, oxazepam) are the drugs of choice for treatment of 
acute alcohol withdrawal (including alcohol withdrawal delirium), but for a maximum 
of 7 days.148
A
To see the original source of the recommendations and grading, as well as supporting sources, click on the recommendation 
number in the left column.
2.4.1 Background
Alcohol dependence is characterised by craving, tolerance, preoccupation with alcohol and 
continued drinking in spite of harmful consequences (eg liver disease). From a clinical perspective, 
alcohol dependence can be subdivided into mild, moderate or severe categories. People with mild 
dependence (based on alcohol dependence assessment tools) usually do not need assisted alcohol 
withdrawal. People with moderate dependence usually need assisted withdrawal, which can be 
managed in a community setting. People who are severely alcohol dependent need assisted alcohol 
withdrawal, typically in an in-patient or residential setting.149
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The onset of alcohol withdrawal is usually 6–24 hours after the last drink. In some severely 
dependent drinkers, withdrawal can occur while the patient is still intoxicated due to drops in blood 
alcohol level.30
About 95% of people with alcohol dependence can stop drinking without major withdrawal 
symptoms (ie delirium, seizures).30 Supportive care alone is often effective in minor alcohol 
withdrawal. Medication may not be necessary with lower daily alcohol consumption or for periodic 
drinkers. Seizures (usually a single episode) occur in approximately 5% of people with alcohol 
dependence when withdrawing from alcohol, and delirium tremens are typically seen in the most 
severe forms of alcohol withdrawal.30
2.4.2 Management of alcohol withdrawal in general practice
Alcohol dependence may require complex multidisciplinary therapy, including social support 
systems.
2.4.2.1 Assessment
Formal assessment tools can help determine if the patient is best suited to alcohol withdrawal in 
the primary care or specialist alcohol services setting. 
The routine screening tool is the Alcohol Use Disorders Identification Tool (AUDIT or AUDIT-C) 
(refer to Resource F). Other tools include Severity of Alcohol Dependence Questionnaire (SADQ) 
to assess the severity of dependence; and the Clinical Institute Withdrawal Assessment of 
Alcohol State, revised (CIWA-Ar) or Alcohol Withdrawal Scale (AWS) for severity of withdrawal.
Patients may be suitable for home alcohol withdrawal if they:
• have no history of seizures or delirium tremens
• do not pose a suicide risk
• have social support
• show no significant polydrug misuse 
• are not dependent on benzodiazepines.149
2.4.2.2 Assisted withdrawal approaches
When conducting an assisted withdrawal from alcohol, there are three commonly used 
approaches:30
• benzodiazepine loading – involves giving a large dose (up to 80 mg of diazepam) on day one 
in an in-patient setting, and then no further benzodiazepines 
• tapering dose regimes – a predetermined (fixed) dose of benzodiazepine is administered in 
tapering doses over 2–6 days 
• symptom-triggered sedation – doses of benzodiazepine are administered according to the 
severity of withdrawal symptoms.
There is limited evidence for selecting one approach over another, however, the first approach is 
more suited to an in-patient setting. In a comparison of fixed schedule and symptom triggered 
regimens, the latter two approaches were favoured.150
2.4.2.3 Benzodiazepines
Benzodiazepines have been shown to be one of the most effective drug classes in the 
management of alcohol withdrawal syndrome. The rationale of the use of benzodiazepines is to 
modulate CNS hyperactivity due to the alcohol withdrawal, by interacting with GABA receptors.150
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A 2010 systematic review found benzodiazepines have a protective benefit against alcohol 
withdrawal symptoms, in particular seizures (when compared to placebo), and have a potentially 
protective benefit for many outcomes when compared with other drugs. This review did not find 
a statistical significance among the performance of different benzodiazepines.150
Avoid prescribing benzodiazepines to patients who are dependent on alcohol before enrolling 
them in, or referring them to, community withdrawal. Prescribing a ‘small dose of diazepam’ to 
help patients who claim to have stopped or reduced their alcohol consumption should also be 
avoided. Benzodiazepines can increase alcohol cravings and relapse rates.151
2.4.2.4 Baclofen and carbamazepine
Baclofen has been used to rapidly reduce symptoms of severe alcohol withdrawal syndrome. 
However, the evidence for recommending baclofen is insufficient to support its use in most 
situations.152 Carbamazepine has been effective in trials, but its role is as yet unclear.153 These, 
and several other drugs, may be useful adjuncts but cannot currently be recommended for 
clinical monotherapy.
2.5 Acute mania (bipolar disorder)
 Key points
• Benzodiazepines can be used to calm or sedate and control aggressive, overactive or disturbed 
behaviour in manic episodes until a mood stabiliser takes effect.
2.5.1 Background
Bipolar disorder is a recurrent, disabling condition. Patients experience periods of mania or 
hypomania, depression and mixed episodes or ‘dysphoric mania’ (both manic and depressive 
symptoms). Bipolar disorder is commonly subdivided into bipolar disorder I (at least one manic 
episode) and bipolar disorder II (hypomania and depression only).154
Bipolar disorder has a lifetime prevalence of up to 1.6%.154
2.5.2 Management of manic episodes in general practice
For acutely manic patients, referral to a specialist psychiatric service for in- or out-patient care is 
recommended.154
There are two components to managing acute mania with medication:154
• mood stabilisation with drugs (eg lithium, sodium valproate, carbamazepine) or one of the new 
second-generation antipsychotics
• adjunct therapy to control acute agitation while mood stabilisers start to take effect (about 1 week 
for most patients).
Adjunct therapy usually consists of an antipsychotic or benzodiazepine (or a combination). This 
calms or sedates the person with mania as a temporary measure, until the mood stabiliser starts to 
be effective.154
In most cases, the benzodiazepine or antipsychotic would be withdrawn once the acute episode 
has resolved, and then only the mood stabiliser continued. It is common practice to taper down and 
discontinue benzodiazepines within 2–3 weeks of achieving adequate symptom control in mania.154
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2.6 Epilepsy
 Key points
• Clonazepam has been the most commonly used benzodiazepine for the long-term treatment of 
epilepsy.
Evidence statements Grade
Carbamazepine, sodium valproate, lamotrigine and oxcarbazepine can all be regarded as first-
line treatments for partial and secondary generalised seizures.155
A
Sodium valproate and lamotrigine are drugs of choice for primary generalised seizures and 
should also be prescribed if there is any doubt about the seizure type and/or syndrome 
classification.155
A
2.6.1 Background
Epilepsy affects approximately 224,000 Australians (1 in 100) and is the most common chronic brain 
disorder. Nearly 10% of Australians will have a seizure during their lifetime, and one-third of those will 
be diagnosed with epilepsy.156
2.6.2 Management of epilepsy in general practice
In acute epilepsy, diazepam, lorazepam and midazolam are the drugs most commonly used to 
control prolonged seizures.155
In chronic epilepsy, the use of benzodiazepines is now rare. They have limited usefulness in long-
term management due to the rapid development of tolerance to anticonvulsant effects and the 
associated side effects (eg sedation and psychomotor slowing).155
Benzodiazepines are considered adjunct to standard antiepileptic drugs, and used when these have 
failed to achieve acceptable control.155
Benzodiazepines for seizure prophylaxis should only be used on advice from a specialist neurologist 
or paediatrician. 
Prescription of benzodiazepines for epilepsy within Australia requires an authority prescription. Take 
care with monitoring and detecting problematic use.
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3. Contraindications and precautions 
in special groups
3.1 Overview
Benzodiazepines should not be prescribed, or prescribed with extreme caution, to:
• women who are, or may be, pregnant
• patients with active SUDs, including alcohol (unless it is a part of an alcohol withdrawal program)
• patients with medical or mental health conditions that may be worsened by benzodiazepines (eg 
fibromyalgia, chronic fatigue syndrome, depression, bipolar disorder or impulse control disorders)
• patients being treated with opioids for chronic pain or addiction
• patients experiencing grief reactions, as benzodiazepines may suppress and prolong the grieving process.
3.2 Paediatric patients
Benzodiazepines are generally not recommended for use in children. 
Benzodiazepines may cause aggression, anxiety, nervousness and disinhibition in children and 
adolescents. Routine use for anxiety disorders cannot be recommended.157
The use of benzodiazepines in the paediatric population is clinically limited.158 Control of acute febrile or 
epileptic seizures is the primary indication. Seizures commonly occur in the paediatric populations and 
while most self-terminate within 5 minutes, those lasting longer may warrant medication to control the 
seizure and avoid status epilepticus (and neurological compromise).159 Buccal or intranasal midazolam 
and buccal or rectal diazepam are effective for the treatment of acute seizures in children.160 
Note that children may have access to benzodiazepines through their parents, their peers or potentially 
via the internet.
3.3 Women who are pregnant or breastfeeding
Benzodiazepines should be avoided during pregnancy and breastfeeding. Non-drug approaches for 
anxiety and insomnia are preferred. 
Women who become pregnant and are already taking benzodiazepines should be tapered down to the 
lowest effective dose, or have it completely withdrawn. With good withdrawal management, there is no 
evidence that withdrawal is likely to cause problems with the pregnancy.38
As benzodiazepines are highly fat soluble, they rapidly cross the placenta. Benzodiazepines taken early 
in pregnancy have been linked to congenital abnormalities (eg oral clefts, pyloric stenosis and alimentary 
tract atresia).161 This association is considered controversial, and data published in the last 10 years 
do not indicate an absolute contradiction to benzodiazepines in the first trimester.162 However, avoiding 
benzodiazepines or tapering off (completely or to the lowest possible dose) is recommended.163
Benzodiazepines taken later in pregnancy (late third trimester), during labour or while breastfeeding are 
associated with risks to the fetus/neonate. They can cause neonatal drowsiness, respiratory depression, 
poor temperature regulation, poor feeding, hypotonicity (‘floppy baby syndrome’) and neonatal 
withdrawal syndrome.35,164
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Neonates exposed in utero may benefit from breastfeeding to reduce neonatal withdrawal.165,166
Where a hypnotic is necessary, zolpidem has been suggested.163 However, two studies have reported 
an association between zolpidem and an increased risk of adverse pregnancy outcomes, including 
small-for-gestational age, low birth weight and preterm deliveries.35
Note that women misusing benzodiazepines during pregnancy may also be using other drugs including 
alcohol.
3.4 Older patients
Patients over 60 years of age have the most significant risk of harm with benzodiazepine use (particularly 
if the patient has additional risk factors for cognitive or psychomotor adverse events) relating to falls, 
fractures and cognitive decline.50,167
Benzodiazepines are used by approximately 15% of people over 65 years of age in Australia.168 Use of 
benzodiazepines in this age group is often chronic, despite the combination of harms associated with 
long-term, physiological changes with ageing (eg hepatic metabolism impairment) and the potential for 
multiple coexisting pathologies and drug interactions. 
Older patients are more sensitive to the CNS depressant effects of psychotropic medications including 
benzodiazepines. This may result in confusion, night wandering, amnesia, pseudo-dementia38 (refer to 
1.5.1.1 Cognitive impairment), ataxia, falls and fractures. 
In older patients, all psychotropic medications have been associated with an increased risk of fractures. 
The risk increase is moderate and similar across all psychotropic medications. One meta-analysis 
demonstrated that the relative risk of fractures was 1.34 (95% CI=1.24–1.45) for benzodiazepines, 1.60 
(95% CI=1.38–1.86) for antidepressants, 1.59 (95% CI=1.27–1.98) for antipsychotics and 1.38 (95% 
CI=1.15–1.66) for opioids.169
Older people presenting with anxiety symptoms should be treated initially with antidepressants and 
psychological therapies, rather than benzodiazepines.170
Sedative use for insomnia has shown statistically significant improvements in sleep, but the magnitude 
of effect is small and the benefits of these drugs may not justify the increased risk.167 Clinical judgement 
is required.
Zolpidem and other Z drugs have become preferred drugs to manage insomnia. They are widely 
used among older adults because of perceived improved safety profiles compared with traditional 
benzodiazepines. However, accumulating data in recent years in patients over 65 years of age suggest 
possible safety concerns of these medications (zolpidem specifically) including effects on balance and 
memory and increased fracture risk. Until better studies or pharmacovigilance data become available 
to guide patient selection for prescribing zolpidem and other Z drugs, judicious use of these hypnotic 
agents in older adults is warranted.171
Reduction in the use of benzodiazepines in the elderly is a worthwhile goal if this can be achieved 
without psychotropic substitution. Older patients require planned interventions including CBT and 
stepped-dose reduction to reduce long-term benzodiazepine prescription.
3.4.1 Patients living in residential aged care facilities
Prescribing for patients living in residential aged care facilities (RACFs) (and other residential facilities) 
carries all of the risks associated with benzodiazepine use in older patients and presents further 
special difficulties. 
Accreditation of RACFs has resulted in a heightened awareness of the facility’s responsibilities for 
quality use of medicines. 
Medication may occasionally be required to control anxiety, agitation or other disturbed behaviours. 
Staff should be knowledgeable in the appropriate management of challenging behaviours. Where 
staff have received education in geriatric care, and where the organisational culture is supportive, 
there is less use of benzodiazepines.170
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In a study of sleep quality in patients using benzodiazepines in RACFs, patients who were long-term 
users slept more poorly than those who were non-users. The effects were worse in patients taking 
long-acting benzodiazepines.172 Although patients, doctors, nursing staff and families often fear the 
consequences of benzodiazepine withdrawal in older patients, there is no evidence that patients 
experience an ‘unmasking’ of depression or anxiety.173
Successful reduction in the rates of benzodiazepine use in RACF patients results in benefits (eg 
increased mobility and alertness, reduced incontinence and improved wellbeing).174 Discontinuation 
of benzodiazepines can often be achieved gradually in RACFs, providing patient, family and nursing 
staff are cooperative.175
Benzodiazepines have been associated with increased fracture risk in patients living in RACFs. 
However, a reduction in benzodiazepine use may not lead to a decrease in fracture risk if substitution 
medications are used.176 Reduction in benzodiazepine use for RACF patients is worthwhile if it can 
be achieved without psychotropic drug substitution.
3.5 Patients with chronic non-malignant pain 
Use of multiple psychoactive medications (including benzodiazepines) is common in people who have 
chronic non-malignant pain (CNMP). Where available, it is advisable that a specialist pain or addiction 
service becomes involved in the care of these patients.177
The relationship bewteen pain, mental illness, SUD and dependence, and the social environment are 
complex. A range of addictive drugs has been misused in the context of CNMP including alcohol, 
benzodiazepines, cannabis, opioids and stimulants. Estimates of dependence (on any drug including 
alcohol) among people with chronic pain varies. In patients on long-term opioids, prevalence of DSM-5 
opioid-use disorder may be as high as 26%.178
Benzodiazepines have little place in the management of chronic musculoskeletal pain. There is sparse 
evidence that these are clinically effective as muscle relaxants. The decision to use benzodiazepines 
in the context of multiple sclerosis or muscle disorders should be taken on a case-by-case basis with 
specialist consultation.
There is a strong association between sleep disturbance and CNMP. Evidence suggests that pain and 
sleep exist in a complex relationship in which pain causes sleep disturbance and sleep disturbance 
intensifies pain. This association can impair a patient’s daily function and decrease quality of life.179 
Assessment of a patient’s sleep disturbance involves review of the contributing impacts of lifestyle, 
comorbid anxiety or depression, and uncontrolled pain to focus management on an individualised basis.
Benzodiazepines present additional risk for someone being prescribed opioids in terms of overdose 
(fatal and non-fatal) and psychomotor impairment. Driving presents a particular risk. 
CBT can be useful in addressing emergent anxiety symptoms. Simple reassurance and attention to 
sleep hygiene can be effective with managing the emergent sleep disturbance. 
3.6 People with comorbidity – Mental illness 
and problematic drug use
For the purposes of this guide, comorbidity will refer to situations where people have problems related 
both to their use of substances (from hazardous through to harmful use and/or dependence) and to their 
mental health (from problematic symptoms through to highly prevalent conditions such as depression 
and anxiety, and to the low-prevalence disorders such as psychosis).177
While it is common to refer to a patient’s psychiatric disorder or SUD as primary or secondary, this may 
have limited clinical use. It is important to establish whether substance use may be contributing to the 
patient’s psychiatric problems.177
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Symptoms of psychiatric disorders (eg depression, anxiety and psychosis) in patients misusing drugs 
and/or alcohol are the rule rather than the exception. In addition, these psychiatric disorders increase 
the risk of harmful substance use and patients may be physically unwell. These patients are often the 
most challenging to engage and treat, and their prognosis is frequently poor.177
The number of placebo-controlled trials is small, and there remains little evidence to guide treatment.177 
Available evidence suggests that a substantial proportion of patients with a comorbid SUD mental 
illness who are treated with benzodiazepines will develop some form of dependence. Therefore, 
benzodiazepines should largely be avoided, except in the context of withdrawal.180
Patients with personality disorders have a higher risk of dependence and dose escalation, hence 
benzodiazepines should be avoided in this group.
3.7 Patients who misuse alcohol and/or other 
drugs (prescribed and illicit)
Patients who have problematic drug use belong to a complex group at high risk of adverse events. 
A common drug combination that should be noted is alcohol and benzodiazepines.180 When 
benzodiazepines are combined with other CNS depressants (eg alcohol, opioids), patients are at 
risk of respiratory depression, heavy sedation, coma and death. It has been reported that the use of 
antidepressant drugs in combination with benzodiazepines may also increase the risk of overdose, 
especially in the case of older TCAs.181 Alcohol and benzodiazepines can produce cross tolerance, and 
regular use of both can make withdrawal more severe and/or protracted.180
Apart from the risk of overdose, harms associated with polydrug use (particularly among people who 
inject drugs) include a higher rate of infectious and metabolic complications, as well as psychiatric, 
social and forensic consequences, with an increasing cost to society.182,183 People who are participating 
in medication-assisted opioid dependence treatment, and who take benzodiazepines regularly or 
intermittently, tend to do very poorly, with a higher risk of adverse outcomes.21
There is little evidence to guide practitioners in the management of this often difficult-to-treat 
population. However, when treating polydrug users, it is recommended not to initiate prescription of 
benzodiazepines. For polydrug users already taking them, it is recommended to reduce and cease 
prescription of benzodiazepines in a supervised manner.153
Therapeutic monitoring and prescribing should only occur if GPs have extensive experience in addiction 
medicine, or in conjunction with specialist supervision. When working with known polydrug users, it 
is essential to collaborate with local drug and alcohol services, and to provide clear guidelines on the 
accepted harm-minimisation strategies. Clear boundaries are crucial.
Maintenance benzodiazepine prescribing in illicit drug users cannot be recommended on the basis of 
existing evidence. Although it may reduce illicit benzodiazepine use in some patients,153 it may not be 
in the best interests of the patient or the wider community. The very rare exception would be under 
explicit agreement concerning specified short-term indications (such as outpatient alcohol withdrawal) 
as advised by a drug and addiction medicine specialist with daily, or at most weekly, dosing at a 
nominated pharmacy and monitoring with urinary drug test. Drug screens may be useful to monitor 
other benzodiazepines and drug use, especially in this population. 
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3.8 Prescribing to patients who drive
Summarising the extensive literature on benzodiazepines and driving, the risk of accident increases 
proportionally to dose. However, there is no dose without increased risk – including stable, longer term 
dosing. Risk is highest at initiation, with long-acting benzodiazepines and when benzodiazepines are 
taken with other sedatives, especially alcohol.
Benzodiazepines have especially been shown to impair vision, attention, information processing, 
memory, motor coordination and combined-skill tasks. All drivers should be advised of increased crash 
risk when taking benzodiazepines. Patients who experience any degree of sedation should be cautioned 
not to drive.
According to Austroads, a person is not fit to hold an unconditional licence if they have an alcohol 
disorder or other SUD (eg substance dependence, heavy frequent alcohol or other substance use) that 
is likely to impair safe driving.184
The state or territory driver licensing authority may consider a conditional licence. This is subject to 
periodic review, taking into account the nature of the driving task and information provided by the 
treating doctor as to whether the following criteria are met:184
• the person is involved in a treatment program and has been in remission* for at least 1 month
• there is an absence of cognitive impairments relevant to driving
• there is absence of ‘end-organ effects’ that impact on driving.
* Remission is attained when there is abstinence from the use of impairing substance(s) or where substance use has 
reduced in frequency to the point where it is unlikely to cause impairment. Remission may be confirmed by biological 
monitoring for the presence of drugs.
Some patients with SUD will continue to drive after being warned not to do so. If GPs are aware that a 
patient continues to drive in a dangerous way, they should: 
• more strongly recommend the patient stops
• advise the patient that the GP has an obligation to report behaviours that are dangerous to the 
patient and others
• consider reporting dangerous behaviour to state or territory licensing authorities. 
This is a difficult situation as it will damage the doctor–patient relationship. However, in some cases the 
risk of damaging the relationship is outweighed by the risk of the patient (and others) being hurt or killed. 
If in doubt, contact your medical indemnity provider.
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4. Duration of benzodiazepine therapy
4.1 Optimal duration of therapy
Guidelines and formularies typically give durations of 1–4 weeks for benzodiazepine therapy, depending 
on the indication. Short-term therapy is generally advised to reduce the risk of dependence and 
withdrawal, as well as other potential harm such as cognitive impairment. Short-term therapy does not 
reduce the risk of accidents or falls. 
Dependence is recognised as a risk in some patients who receive treatment for longer than 1 month, 
and health professionals should be conscious of this when considering the relative benefits and risks of 
treatment.25
The 1–4 week time frame is not based on risk–benefit data; rather that no substantive placebo-
controlled trials of hypnotics have been carried out for longer than a few weeks. The available evidence 
does not suggest there is an unfavourable risk–benefit transition at 3–4 weeks for any agent.101
Patients who are prescribed benzodiazepines for problems relating to anxiety or sleep usually do 
not escalate their doses even over a lengthy period of use.185 A 2013 study found most patients use 
benzodiazepines according to guidelines, and only 0.9% ended up as excessive users after 3 years.76 
Excessive use occurred mostly in individuals with alcohol and drug histories.
Lacking the means to determine the optimal duration of therapy, a rational approach is to allow the 
duration of treatment to be determined by a series of risk–benefit decisions and shared decision making, 
with periodic trials of tapering and discontinuing medication to determine whether continued therapy 
is indicated.101,186 This approach provides an ‘exit strategy’ and thereby addresses concerns that once 
started, hypnotic therapy could be unending.101
Clinical discipline and accountable prescribing are essential when considering long-term benzodiazepine 
therapy.
4.2 Prescribing benzodiazepines for longer 
than 4 weeks 
While the optimum duration of therapy is not clear from the evidence, there are very few specific 
indications for the chronic use of benzodiazepines. The decision to prescribe benzodiazepines longer 
term should be uncommon and made with caution. Assume that all patients are at risk of dependence.
Benzodiazepines may be used for longer than 4 weeks in selected cases. Patients who are terminally ill 
or severely handicapped, where it is clear that the benefits outweigh the risks and side effects, or where 
a detailed individual assessment has been made with a patient and their family or carers. 
Benzodiazepines may also be indicated in certain neurological disorders (eg stiff person syndrome) and in 
neuromuscular conditions where spasticity is problematic. Increasingly, benzodiazepines are being used 
off-label for indications (eg drug-induced movement disorders, restless legs syndrome, acute psychotic 
agitation, terminal agitation, nausea and vomiting, intractable pruritus and intractable hiccup).187 
Recommendations supporting the long-term use of benzodiazepines for any mental illness or chronic 
sleep disorder come from evidence limited to shorter time frames. Hence, longer duration of prescribing 
should occur in conjunction with heightened clinical surveillance.
The principles of universal precautions apply. Ensure a clear diagnosis is formed, comprehensive 
assessment is undertaken, clear treatment plan is discussed with the patient and information is provided 
to the patient to enable informed consent. The negotiated treatment plan will have clearly defined time 
limit and goals of treatment.
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4.3 Rationale for long-term benzodiazepine 
prescribing
Benzodiazepines are generally regarded by clinical practice guidelines as a short-term therapeutic 
option. Long-term use, beyond 4 weeks, is not generally advocated by clinical practice guidelines, 
hence long-term therapy should be should be uncommon and made with caution.
Prescribing benzodiazepines, like other aspects of clinical practice, should be based on thoughtful 
consideration of the likely risks and benefits, and the risks and benefits of alternative interventions. This decision 
should be made in conjunction with the patient and their carers, where appropriate.100 Benzodiazepines may 
be prescribed longer term where:
• patients do not respond to, or cannot tolerate, numerous first-line therapies130,188
• use is intermittent 
• specialists make a recommendation and are able to provide a rationale of therapy.
For some patients, benzodiazepine alternatives fail, have limited benefit, are unavailable or clinically 
inappropriate. If there is no history of drug dependence, positive indicative ‘lifestyle’ factors are present 
and a clinical decision for benzodiazepine treatment can be justified, then long-term therapy should 
not necessarily be regarded as a deviation from good clinical practice.25 Supervised benzodiazepine 
treatment may remain an acceptable long-term therapeutic option for some patients.
4.4 Management of long-term benzodiazepine 
prescriptions
Many patients are able to safely take short courses of benzodiazepines, or to use them intermittently 
longer term, on a ‘as required’ basis and to stop them when no longer needed.25,113
In a situation where the clinical decision is that the ongoing use of a benzodiazepine is the most 
appropriate management, this requires ongoing monitoring of health outcomes and continuing vigilance 
for potential hazards throughout treatment.25
The responsible specialist or GP should clearly outline a prescribing plan that should be documented in 
the patients’ notes or management plan.
The prescribing plan may include instructions that:
• regular prescription reviews take place 
• no repeat prescriptions will be made without face-to-face contact
• all prescriptions will be made by one doctor within a single practice
• one pharmacy will dispense all medication.
Benzodiazepine prescriptions should be at the lowest effective dose and given intermittently, with regular 
reviews of the treatment plans and regular attempts at withdrawal. 
At the time of benzodiazepine prescription renewal or medication review, GPs should continue to 
discuss the risks of long-term benzodiazepines and the benefits of discontinuation (eg cognition, mood, 
sleep and energy level) and advise the patient to reduce or discontinue the benzodiazepines if there are 
issues. GPs should document this communication.
Patients should be monitored closely for problematic use or any therapeutic dose dependence behaviour. 
Any escalation of dose or inappropriate use would lead to a complete review of prescribing and attempted 
withdrawal of benzodiazepine, along with a review of alternative therapy.
Refer to Resource E.2 for an example of a prescription plan/agreement.
All GPs should develop strategies to manage inappropriate requests for benzodiazepines.
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5. Discontinuing benzodiazepines
5.1 Discontinuing after short-term use
For patients on less than 4 weeks of benzodiazepine therapy, it should be possible to stop medication 
without tapering. Caution should be exercised with patients who are at risk of seizures.
5.2 Discontinuing after longer term use – 
Withdrawal
Withdrawal is possible for most patients on longer term benzodiazepines, although the process of 
reduction may be difficult and lengthy. The withdrawal process is aided by a good therapeutic alliance 
between the GP and patient, with specialist support where needed. Discontinuation is usually beneficial 
as it is followed by improved psychomotor and cognitive functioning, particularly in the elderly.189 Up to 
15% of patients who experience withdrawal will go on to have protracted symptoms lasting months to 
years.2
Withdrawal strategies will vary with the type of dependence (therapeutic dose, prescribed high dose, 
recreational high dose or polydrug). Withdrawal symptoms are highly variable and each patient will need 
tailored withdrawal management that will also address any underlying problems. Withdrawal symptoms 
may appear in 1–2 days for agents with shorter half-lives, but may not appear until 3–7 days for agents 
with longer half-lives.
Table 4. Acute withdrawal symptoms
Anxiety symptoms
Distorted perceptions
Major incidents 
Mainly when high doses 
are stopped abruptlyPsychological Physical
• Anxiety
• Panic attacks
• Insomnia
• Poor memory
• Depression
• Paranoia
• Intrusive memories
• Cravings
• Nightmares
• Excitability
• Agoraphobia
• Social phobia
• Obsessions
• Rage, aggression
• Irritability
• Agitation
• Tremor
• Headache
• Weakness
• Dizziness
• Nausea
• Vomiting
• Diarrhoea
• Constipation
• Palpitations
• Rashes
• Tingling, numbness, 
altered sensation
• Fatigue
• Flu-like symptoms
• Hypersensitivity to 
sound, light, touch, 
taste
• Abnormal body 
sensation eg itching, 
pain, stiffness, blurred 
vision, paraesthesia, 
muscle twitching, 
tinnitus, burning 
sensations
• Feeling self or world 
to be abnormal 
(depersonalisation or 
derealisation)
• Fits (1–2% of patients)
• Delirium (rare)
• Transient 
hallucinations (visual, 
tactile, auditory) or 
illusions (rare)
• Psychosis (very rare)
Reproduced with permission from Ford C, Law F. Guidance for the use and reduction of misuse of benzodiazepine 
prescribing and other hypnotics and anxiolytics in general practice. 2014.38
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Protracted benzodiazepine withdrawal symptoms include:30
• anxiety
• depression
• diarrhoea, constipation, bloating
• insomnia
• irritability
• muscle aches
• poor concentration and memory
• restlessness
• less commonly, perceptual disturbances and panic attacks
• occasionally, seizures and symptoms of psychosis.
The symptoms and duration of benzodiazepine withdrawal can vary, mostly impacted by the level of 
dose reduction. Although, other contributing factors can include a history of polydrug dependence, 
seizures, anxiety, depression or trauma, or when the total daily dose is not clear (due to doctor shopping 
or illegal purchase).
5.2.1 Patients taking ‘therapeutic doses’
For patients who have early/mild dependence, minimal interventions such as advisory letters, other 
information provision or GP advice should be offered. Where dependence is established, gradual 
dose reduction of prescribed benzodiazepine is recommended (both grade A recommendations from 
the British Association for Psychopharmacology).153
Switching from a short half-life benzodiazepine to a long half-life benzodiazepine before gradual 
taper should be reserved for patients having problematic withdrawal symptoms on reduction (grade 
D recommendation from the British Association for Psychopharmacology).153
Additional psychological therapies increase the effectiveness of gradual dose reduction, particularly 
in patients with insomnia and panic disorder. Consideration should be given to targeted use of these 
interventions (grade B recommendation from the British Association for Psychopharmacology).153
5.2.2 Patient taking high doses of benzodiazepines or 
who are users of illicit drugs (polydrug users)
So called ‘harm-reduction dosing’ or maintenance prescribing of benzodiazepines for patients 
using polydrugs cannot be recommended on the basis of existing evidence, as prescribing 
benzodiazepines does not appear to prevent use of other drugs.153 There are some evidence that 
maintenance dosing of benzodiazepines may reduce high-dose problematic benzodiazepine use in 
some patients (grade D recommendation from the British Association for Psychopharmacology).153
5.3 General principles for the management of 
withdrawal of benzodiazepines
If dependence on benzodiazepines has become established, it is often difficult to treat and can become 
a long-term, distressing problem.25 All patients with dependence should be encouraged to discontinue 
the drug and offered a detoxification program at regular intervals. For some patients, discontinuation 
will be difficult, but the effort should be made. For other patients, a reduction in dose, rather than 
discontinuation, will be the first goal.
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Evidence-based recommendations for general practice management of benzodiazepine withdrawal are 
difficult due to a lack of data. The following are general principles: 
• Review the patients’ prescription records and discuss the situation to those receiving long-term 
benzodiazepines.
• Send patients letters suggesting methods of tapering off benzodiazepines (this may be enough to 
motivate them to withdraw). 
• Teach patients ways to deal with anxiety and insomnia (either as primary conditions or due to 
withdrawal).
• Acknowledge that withdrawing from benzodiazepines can be stressful.
• Encourage family and friends to provide encouragement and practical help during withdrawal.
• Refer patients to appropriate services (eg psychologist or support groups). Only refer to drug 
or alcohol dependence services if the service has shown specific interest in benzodiazepine 
dependence or the patient also has a drug or alcohol problem.
• Advise patients to make changes in lifestyle such as regular exercise.
• Advise patients to avoid alcohol.
• Advise patients to avoid mild stimulants (eg coffee and chocolate [theobromine]) as these can cause 
anxiety, panic and insomnia.
• Postpone advice on smoking cessation until after the benzodiazepine has been withdrawn.189
Benzodiazepine reduction requires a team approach with regular communication between the prescriber 
and other practitioners involved in the patient’s care (eg pharmacist, counsellor, psychiatrist, addiction 
services). 
5.3.1 Resources
Specialist services such as Reconnexion, www.reconnexion.org.au, offer free telephone support 
(1300 273 266) to help with benzodiazepine withdrawal. 
5.4 Tapering dosing
The clearest strategy for withdrawing benzodiazepines in primary care is to taper the medication.189 
Slow discontinuation of benzodiazepines is recommended to avoid withdrawal symptoms (eg rebound 
anxiety, agitation, insomnia or seizures) particularly when use exceeds 8 weeks. However, clear evidence 
for the optimal rate of tapering is lacking. The British National Formulary recommends a minimum of 6 
weeks,190 while Lader recommends a maximum of 6 months.189 The exact rate of reduction should be 
individualised according to the drug, dose and duration of treatment (refer to Table 5).
Two-thirds of patients can achieve cessation with gradual reduction of dose alone. Others need 
additional psychological therapies and a limited number of patients benefit from additional 
pharmacotherapy.191 CBT performed in a single, extended (20-minute) consultation with a GP, with 
a handout, has been shown to increase non-use at 1 year from 15% to 45%.192 A systematic review 
comparing routine care to brief interventions, gradual dose reduction and psychological interventions 
found all interventions increased benzodiazepine discontinuation over routine care, with gradual dose 
reduction plus psychological interventions the most effective.191 
All patients on a reduction regime must obtain prescriptions from one prescriber and through one 
pharmacy, where time-limited dispensing may be required (eg once or twice a week at a specified time). 
Plans should be in place to cover absences of the usual prescribing doctor from the practice. Consider 
working closely with the patient’s pharmacist with staged supply or supervised dosing to assist the 
patient with dose reduction and cessation, if they are unable to manage this themselves.
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Table 5. Recommendations for tapering benzodiazepines
Duration of use
Recommended taper 
length
Comments
<6 to 8 weeks Taper may not be required Depending on clinical judgment and patient 
stability/preference, consider implementing a taper, 
particularly if using a high-dose benzodiazepine or 
an agent with a short or intermediate half-life, such 
as alprazolam or triazolam
8 weeks to 6 months Slowly over 2–3 weeks Go slower during latter half of taper. Tapering 
will reduce, not eliminate, withdrawal symptoms. 
Patients should avoid alcohol and stimulants during 
benzodiazepine withdrawal
6 months to 1 year Slowly over 4–8 weeks
>1 year Slowly over 2–4 months
Copyrighted 2015. Frontline Medical Communications. 117258:0515BN
A common first step in withdrawal is to substitute diazepam for the benzodiazepine being taken.189 The 
slower elimination of diazepam creates a smoother taper in blood level.102
Refer to Resource D.2B for withdrawal protocols.
5.5 Additional pharmacotherapies
Pharmacotherapy interventions have limited use in benzodiazepine withdrawal. Generally, other drugs 
are used to address symptoms rather than substitute for benzodiazepines.
Carbamazepine – Carbamazepine has shown some usefulness, however, there is not enough evidence to 
recommend its use.193
Antidepressants – There is limited evidence that antidepressants help in benzodiazepine withdrawal, 
unless depression (or anxiety disorders/panic disorders) are present or emerge during withdrawal.191,193 
Melatonin – Melatonin may help benzodiazepine reduction in older people with insomnia.194
5.6 Should every patient be withdrawn?
There may be a small number of patients whose quality of life improves with the stable use of 
benzodiazepines. This may justify long-term therapy. The decision to continue long-term benzodiazepine 
treatment needs to be clearly documented. The decision may also involve a second opinion by a 
specialist in an area relevant to the patient’s needs. These patients still require regular, ongoing review 
and re-assessment of the risks and benefits of benzodiazepine use. 
Attempts at withdrawal are more likely to succeed if the patient is able to contemplate the ultimate 
goal of cessation, and the doctor and patient are able to work together in a productive therapeutic 
relationship to achieve this. 
Some patients struggle to reduce and cease benzodiazepine use. However, this group can often reduce 
their daily dose markedly and this is accompanied by a decrease in risk and side effects. They may 
continue on low-dose benzodiazepines (eg 2–5 mg diazepam daily) for an extended period. Continued 
regular review may assist in the majority who will successfully cease benzodiazepines in the longer term. 
This decision should be made on a case-by-case basis.
For patients who have complex, multiple morbidities, GPs should seek advice from mental health and 
addiction specialists, as well as other relevant specialists (eg neurologists) to assist with development of 
the best plan to assist the patient. 
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Resources
Resource A. Examples of responses to patient 
requests for benzodiazepines 
Purpose
To provide GPs with examples of responses to specific inappropriate and maladaptive patient requests for 
benzodiazepines. 
Reducing the incidence of requests
Before the actual consult, there are a number of things that practices can do to decrease the incidence of 
inappropriate and maladaptive requests for medications:
• When new patients make an appointment, ask the receptionist to give the following information, ‘The doctor, 
when seeing you for the first time, will do a detailed assessment and may need additional information from 
your previous doctors prior to making any treatment decisions, including prescribing medicines’.
• Inform patients of practice-wide policies regarding prescribing, including reviewing prescribing for existing 
patients. This may involve a sign in the waiting room.
• Develop clear plans for all staff on how to respond to requests for benzodiazepines using scripted 
response.
Example responses to inappropriate requests for medications
Alprazolam and temazepam are frequently used in the scenarios below, but may be substituted for 
other benzodiazepines. Some responses are specific for alprazolam or temazepam as both medications 
have undergone changes to their Pharmaceutical Benefits Scheme (PBS) listing and Therapeutic Goods 
Administration (TGA) scheduling.
Table A.1 gives some examples of responses to patient requests and includes a rationale for the response. 
Note that all responses are examples only and should be adapted to individual clinical circumstances.
Table A.1. Sample responses to inappropriate requests for medications
Patient request Sample responses Comments
I need something to 
help me to sleep.
Sometimes poor sleep indicates more 
serious underlying problems. Can you tell 
me more about your sleep issues?
or
What have you tried to help you sleep?
or
Sleeping tablets have been used in 
the past to help people with sleeping 
problems. However, we now know these 
can have side effects and can be risky so 
we don’t always prescribe them.
You need to make a detailed assessment and 
diagnose the condition rather than treating a 
symptom.
Don’t assume that if someone asks you to assist 
them with sleep that they are looking for sleeping 
tablets.
Offer a hierarchy of alternatives, including sleep 
hygiene and cognitive behaviour therapy (CBT).
Give the patient written information.
Ok, you won’t give 
me alprazolam, 
how about some 
Serepax or Rivotril?
This is clearly an inappropriate request.
We don’t just prescribe the medications 
people ask for. 
My job as a professional is to make a 
diagnosis and do what I think is best for 
my patients.
You can only legally prescribe drugs for the medical 
treatment of a patient under your care, and must 
take all reasonable steps to ensure a therapeutic 
need exists.
You can’t legally prescribe drugs merely to support 
the drug dependence of a person. 
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Table A.1. Sample responses to inappropriate requests for medications
Patient request Sample responses Comments
No, I’ve tried all this. 
The only thing that 
works for me is a 
sleeping pill. I want 
medication.
Have you used medication before? Who 
prescribed it to you?
or
I am concerned about that, as a request 
like this can sometimes be a sign of 
dependence on the medication. Can we 
talk about how much you are taking?
or
Sleeping pills are not the first choice in 
treating insomnia. These come with risks 
and limitations.
or
Sleeping medicines only provide a short-
term benefit. If you’re having trouble 
sleeping, it may be because you’ve become 
dependent on them. Using non-drug 
methods has been shown to have a better 
long-term benefit.
or
It’s my/our practice’s policy not to prescribe 
sleeping tablets.
or
I am concerned that providing ongoing 
medication is not good for your overall 
health. Can we trial a graduated withdrawal 
program, or can I refer you to a specialist?
or
Your sleep problems can be a result of your 
drug use. Giving tablets is just treating a 
symptom. I’d like to get to the cause and 
help you with your drug problem.
or
Thank you for coming to see me. It was 
nice to meet you. I am unable to prescribe 
the medications that you requested today 
because I don’t believe it is in your best 
interest and that’s not the way we now 
practice medicine. I have mentioned 
alternative methods of exploring and 
treating your problem. Please give my 
advice some further thought and if you 
decide you would like to avail yourself of the 
treatment that I am able to offer you, I look 
forward to seeing you again. In that case, 
please make another appointment.
A patient asking for medication (especially specific 
medication) is a possible red flag that the patient 
is drug seeking.
Ask the patient why they have not returned to the 
doctor who previously prescribed medication to 
them. Stress the advantages of continuity of care.
Ask the patient about what sleep hygiene 
practices they have tried and gauge their 
knowledge. Provide further information about 
sleep hygiene as needed.
Educate the patient about the problems 
associated with sleeping tablets, including 
abnormal sleep often with early awakening, as 
well as the risks.
Play a broken record on this advice. Remember, 
patients may no longer derive any relief from the 
medication, but they feel very much worse when 
they stop it.
If the patient does not accept your advice and 
continues to pressure you, one last resort option 
is to stand up from your chair while maintaining 
eye contact with the patient, walk to and open 
the door of your consulting room and say 
something like, ‘Thank you for coming to see me 
… (or) It was nice to meet you … I am unable to 
prescribe the medications that you request today 
because I don’t believe it is in your best interest 
…. if you decide … ’
Doctor, I need a 
script for my panic 
attacks.
Let’s first talk about what you have been 
experiencing to ensure we have the right 
diagnosis. Then we’ll talk about which 
treatment is most likely to help you. 
Medication is not necessarily the first 
option in treating this condition and in 
some cases it can actually be a cause of 
anxiety.
Panic attacks are a symptom, not a condition, 
and their cause needs to be diagnosed.
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Table A.1. Sample responses to inappropriate requests for medications
Patient request Sample responses Comments
I want/need a 
prescription for 
alprazolam (or other 
benzodiazepines).
We don’t prescribe this medication(s). 
Let’s talk about how I can help you with 
your sleep problem without drugs.
or
The rules around these medications have 
changed due to the range of harms they 
were causing.
or
I’m sorry, it’s my/our practice policy not to 
prescribe alprazolam.
or
I don’t prescribe these medications. But 
I’d like to know more about why you are 
on these medications, and the best way 
to manage this. Can we talk about how 
you came to be on these tablets?
or
I am concerned about that. Sometimes 
a request of this nature is a sign that 
someone has become dependent on the 
medication. Can we talk about how much 
you are using?
Provide sleep hygiene leaflet and CBT 
information. 
Alprazolam has been rescheduled as Schedule 
8 (S8) drug. 
Why don’t you 
prescribe sleeping 
tablets?
We prescribed them in the past, but we 
have generally reduced their use (to very 
specific circumstances). 
or
We now realise they only provide short-
term benefits and can lead people to 
adopt unhealthy and unsafe ways of 
dealing with their sleep and other life 
problems.
or
The health department has warned us not 
to prescribe some benzodiazepines as 
they are causing serious problems. 
If really being pushed inappropriately:
I am sorry, you are asking me to do 
something which I consider to be 
inappropriate or unsafe.
While I can understand your situation, 
I cannot prescribe outside legal 
frameworks or if I consider that the 
medication will not help.
It is preferable that you openly and honestly 
communicate your true clinical concerns about 
the medication requested; advising the patient 
of the time limited ‘benefit’ and the serious risks. 
Emphasise your duty of care to ‘first do no 
harm’ and help.
If you do not feel confident or able to have this 
frank discussion with the patient at this time, you 
may alternatively provide literature that explains 
this clinical perspective. Some clinicians find it 
helpful to provide a letter jointly signed by an 
authoritative source (‘borrowed protection’*). 
This may sometimes be necessary when a 
patient is demonstrating apparent drug-seeking 
behaviour and persisting in their pressure on you 
to prescribe inappropriately, especially if they 
are asking you to do something that is medically 
unsound or even unethical. This response can 
offload the pressure being placed on you and 
deflect it back onto the patient.
(In a patient with 
substance use 
disorder [SUD])
But the tablets/
capsules have 
helped me cut down 
my morphine use.
This is a serious problem and 
benzodiazepines have never been shown 
to help.
If you have a morphine problem, you 
need proper treatment. I think you need 
the best help you can get. I can treat you 
for morphine dependence with a more 
effective treatment, or, if after further 
assessment, I think you need specialised 
treatment, I can refer you for specialist help.
There is no evidence that prescribing 
benzodiazepines helps heroin or morphine users 
control their opioid use. On the contrary, these 
drugs are commonly used to supplement, boost 
or counteract the effects of other unsanctioned 
drug use.
There is ample evidence that benzodiazepine 
use by opioid users causes harm.
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Table A.1. Sample responses to inappropriate requests for medications
Patient request Sample responses Comments
But Dr X prescribes 
them (Dr X being 
someone in your 
practice or one 
nearby).
That’s Dr X’s decision, but the other 
doctors in this practice don’t prescribe 
them.
or
That’s Dr X’s decision, but other doctors 
in this practice insist on continual 
monitoring of patients they prescribe this 
medication.
or
That’s Dr X’s decision, but other doctors 
in this practice have very strict prescribing 
criteria.
or
If that doctor prescribed it for you before, 
it may be best for you to go back to him/
her. They know your history better than I 
do, and it’s best to continue with the one 
doctor
Discuss this issue with Dr X. Develop a practice 
policy (or local area policy) if your ability to 
handle requests for drugs is compromised.
Dr X can contact the Clinical Director of the 
Alcohol and Drug Services for advice about 
appropriate prescribing of benzodiazepine 
medications.
Ask the patient why they have not returned 
to the doctor who previously prescribed the 
medication. Stress the advantages of continuity 
of care.
Why don’t 
you prescribe 
alprazolam?
I am sorry, it’s my/our practice policy not 
to prescribe alprazolam.
or
Xanax, one of the brands of alprazolam, 
has been taken off the market in Australia 
and there have been restrictions placed 
on this medication because of concerns 
on safety. Many people have suffered 
significant side effects from this drug and 
there have been a number of deaths.
Refer to the guide on prescribing S8 opioids and 
drugs of dependence.
Remember that alprazolam can only be 
prescribed as a PBS benefit on an Authority 
prescription for one indication, ‘Panic disorder 
where other treatments have failed or are 
inappropriate’. Other anxiety disorders are not 
included in that indication.
If I don’t get 
alprazolam I’ll 
be desperate. I’ll 
have to go and 
<prostitute myself, 
do an armed hold-
up, go back to using 
drugs>.
That’ll be completely your decision, and 
not something I can support. However, I 
can help you with your drug problem and 
sleeping/anxiety problem without the need 
for alprazolam.
If the patient threatens to harm you or your 
staff: 
This practice takes these sorts of threats 
seriously and has serious consequences. 
Are you sure about what you just said?
or
Activate practice duress alarms or 
processes.
or
I do not believe it is safe or appropriate to 
prescribe the medication you are asking 
me to prescribe under these conditions.
or
This practice takes these sort of threats 
seriously. I am sorry, I cannot supply the 
services that are necessary for your care. 
I cannot continue with this consultation, 
thank you.
It is not possible to establish or maintain a 
genuinely therapeutic relationship† with any 
patient who uses such emotional manipulation 
to influence your clinical decision making.
Continue to offer the patient help. There is 
no need to accept responsibility for another’s 
behaviour or threat. Be very clear and firm, 
though empathetic, in your responses.
You may elect to call the police if you consider 
the threat to be a serious one. You can call staff 
at your local drug of dependence unit to notify 
them of the events and your clinical actions. 
They will provide you with advice and support.
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Table A.1. Sample responses to inappropriate requests for medications
Patient request Sample responses Comments
(In a patient with 
[SUD])
I’m trying to get off 
drugs and I need 
some help with 
sleep.
If you’ve got a problem with drug 
dependence, there’s a very significant, and 
proven, risk of you becoming dependent on 
other drugs too. Have you seen a specialist 
about this lately?
or
I want to help you get off drugs, but it would 
be a breach of my duty of care to you to 
prescribe this medication.
I wouldn’t be doing the right thing by you if I 
prescribe this medication.
Sleeping drugs cause their own problems, 
and can make things worse rather than 
better.
You will have some sleep problems 
when you are withdrawing from opioid 
medications like morphine, but this will 
improve with time as your body recovers 
from the effects of this medication. What 
you tell yourself, your self-talk, is very 
important during this time. When you 
experience difficulties settling off to sleep, 
reframe the situation by reminding yourself 
that these symptoms are a result of your 
body repairing itself, like the itch you 
experience when a sore is healing. Remind 
yourself these are ‘good’ symptoms rather 
than ‘bad’ or sinister ones.
Your sleep problem is a common side effect 
of using sedative drugs like morphine, 
sleeping tablets or alcohol – it’s due to 
a rebound effect resulting in increased 
alertness after a period of sedation. It’s 
much better to treat the cause rather than 
the symptom.
You’re going to have this sleep problem 
as long as you continue using these 
medications or drinking. I can help you (or 
refer you for help) with your drug problem if 
you like.
If you are unable to sleep, you need to 
remain positive. Tell yourself: ‘If I am unable 
to sleep tonight, I am not going to let it 
worry me because it won’t do me any 
serious harm. I will just get up and read or 
do something else that relaxes me’.
There is no evidence that prescribing 
benzodiazepines for the treatment of heroin or 
morphine addiction is any use at all. There is 
ample evidence of the harm, including increasing 
the risk of overdose, confusion, amnesia, falls 
and accidents, risky sexual behaviour and 
increased needle sharing.
It is important to say these things to the patient 
in a firm, unwavering and confident manner so 
the patient understands you mean what you say 
and there is no room for negotiation.
Drugs can interfere with sleep either as a 
result of stimulation (caffeine, nicotine or other 
stimulants) or as a response to varying levels 
of sedation (rebound insomnia) associated with 
declining blood levels (trough levels) with alcohol, 
opioid or benzodiazepine medications.
Reinforce the principles of sleep hygiene, 
including never napping during the day no 
matter how tired the patient feels and getting out 
of bed to do something relaxing after 30 minutes 
of trying to get to sleep and trying again when 
feeling ready to sleep.
Talk to the patient about the use of de-
catastrophising techniques. 
You prescribed 
alprazolam for me 
before, why not 
now?
These sorts of drugs are for short-term 
use only. If you’re asking for a repeat, 
we haven’t solved your sleep problem 
(or anxiety problem) and you are on a 
pathway to developing a new problem.
Alprazolam has been found to be so 
problematic that has now been reclassified 
to a more dangerous drug group.
We need to find a more effective longer term 
solution that is not associated with harm.
Prescribing hypnotics for drug-dependent 
patients creates an expectation of further 
prescribing, and causes hostility and aggression 
when expectations aren’t met.
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Table A.1. Sample responses to inappropriate requests for medications
Patient request Sample responses Comments
(In a patient with 
SUD)
I’m trying to cut 
down my drug use 
but you won’t help 
me.
If you have a drug addiction problem, 
benzodiazepines are one of the least 
effective and most dangerous drugs to 
use. I know you want me to give you the 
best treatment, but benzodiazepines will 
not help.
Offer help or refer them to Alcohol and Drug 
Information Service (ADIS), for counselling and 
referral.
Why do you 
want to change 
my medications 
now? You have 
been prescribing 
alprazolam for 
my panic attacks, 
temazepam for my 
sleeping problems, 
diazepam for 
my anxiety and 
clonazepam for 
that seizure that 
I had a long time 
ago. I need these 
medications and I 
might die if you stop 
them.
I know that I have been prescribing these 
medications for you for many years now. 
However, I have been giving a lot of 
thought to your health problems and I 
have been doing some reading on the 
latest medical literature and speaking to 
some experts in the field. 
As you know, medical research continues 
to reveal new things that change the way 
we think and practice medicine. I have 
realised the medications I am prescribing 
for you are no longer in your best interests. 
Because I care about you, I need to do 
something about that. It is my ethical duty 
to provide you with nothing but the best 
possible medical care that I can. So, we 
need to make a number of changes over 
the next several (2–3) months.
I’d like to tell you about the reasons we 
need to make these changes and how 
your health will actually improve over time 
as a result of these changes.
I will be there to guide and support you 
all the way and a medical colleague 
who specialises in making these sorts of 
medication changes has offered his/her 
support and advice as we go. Let’s now 
discuss how we are going to make these 
changes to your treatment and map this 
out.
Doctors often find it difficult to make changes in 
their prescribing of analgesic and psychotropic 
medications, particularly when they are pressed 
for time, and when their patients express strong 
emotional attachment to these medications and a 
deep fear of change.
While prescribing benzodiazepine medications 
in the long term does not generally represent 
good clinical practice, prescribing multiple 
benzodiazepines is poor clinical practice.
Doctors need be aware of the evidence and 
have confidence in their clinical judgement when 
making changes to medications and other 
treatments.
Doctors also need to learn to manage their 
emotions when responding to the emotions and 
pressures of patients. 
It can be important to play a broken record of 
positive reinforcement on the benefits of altering 
treatment to one that is consistent with evidence 
and careful clinical assessment of the patients’ 
circumstances. 
It is important to document changes to a 
treatment plan.
A copy of this treatment plan should be provided 
to the patient so there is clarity, transparency 
and certainty in what is to be offered in the new 
treatment plan.
If the patient declines to comply with this change 
of treatment plan, the doctor must then consider 
whether to continue providing suboptimal care, 
and whether it is possible to maintain a genuine 
therapeutic relationship.
While recognising that practical challenges 
may arise in rural and remote areas, it may be 
appropriate for the doctor to ask the patient to 
go away and think about what is proposed and 
return when they are ready to embark upon the 
new treatment plan.
Please give me 
<drug name> just 
this once and I 
won’t ask again
I’m sorry but we don’t prescribe those 
drugs in our practice.
I am concerned about that, as sometimes 
a request like this can be a sign that a 
patient has become dependent on the 
medication. Can we talk about how much 
you are taking?
You may use ‘we’ and ‘our practice’ to 
suggest a collective decision and if you do 
not have confidence to say ’no’ when under 
such emotional pressure. This avoids direct 
confrontation.
However, it is better to own your clinical 
decisions and to communicate them in a 
confident, positive light.
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Table A.1. Sample responses to inappropriate requests for medications
Patient request Sample responses Comments
(In a patient with 
SUD)
I’ve been waiting 
for hours to see you 
and you won’t even 
help.
I am sorry you had to wait. I am very 
keen to help you, but your treatment 
depends on finding the best solution to 
your problem. Now let’s talk about your 
problem and explore ways I can help you.
Some patients may use waiting time to coerce 
doctors. This can be averted by a sign in the 
waiting room indicating that particular drugs are 
not prescribed by doctors in the practice.
Never allow yourself to be a ‘victim’ of 
inappropriate or manipulative patient behaviour.
Ok, if you can’t give 
me temazepam, 
could you please 
prescribe some 
deptran or 
seroquel? Another 
doctor gave me that 
to help me sleep.
I’m sorry, we can help you with your sleep 
problem, but we can’t prescribe other 
drugs that might also cause harm.
Many drugs prescribed for insomnia, including 
antidepressants such as doxepin and 
antipsychotic medications like seroquel or zyprexa 
are misused by injecting drug users (IDUs).
It is important not to substitute benzodiazepines 
with drugs (eg antidepressants and major 
tranquillisers) that may cause a range of serious 
side effects, especially when misused.
If I don’t get benzos 
I’m going to fit. 
I had a seizure 
once before when 
I was detoxing (or 
withdrawing).
I’m sorry to hear that. But in that case, you 
must be dependent on benzodiazepines. 
We’re not allowed to prescribe drugs 
to sustain drug dependence (consider 
showing the patient the relevant section of 
the legislation).
You need referral for detoxification. I can 
offer you three options for help: 
• I can arrange treatment.
• I can give you a specialist contact to 
call for advice. 
• If, after further assessment, I believe 
it is appropriate and safe for you, I 
might be able to offer you out-patient 
withdrawal.
Benzodiazepine withdrawal for drug-seeking 
patients requires close supervision. Specialist 
withdrawal management is highly advisable 
where there is any history of severe or 
complicated withdrawal (eg seizures or delirium) 
where the patient has been taking diazepam 
50 mg daily or more or its equivalent dose 
for other benzodiazepine medications, where 
there is significant comorbidity, where there is 
unsanctioned or hazardous alcohol or other drug 
use in the patient’s present living environment or 
where there is a past history of failed ambulatory 
withdrawal management.
A note on staff safety
All practices must implement strategies to ensure the occupational health and safety (OHS) of general practitioners (GPs) and other members of 
the practice team. This includes having a risk management strategy that details the necessary steps to protect doctors and practice staff from 
potential patient violence.  
A doctor duress system is recommended in each consulting room and doctors should feel confident to use it in any situation where they feel 
under threat. 
For tips on minimising risks of violence, practices can refer to General Practice – A safe place: tips and tools, available at www.racgp.org.au/
your-practice/business/tools/safetyprivacy/gpsafeplace
For advice on managing aggressive, violent or threatening patients, refer to www.miga.com.au/library/10RRAR08.pdf 
*Borrowed protection
If you have reason to believe you may be at immediate risk, or if you do not feel confident to manage a particular clinical circumstance safely or 
effectively, it may be wise to tell the patient that it is not your responsibility for the decision, but defer to a ‘higher’, less identifiable authority. For 
example, ‘I can’t prescribe X because of health department regulations.’ Using ‘borrowed protection’ should be limited to when you feel it is 
absolutely necessary. It is usually therapeutically more appropriate for you to communicate clearly and with confidence that you will not prescribe 
particular medications when you do not believe this is in the best interests of the patient, and then also explain alternative treatment approaches. 
This approach lets the patient know that you believe in yourself as a clinician and that you are confident and competent as a doctor.
†The presence of a therapeutic doctor–patient relationship in a consultation is a key to recognising a patient who wants help and a 
person seeking drugs.
The establishment of a therapeutic relationship requires mutual openness and truth telling. A relationship in which a patient tells a doctor what 
medications they want, regardless of the clinical circumstances, is not a therapeutic one. A patient who is not open to an honest discussion 
about the benefits, risks and harms associated with their prescribed and non-prescribed medications, or to treatment goal setting and planning, 
is not engaging in treatment. They are not demonstrating they are ready to join the doctor in a genuine therapeutic relationship. 
When this relationship does not exist, the challenge for the GP is to speak and work with the drug-seeking person in a way that is insightful and 
sensitive to their circumstances and to encourage and motivate them to accept constructive, safe and appropriate clinical assistance. 
This tool has been adapted with permission from the work of Adrian Reynolds, Clinical Director, Alcohol and Drug Service, 
Department of Health & Human Services, Tasmania and Dr Malcolm Dobbin, Senior Medical Advisor (Alcohol and Drugs), 
Department of Human Services, Victoria.
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Resource B. Drug interactions
Clinically significant medication interactions with benzodiazepines.
Drugs that increase serum levels of 
benzodiazepines (through action on 
hepatic metabolic pathways) 
Drugs that have sedative effects 
significantly enhanced by benzodiazepines
• Ketoconazole 
• Itraconazole 
• Macrolides 
• Fluoxetine 
• Cimetidine 
• All full-agonist opioids, including methadone 
• Partial agonist opioids such as buprenorphine 
• Alcohol
• Antipsychotics or other sedating medication 
• Barbiturates 
• Sedating anti-histamines 
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Resource C. State and territory contacts
State/ 
territory Legislation Contact (web)
Legislative 
contact (phone)
24-hour 
clinical 
advisory 
services
Australian 
Capital 
Territory
Medicines, Poisons 
and Therapeutic 
Goods Act 2008
www.legislation.act.gov.
au/a/2008-26/default.asp
Pharmaceutical Services
http://health.act.gov.au/health-
services/population-health/health-
protection-service/pharmaceutical-
services/pharmaceutical-services 
Pharmaceutical 
Services Section, ACT 
Health
02 6205 0998
DACAS – 
Australian 
Capital Territory
03 9418 1082
New South 
Wales
Poisons and 
Therapeutic Goods 
Act 1966
www.austlii.edu.au/au/
legis/nsw/consol_act/
patga1966307
Pharmaceutical Services
http://www.health.nsw.gov.au/
pharmaceutical/pages/default.aspx 
Pharmaceutical 
Services Unit, Legal and 
Regulatory Services 
Branch, NSW Health
02 9391 9944
DASAS
02 9361 8006 
(Sydney)
1800 023 687 
(Rural)
Northern 
Territory
Medicines, Poisons 
and Therapeutic 
Goods Act 2014
http://notes.nt.gov.au/
dcm/legislat/legislat.nsf/d9
89974724db65b1482561c
f0017cbd2/86a3e80a889a
330369257d4f001810d5?
OpenDocument
Poisons Control
www.health.nt.gov.au/
Environmental_Health/Medicines_
and_Poisons_Control/index.aspx
Poisons Control Unit, 
Department of Health 
and Community 
Services
08 8922 7341
DACAS – 
Northern 
Territory
1800 111 092
Queensland Health (Drugs and 
Poisons) Regulation 
1996
www.legislation.qld.gov.au/
LEGISLTN/CURRENT/H/
HealDrAPOR96.pdf
Medicines Regulation  
and Quality
www.health.qld.gov.au 
Medicines Regulation 
and Quality, 
Queensland Health
07 3328 9890
GPs can phone 
ADIS 1800 
177 833 to be 
put through 
to ATODS for 
clinical advice
South 
Australia
Controlled 
Substances Act 
1984
www.legislation.sa.gov.
au/lz/c/a/controlled%20
substances%20act%20
1984.aspx
Medicines and Technology 
Policy and Progams
http://www.sahealth.sa.gov.au/
wps/wcm/connect/public+content/
sa+health+internet/about+us/
department+of+health/public+health+
and+clinical+systems/medicines+and
+technology+policy+and+programs 
Drugs of Dependence 
Unit, Department for 
Health
1300 652 584
DACAS – 
South Australia
08 8363 8633
Tasmania Poisons Act 1971 Pharmaceutical  
Services Branch
http://www.dhhs.tas.gov.au/
psbtas/welcome 
Pharmaceutical Services 
Branch, Department 
of Health and Human 
Services
03 6166 0400
DACAS –
Tasmania 
1800 630 093
Victoria Drugs, Poisons 
and Controlled 
Substances Act 1981
www.austlii.edu.au/au/
legis/vic/consol_act/
dpacsa1981422
Drugs and Poisons 
Regulation
http://www.health.vic.gov.au/dpcs/
index.htm 
Drugs and Poisons 
Unit, Department of 
Human Services
1300 364 545
DACAS – 
Victoria
1800 812 804
Western 
Australia
Poisons Act 1964
www.austlii.edu.au/au/
legis/wa/consol_act/
pa1964121
Pharmaceutical  
Services Branch
http://www.public.health.wa.gov.
au/1/872/2/pharmaceutical_
services.pm 
Pharmaceutical 
Services Branch, 
Department of Health
08 9222 6883
CAS
08 9442 5042
DACAS – Drug and alcohol clinical advisory service; DASAS – Drug and alcohol specialist advisory service; ADIS – Alcohol and drug information 
service; CAS – Clinical advisory service; ATODS – Alcohol, tobacco and other drugs
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Additional resources for Schedule 4 and Schedule 8 drug 
information
New South 
Wales
Summary of Controls on the Prescribing and Handling of Drugs of Dependence, www.
health.nsw.gov.au/pharmaceutical/Documents/drugsofdependence-controls.pdf 
Northern 
Territory
Remote Health Atlas; Restricted S4 Medicines, http://remotehealthatlas.nt.gov.au/
restricted_schedule_4_medicines.pdf 
Queensland Regulatory requirements and resources, www.health.qld.gov.au/clinical-practice/guidelines-procedures/medicines/drugs-of-dependence/regulation/default.asp
South 
Australia
Drugs of Dependence, www.sahealth.sa.gov.au/wps/wcm/connect/Public+Content/
SA+Health+Internet/Clinical+resources/Clinical+topics/Medicines+and+drugs/
Drugs+of+dependence/
Victoria
Things medical practitioners need to know – key prescribing requirements, http://docs.
health.vic.gov.au/docs/doc/Things-medical-practitioners-need-to-know--key-prescribing-
requirements 
Western 
Australia
Requirements for the prescribing of S4 and S8 Medicines in Western Australia, www.
public.health.wa.gov.au/cproot/3565/2/Prescribing_S4_S8_080825.pdf 
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Resource D. Communication with patients
D.1 Benzodiazepine fact sheet for patients*
What are benzodiazepines?
Benzodiazepines are a group of prescription-only medicines that have a sedating and calming effect on the 
brain and nervous system. They are also known as sedatives or tranquillisers. Examples of benzodiazepines 
include medicines containing one of the following active ingredients: diazepam, lorazepam, oxazepam, 
temazepam and alprazolam.
They come in tablet and capsule form, and some are available for intravenous use in hospital settings.
How do benzodiazepines work?
Benzodiazepines differ in how quickly the active ingredient starts to work and how long the effect lasts. The 
effect of the medicine also depends on the prescribed dose, and on the individual (eg height, weight, health 
status and previous experience with benzodiazepines), which can impact on how the medication will work. 
Benzodiazepines can help treat symptoms of anxiety and sleeping problems (eg insomnia). As non-medicine 
therapies have proven benefit in these conditions, benzodiazepines are generally considered only if these 
options are inappropriate or have failed. 
If you have been diagnosed with an anxiety disorder, benzodiazepines can make you feel calmer. If you have 
insomnia, benzodiazepines may help you fall asleep. They are sometimes used for other reasons, such as a 
medication before an operation to alleviate nervousness.
After taking benzodiazepines, people can describe feeling drowsy, relaxed, confused/fuzzy and having a heavy 
sensation in their arms and legs. Coordination and reflexes can be effected too, which means you should not 
take benzodiazepines if you need to be focused and coordinated (eg drive a car or operate heavy machinery). 
Benzodiazepines are usually taken for a set period until the intended therapeutic effect is achieved. Then, the 
dose is reduced and plans to stop it are made. 
If you take benzodiazepines for a prolonged time, the body may adapt and get used to the effects of 
the medication. Stopping the medication can lead to withdrawal symptoms that includes anxiety and 
restlessness. Withdrawal symptoms are often mild, but can be severe if you are on high doses of a 
benzodiazepine. Serious side effects, including seizures, can occur if you stop taking high doses suddenly.
Can benzodiazepines be addictive?
Although addiction (cravings, abuse, misuse, compulsive or uncontrollable benzodiazepine-seeking behaviour) 
is possible with benzodiazepines, it is rare in people who are taking therapeutic doses for a specific reason 
over a short period as prescribed by their doctor. 
You may be at a greater risk of developing an addiction to benzodiazepines if you have a history of drug 
dependence, or if you are currently misusing any substance including alcohol or strong pain killers (opioid drugs). 
Before prescribing a benzodiazepine, your doctor will ask you questions about these sorts of things to help 
prevent addiction.
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What are the possible side effects of benzodiazepines?
Benzodiazepines are associated with a number of side effects including:
• drowsiness and unsteadiness, potentially increasing the risk of a fall
• impairment in judgement and dexterity, making tasks such as driving or using heavy machinery more difficult
• forgetfulness, confusion, irritability
• paradoxical aggression and excitability (although this is rare, it is the opposite effect to what is expected with 
these medicines).
Taking benzodiazepines in combination with other drugs or alcohol can be very dangerous, and in some 
cases fatal.
Can I take benzodiazepines for a long time?
Benzodiazepines are usually taken for a short length of time. In rare instances, some patients will 
require long-term therapy with benzodiazepines. This is after a serious consideration of risks and 
benefits of long-term therapy between you and your doctor. If you and your doctor have decided that 
benzodiazepines are an important part of your long-term treatment, then you should continue to take 
them as prescribed and keep checking in with your doctor for review. 
If you have been taking benzodiazepines regularly for longer than 4 weeks and wish to stop them, your 
doctor would be happy to advise you on how to do this. Do not stop or significantly alter the dose 
abruptly. Many people can stop taking benzodiazepines without difficulty. For others, gradual reduction 
helps prevent or reduce any withdrawal symptoms.
Where can I get more information?
• Reconnexion, www.reconnexion.org.au, an Australian not-for-profit organisation that offers programs, 
counselling, telephone information and support for people with anxiety, stress, depression and 
benzodiazepine dependence and related conditions.
• The Victorian Government’s Better Health Channel website, www.betterhealth.vic.gov.au
• The Australian Drug Foundation’s help and support page, www.druginfo.adf.org.au/contact-numbers/
help-and-support, lists sources of information and advice.
*  Kenny T, Harding M. Benzodiazepines and Z Drugs [Internet]. London: patient.co.uk; 2014 [updated October 2014]. 
Available at http://patient.info/health/benzodiazepines-and-z-drugs [Accessed 11 June 2015].
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D.2 Benzodiazepine reduction in the practice population
D.2A Practice letter to patients about benzodiazepine reduction
[Insert practice name] 
Address
Date 
Dear [Patient name]
We are currently undertaking a review of prescriptions for medications collectively known as benzodiazepines and 
sleeping tablets. I am writing to you because our records show that you have received a number of prescriptions 
for one or more of these types of medications in the past 12 months.
A growing body of evidence suggests that if these medications are used for long periods, they can have harmful side 
effects, including anxiety symptoms, memory and sleep problems, and they can be addictive. We do not recommend 
long-term use.
We are writing to ask you to consider cutting down your dose of tablets and perhaps stopping them completely at some 
time in the future. As each person is different, we would like to discuss this with you in person within the next 3 months. 
The best way to cut down your tablets is to take them only when you feel they are absolutely necessary. It is best to 
cut down gradually; otherwise you may have some withdrawal side effects. You should not stop your tablets suddenly. 
Once you start to reduce your dose you may start to notice that you feel a lot better and you may be able to think about 
stopping altogether. 
Please make an appointment with your GP to discuss this further. If you have not attended to discuss this 
within the next 3 months, we may not be able to continue to prescribe this medicine for you. If you have already 
discussed this with your doctor, or have stopped your medications, this letter does not apply to you.
Yours sincerely, 
 [Dr name]
D.2B Practice guide to reduction and withdrawal of benzodiazepines 
(and Z drugs) in the practice population
• Print a list of patients on repeat prescriptions for benzodiazepines (and Z drugs).
• Identify patients who have repeat prescriptions (including repeat acute prescriptions) of hypnotics 
and anxiolytics. In agreement with the general practitioner (GP), remove drug repeats for patients 
who have not ordered a prescription within the last 6 months.
• Agree on exclusion criteria (with GP) to identify patients not suitable for withdrawal, for example:
 – drug or alcohol problems, unless GP advises otherwise
 – terminal illness
 – acute crisis
 – risk of suicide
 – severe mental illness (liaise with psychiatrist)
 – organic brain disease
 – epilepsy requiring benzodiazepines as part of anticonvulsant therapy
 – benzodiazepine prescriptions for muscle spasm.
• The GP(s) should agree on the final list of patients to be included in the scheme.
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• Invite the patient to discuss a supported withdrawal regime. If the withdrawal is to be managed by 
a GP, then it would be beneficial for the patient to see the same doctor throughout the process.
• Prior to the consultation, use computer records and/or paper notes to gather the required 
information to complete the patient clinical summary. Send the patient self-help information on 
sleep and relaxation.
• In the initial consultation with the patient, reiterate the benefits of withdrawing from 
benzodiazepines and explain the possible treatment withdrawal regimes.
• Find out how often the patient takes the hypnotic/anxiolytic, as some patients stockpile these 
medicines and never take them, some only take them occasionally, whereas others may give 
them to someone else. The anxiolytic/hypnotic can be stopped in these patients. 
• If the patient agrees to participate in the scheme, agree on a treatment regime and arrange a 
follow-up appointment.
• Record the agreed plan in the patient-held record sheet. Provide the patient with information 
leaflets regarding non-drug alternatives to reduce anxiety and sleep problems.
• Following the consultation, document the outcome on the patient’s electronic record and in the 
paper notes. Print out a prescription if one is required (leave the prescription for the GP to sign 
with the clinical summary sheet).
• In the patient’s clinical summary sheet, complete the outcome box and pass it to the responsible GP. 
Once the GP has read it, they should initial it and pass it to the receptionist for filing in the patient’s 
notes.
• Explain the intervention to local pharmacies to ensure a consistent message is conveyed to patients.
• Ensure the patient fully understands how prescriptions will be issued and that all practice staff are 
briefed on this.
• Offer patients general support if they call the practice for advice. If the patient wishes, arrange for 
an appointment to explain the program.
• If the patient is not suitable for withdrawal, consider whether no action should be taken, or to refer 
to the substance misuse services or psychiatric services.
• Classify your patient on your computer system in order to make identification easier. Everyone 
withdrawing from hypnotics/anxiolytics should have this added to their record.
Reduction protocols to support the withdrawal from hypnotics 
Different withdrawal plans are given for guidance only. The rate of withdrawal should be individualised 
according to the drug, dose and duration of treatment. Patient factors such as personality, lifestyle, 
previous experiences and specific vulnerabilities should also be taken into account.
• Throughout the process, it is important to provide advice on good sleep hygiene and basic 
measures to reduce anxiety.
• At each stage, enquire about general progress and withdrawal symptoms.
• If patients experience difficulties with a dose reduction, encourage them to persevere and suggest 
delaying the next step down. Do not revert to a higher dose.
• Offer information leaflets to help with the withdrawal program.
• Reassure patients that if they are experiencing any difficulties with the withdrawal schedule, they 
can contact the practice for advice.
• A copy of the protocol should be given to the patient and the patient’s pharmacy. A copy should 
be also kept in the practice’s records.
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Examples of hypnotic withdrawal schedules
To be adapted and adjusted according to individual patient needs.
Nitrazepam
Start from the most relevant point of the schedule based on the patient’s current dose.
Note that the dosage reduction withdrawal schedule is flexible and should be tailored to individual 
patients.
Table D.2.1. Sample nitrazepam withdrawal schedule
Dose of nitrazepam
Number of 5 mg 
tablets/day
Number of 5 mg 
tablets/week
Starting dose 20 mg 4 28
Stage 1 (1–2 weeks) 15 mg 3 21
Stage 2 (1–2 weeks) 12.5 mg 2½ 18
Stage 3 (1–2 weeks) 10 mg 2 14
Stage 4 (1–2 weeks) 7.5 mg 1½ 11
Stage 5 (1–2 weeks) 5 mg 1 7
Stage 6 (1–2 weeks) 2.5 mg ½ 4
Stage 7 (1–2 weeks) 2.5 mg alternate nights ½ 2
Stage 8 Stop nitrazepam
Temazepam
Start from the most relevant point of the schedule based on the patient’s current dose.
Note that the dosage reduction withdrawal schedule is flexible and should be tailored to each individual 
patient.
Table D.2.2. Sample temazepam withdrawal schedule
Dose of temazepam
Number of 10 mg 
tablets/day
Number of 10 mg 
tablets/week
Starting dose 30 mg 3 21
Stage 1 (1–2 weeks) 25 mg 2½ 18
Stage 2 (1–2 weeks) 20 mg 2 14
Stage 3 (1–2 weeks) 15 mg 1½ 11
Stage 4 (1–2 weeks) 10 mg 1 7
Stage 5 (1–2 weeks) 5 mg ½ 4
Stage 6 (1–2 weeks) 5 mg alternate nights ½ 2
Stage 7 Stop temazepam
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Zopiclone
Start from the most relevant point of the schedule based on the patient’s current dose.
Note that the dosage reduction withdrawal schedule is flexible and should be tailored to each individual 
patient.
Table D.2.3. Sample zopiclone withdrawal schedule
Dose of zopiclone
Number of tablets/
day
Number of tablets/
week
Starting dose 15 mg 2 x 7.5 mg 14 x 7.5 mg
Stage 1 (1–2 weeks) 11.25 mg 1 x 7.5 mg
1 x 3.75 mg
7 x 7.5 mg
7 x 3.75 mg
Stage 2 (1–2 weeks) 7.5 mg 1 x 7.5 mg 7 x 7.5 mg
Stage 3 (1–2 weeks) 3.75 mg  1 x 3.75 mg 7 x 3.75 mg
Stage 4 (1–2 weeks) 3.75 mg alternate nights 1 x 3.75 mg 4 x 3.75 mg
Stage 5 Stop zopiclone
Zolpidem 
Start from the most relevant point of the schedule based on the patient’s current dose.
Note that the dosage reduction withdrawal schedule is flexible and should be tailored to each individual 
patient.
Table D.2.4. Sample zolpidem withdrawal schedule
Dose of zolpidem
Number of 5 mg 
tablets/day
Number of 5 mg 
tablets/week
Starting dose 10 mg 2 14
Stage 1 (1–2 weeks) 7.5 mg 1½ 11
Stage 2 (1–2 weeks) 5 mg 1 7
Stage 3 (1–2 weeks) 2.5 mg ½ 4
Stage 4 (1–2 weeks) 2.5 mg alternate nights ½ 2
Stage 5 Stop zolpidem
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Reduction protocols for anxiolytics
Different withdrawal plans are given for guidance only. The rate of withdrawal should be individualised 
according to the drug, dose and duration of treatment. Patient factors such as personality, lifestyle, 
previous experiences and specific vulnerabilities should also be taken into account.
• Throughout the process, it is important to provide advice on good sleep hygiene and basic 
measures to reduce anxiety.
• At each stage, enquire about general progress and withdrawal symptoms.
• If patients experience difficulties with a dose reduction, encourage them to persevere and suggest 
delaying the next step down. Do not revert to a higher dosage.
• Offer information leaflets to help with the withdrawal program.
• Reassure patients that if they are experiencing any difficulties with the withdrawal schedule, they 
can contact the practice for advice.
• Give the patient and the patient’s pharmacy a copy of the protocol. Keep a copy in the practice’s 
records.
• If a patient has complex needs, refer to appropriate specialist services for further advice.
• Lorazepam and oxazepam have short half-lives making withdrawal effects more pronounced. 
Patients treated with these drugs may need to be converted to diazepam during the withdrawal 
process. Initial dose reductions should be made using their current medication, followed by 
conversion to diazepam, and subsequent reduction of the diazepam dose according to the 
following schedules.
Note: Some patients will prefer to remain on the original drug for the duration of the withdrawal.
Table D.2.5. Diazepam equivalent doses
Approximate equivalent doses to diazepam 5 mg
Lorazepam 0.5 mg
Oxazepam 15 mg
Clonazepam 0.25 mg
Resource D.2B is adapted with permission from Educational pack – Material to support appropriate prescribing of 
hypnotics and anxiolytics across Wales – Welsh Medicines Partnership, April 2011. For more information visit: http://
awttc.org/about_wmp.html 
63Prescribing drugs of dependence in general practice, Part BBenzodiazepines 
D.3 Stopping benzodiazepines (benzodiazepine withdrawal) 
fact sheet for patients
How would I benefit by stopping benzodiazepines?
People who have been on long-term benzodiazepines often feel like they need to stay on them. This 
may be because of fears about returning symptoms of anxiety or sleeplessness, or due to withdrawal 
symptoms or needing the medication to feel normal.
While you might feel ‘normal’ when you take benzodiazepines, studies have found people who stopped 
taking them have:
• improved memory and reaction times
• increased levels of alertness
• improved quality of life (more vitality, better ability to function).
Stopping benzodiazepines also reduces your risk of falls, accidents, fractures and other injuries.
How should I stop taking benzodiazepines?
The best place to start is by talking to your general practitioner (GP). Some people can stop quickly 
and easily; others need a more gradual approach with additional support. Your GP can advise you 
on the rate at which you should reduce the dose and help you to consider other ways of dealing with 
your worries or sleeping problems. Sometimes your GP will change your prescription to a different 
benzodiazepine before withdrawing.
If you are taking other addictive medicines, in addition to benzodiazepines, you may need specialist help 
to come off the various medicines. Your GP will be able to advise you or refer you to local services that 
can help.
Some tips for withdrawing from benzodiazepines:
• Choose when to start reducing – If you have been taking benzodiazepines to help you cope 
with a personal crisis, it may be advisable to wait until things settle down before starting to reduce 
the dose. Consider starting while on holiday, when you have less pressure from work, fewer family 
commitments or less stress.
• Do not try to stop suddenly – Unless your GP has advised you to do so. You should reduce your 
medication in a slow, gradual process, as this often gives a better chance of long-term success. You 
can go as slowly as you need to.
• Do not increase the dose – It is common to have a bad patch at some time during the withdrawal. 
You might be tempted to go back to the higher dose, but it is best to stick with the current dose. 
Don’t consider a further reduction until you feel ready; this may take several weeks.
• Get help and support – Consider asking family or friends for encouragement and support, or 
consider joining a self-help group. Advice and support from other people in similar circumstances, or 
those who have come off a benzodiazepine, can be very encouraging. 
• Keep a record – Keeping a diary can help as it records your progress and achievements. This in itself 
will give you more confidence and encouragement to carry on.
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How do I cope with withdrawal symptoms?
Not everyone experiences the same degree or type of symptoms when withdrawing from 
benzodiazepines. The best way to cope is to go slowly to minimise the withdrawal symptoms. It can 
also help to know what to expect and know that these will pass.
• Panic attacks commonly occur due to the effects of adrenaline and rapid, shallow breathing 
(hyperventilation). When this happens, you may experience palpitations, sweating, unsteady legs and 
trembling. Regaining control of your breathing can help to alleviate the symptoms.
• Anxiety is also common upon withdrawal, especially if dose reduction is not gradual enough.
• Agoraphobia can present in a range of forms from a reluctance to go out in public to feeling 
completely unable to do so. However agoraphobic feelings usually lessen as withdrawal continues.
• Aches and pains are very common during withdrawal. 
• Problems with sleeping can occur during withdrawal. Strategies such as ensuring enough exercise 
during the day, resolving concerns before bedtime and not trying to force sleep can help.
• Stomach and bowel problems such as diarrhoea and irritable bowel syndrome are very common 
during withdrawal and can be very distressing. Your GP may be able to recommend a diet and 
indigestion remedies that can improve these symptoms, which usually disappear after withdrawal is 
complete.
• Hot flushes and shivering are also common. 
• Sinus problems are experienced by many people as they withdraw.
• Vivid dreams and nightmares are another common occurrence during withdrawal. However this may 
in fact be a good sign, as it can indicate your sleep and your body are re-adjusting to normal.
Where can I get some more information and help?
Reconnexion, www.reconnexion.org.au, an Australian not-for-profit organisation that offers programs, 
counselling, telephone information and support for people with anxiety, stress, depression and 
benzodiazepine dependence and related conditions.
*  Kenny T, Harding M. Stopping Benzodiazepines and Z Drugs [Internet]. London: patient.co.uk; 2014 [updated October 
2014]. Available at www.patient.co.uk/health/stopping-benzodiazepines-and-z-drugs [Accessed 11 June 2015].  
Welsh Medicines Partnership. Educational pack – Material to support appropriate prescribing of hypnotics and anxiolytics 
across Wales. Wales: Welsh Medicines Partnership; 2011. Available at www.awmsg.org/docs/awmsg/medman/
Educational%20Resource%20Pack%20-%20Material%20to%20support%20appropriate%20prescribing%20of%20
hypnotics%20and%20anxiolytics%20across%20Wales.pdf [Accessed 12 June 2015].
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D.4 Sleep hygiene and stimulus control fact sheet for patients
Sleep hygiene
Good sleep hygiene refers to actions you can take to improve and maintain good sleep. These actions 
include: 
• Sleep as long as necessary to feel rested (usually 7–8 hours for adults), then get out of bed.
• Maintain a regular sleep schedule.
• Try not to force sleep.
• Avoid caffeinated beverages after lunch.
• Avoid alcohol near bedtime (late afternoon and evening).
• Avoid smoking or other nicotine intake, particularly during the evening.
• Adjust the bedroom environment as needed to decrease stimuli (eg reduce ambient light, turn off the 
television or radio).
• Resolve concerns or worries before bedtime.
• Exercise regularly for at least 20 minutes, preferably more than 4–5 hours prior to bedtime.
• Avoid daytime naps, especially if they are longer than 20–30 minutes or occur late in the day.
• Avoid going to bed until you are drowsy and ready to sleep.
• If you are not asleep within 15–20 minutes, get out of bed and return only when drowsy. 
Stimulus control
People with insomnia may associate their bed and bedroom with the stress of not sleeping, rather than 
the more pleasurable anticipation of sleep. The longer you stay in bed trying to sleep, the stronger the 
association becomes. This perpetuates the difficulty of falling asleep. 
Stimulus control therapy is designed is to disrupt this association by enhancing the likelihood of sleep. Your 
sleep may not improve immediately. However, sticking with this should improve your ability to get to sleep.
Stimulus control instructions
• Go to bed only when sleepy.
• Get out of bed if unable to sleep after 15–20 minutes, leave the bedroom and do something relaxing 
(eg reading or listening to soothing music). Avoid stimulating activities such as eating or watching TV. 
Return to bed only when sleepy. (Repeat as necessary.)
• Use the bed/bedroom only for sleep (not reading, watching TV or worrying).
• Arise at the same time each day (including weekends).
• Do not take naps during the day. 
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Sleep restriction therapy 
Some people with insomnia stay in bed longer to try to make up for lost sleep. This causes a shift in 
your day/night cycle. It makes sleep onset the following night more difficult and results in the need to 
stay in bed even longer. 
Sleep restriction therapy limits the total time allowed in bed, including naps and other sleep periods 
outside of bed, in order to increase your drive to sleep and improve the efficiency of your sleep.
Sleep restriction therapy begins by decreasing the time you spend in bed to the same amount of time 
that you actually sleep (usually this is determined from a sleep diaries or logs), but not less than 5 hours 
per night. 
On a daily basis, you record the amount of sleep obtained the previous night and the amount of time 
spent in bed. Once you are spending more than 85% of the time in bed asleep, you increase the time 
spent in bed (by 15–30 minutes). 
You repeat this process until you achieve improved sleep without residual daytime sleepiness. 
Naps are not permitted.
Relaxation
You may implement relaxation therapy before going to sleep. There are two common techniques for 
relaxation therapy: 
• Progressive relaxation is based upon the theory that you can learn to relax one muscle at a time 
until the entire body is relaxed. Beginning with the muscles in your face, you contract the muscles 
gently for 1–2 seconds and then relax. You repeat this several times. Use the same technique for 
other muscle groups, usually in the following sequence: jaw and neck, upper arms, lower arms, 
fingers, chest, abdomen, buttocks, thighs, calves and then feet. Repeat this cycle for approximately 
45 minutes, if necessary. 
• The relaxation response begins by lying or sitting comfortably. Close your eyes and allow relaxation 
to spread throughout your body. Use relaxed, abdominal breathing and redirect your thoughts away 
from everyday worries and toward a something like a peaceful word or image.108
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Resource E. Practice policies and forms
E.1 Practice policy example for repeat prescriptions
Purpose
To inform patients about practice policies regarding repeat prescriptions for benzodiazepines.
Example policy 
[Insert practice name]
Date effective:
Review date:
REQUESTS FOR REPEAT DRUG OF DEPENDENCE PRESCRIPTIONS – BENZODIAZEPINES
Patients should be aware of their responsibilities in requesting prescriptions for drugs of dependence, including 
benzodiazepines.  
Patients should note the following:
• All requests for repeat scripts for drugs of dependence will go to your usual doctor. 
• All requests require a clinical review by your doctor. If it appears to your doctor that there is no improvement in your 
daily function or quality of life from the controlled substance, your medication may be discontinued.
• As a patient, you agree to and understand that your usual doctor reserves the right to perform random or 
unannounced urine drug testing. This is a safety issue.
• Patients are responsible for their prescriptions. Lost prescriptions will not be replaced.
• Repeat prescriptions are generally written for a maximum of 1 month supply and will be filled at the same 
pharmacy. 
• Patients have the responsibility to schedule appointments for the next benzodiazepine prescription before leaving 
the clinic or within 3 days of the last clinic visit. 
• Patients have the responsibility for keeping medications in a safe and secure place, such as a locked cabinet or 
safe. If medications are lost, misplaced or stolen your doctor may choose not to replace the medications or to taper 
and discontinue the medications.
• Patients have the responsibility for taking medications as directed and understand that increasing the dose without 
the close supervision of your doctor could lead to cessation of prescribing. Early requests for repeat scripts will not 
be performed.
• Patients have the responsibility to set appointments to review ongoing therapy. This should be monthly and made 
at the last clinic appointment. No walk-in appointments for medication refills will be granted.
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E.2 Prescription plan/agreement for a trial of longer term 
treatment
Purpose
To inform patients of their responsibilities and expected behaviours regarding benzodiazepines.
Example agreement 
This example is based on the Blaustein Pain Treatment Center – Johns Hopkins Medicine therapy agreement and 
should be modified by the practice to suit local circumstances.
[Insert practice name] 
Date effective:
Review date:
PATIENT AGREEMENT FOR BENZODIAZEPINE THERAPY
Benzodiazepines are drugs of dependence. People who take them long term can risk adverse effects including 
becoming dependent (addicted). Therefore, benzodiazepine prescription is highly regulated. These drugs also have a 
high potential for misuse and are therefore closely controlled by the local, state and Federal government. 
Generally, benzodiazepines are used in the short term for reduction of distressing symptoms (eg anxiety and insomnia). 
A trial of long-term benzodiazepine therapy may be considered for severe or resistant mental illness. 
The purpose of this agreement is to give you information about the benzodiazepine medications prescribed at this 
practice, and to assure that you and your general practitioner (GP) comply with all relevant regulations.
Your GP’s goal is for you to have the best quality of life possible given the reality of your clinical condition. The success 
of treatment depends on the mutual trust and honesty in the doctor–patient relationship, and full agreement and 
understanding of the risks and benefits of using potentially addictive drugs to manage your condition.
In signing this agreement, you have agreed to a trial of long-term use of potentially addictive medications as part of 
your treatment. Because your doctor is prescribing such medication to help manage your condition, it is considered 
good practice to agree to the conditions outlined below.
My responsibilities as a patient 
• I agree to see one doctor at one practice for all my health needs and prescriptions. 
• I will have all my medications dispensed at one pharmacy.
• I agree that this medication is prescribed as a trial. If it appears to my doctor that there is no improvement in my 
daily function or quality of life from the controlled substance, my medication may be discontinued. I will gradually 
taper my medication as prescribed by my doctor.
• I will inform my doctor of all medications I am taking, including herbal remedies and illicit medication. Medications 
can interact with drugs of dependence and produce serious side effects. 
• I will fully communicate with my doctor to the best of my ability at the initial and all follow-up visits my pain level and 
functional activity along with any side effects of the medications. This information allows my doctor to adjust my 
treatment plan accordingly.
• I will not request or accept drugs of dependence from any other doctor or individual while I am receiving such 
medication from my doctor at the [insert practice name].
• I understand the use of alcohol together with benzodiazepines is contraindicated.
• I will not use any illicit substances (eg cocaine, amphetamines or marijuana) while taking these medications. Use of 
these substances may result in a change to my treatment plan, including safe discontinuation of my benzodiazepine 
medications when applicable or complete termination of the doctor–patient relationship.
• If I have a history of alcohol or drug misuse/addiction, I must notify my doctor of such history since treatment with 
benzodiazepines may increase the possibility of relapse. 
... Continues on page 69
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... Continued from page 68
• I agree and understand that my doctor reserves the right to perform random or unannounced urine drug testing. If 
requested to provide a urine sample, I agree to cooperate. If I decide not to provide a urine sample, I understand 
that my doctor may change my treatment plan, including safe discontinuation of my benzodiazepine medications 
when applicable or complete termination of the doctor–patient relationship. The presence of a non-prescribed 
drug(s) or illicit drug(s) in the urine can be grounds for termination of the doctor–patient relationship. Urine drug 
testing is not forensic testing, but is done for my benefit as a diagnostic tool and in accordance with certain legal 
and regulatory materials on the use of controlled substances to treat pain.
• I agree to allow my doctor/healthcare provider to contact any healthcare professional, family member, pharmacy, 
legal authority or regulatory agency to obtain or provide information about my care or actions, if my doctor feels it is 
necessary.
• I understand my capacity to drive may be affected and I may be asked to cease driving.
My prescriptions
• I am responsible for my prescriptions. I understand that lost prescriptions will not be replaced.
• I understand that benzodiazepine prescriptions will not be mailed if I am unable to obtain my prescriptions monthly.
• Repeat prescriptions can be written for a maximum of 1 month supply and will be filled at the same pharmacy. 
Pharmacy: ____________________________ Phone number: ___________________________
• It is my responsibility to schedule appointments for the next benzodiazepine prescription before I leave the clinic or 
within 3 days of the last clinic visit. 
Taking my medications
• I understand that the medication is strictly for my own use. My medication should never be given or sold to others 
because it may endanger that person’s health and is against the law.
• I am responsible for keeping my medication in a safe and secure place, such as a locked cabinet or safe. I am 
expected to protect my medications from loss or theft. If my medication is stolen, I will report this to my local police 
department and obtain a stolen item report. I will then report the stolen medication to my doctor. If my medications 
are lost, misplaced or stolen my doctor may choose not to replace the medications or to taper and discontinue the 
medications.
• I am responsible for taking my medications as directed. I agree to take the medication only as prescribed.
• I understand increasing my dose without the close supervision of my doctor could lead to drug overdose, causing 
severe sedation and respiratory depression and death.
• I understand that decreasing or stopping my medication without the close supervision of my doctor can lead to 
withdrawal. Withdrawal symptoms can include yawning, sweating, watery eyes, runny nose, anxiety, tremors, 
aching muscles, hot and cold flashes, ‘goose flesh’, abdominal cramps and diarrhoea. These symptoms can occur 
24–48 hours after the last dose and can last up to 3 weeks.
• Any evidence of drug hoarding, acquisition of any benzodiazepine medication or additional drugs of dependence 
from other doctors (which includes emergency rooms), uncontrolled dose escalation or reduction, loss of 
prescriptions, or failure to follow the agreement may result in termination of the doctor–patient relationship.
Monitoring effects of treatment
• I accept that drug of dependence therapy is only part of my care, and that I must be fully compliant with additional 
care interventions deemed appropriate for my health.
• I accept that set appointments must be made to review ongoing therapy. This should be monthly and made at the 
last clinic appointment. No walk-in appointments for medication refills will be granted.
• If an appointment is missed, another appointment will be made as soon as possible. Immediate or emergency 
appointments will not be granted.
• I will be seen on a regular basis and given prescriptions for enough medication to last from appointment to 
appointment, and sometimes 2–3 days extra if the prescription ends on a weekend or holiday. This extra 
medication is not to be used without the explicit permission of the prescribing doctor unless an emergency requires 
your appointment to be deferred 1 or 2 days.
... Continues on page 70
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... Continued from page 69
• It is my responsibility to notify my doctor of any side effects that continue or are severe (eg sedation, confusion). I 
am also responsible for notifying my doctor immediately if I need to visit another healthcare provider or need to visit 
an emergency room, or if I become pregnant.
• I understand that during the time that my dose is being adjusted, I will be expected to return to the clinic as 
instructed by my clinic doctor. After I have been placed on a stable dose, I may receive longer-term therapy from 
my doctor, but will return to the medical centre for a medical evaluation at least once every 3 months.
• I understand that a reduction of medication will occur if I have deterioration at home or work, or reduction of social 
activities because of medication, or due to medication side effects.
• I understand that while physical dependence is to be expected after the long-term use of benzodiazepines, any 
signs of addiction, abuse or misuse shall prompt the need for substance dependence treatment as well as weaning 
and detoxification from the benzodiazepines.
My behaviour
I understand that cessation of the medication trial, or cessation of the doctor–patient relationship may occur if I display 
any of the following behaviours:
• presenting to the clinic intoxicated, as assessed by clinical staff 
• making any physical threat to any member of staff or other patients
• aggressively complaining about a need for medication 
• persistently requesting to have my medication dose increased despite clinical advice
• taking a few extra, unauthorised doses on occasion 
• visiting multiple doctors for controlled substances (doctor shopping)
• hoarding medication 
• using my medication for non-medical purposes (ie in any other way than prescribed) 
• starting frequent unscheduled clinic visits for early refills
• using consistently disruptive behaviour when arriving at the clinic
• obtaining drugs of dependence from family members (including stealing from older relatives)
• having a pattern of lost or stolen prescriptions
• displaying anger or irritability when questioned closely about my symptoms
• being unwilling to consider other medications or non-pharmacologic treatments
• escalating my dose without authorisation 
• testing positive for a non-prescribed drug(s) or illicit drug(s) in my urine
• injecting an oral formulation 
• forging prescriptions 
• selling medications
• refusing diagnostic workup or investigation
• obtaining controlled substance analgesics from illicit sources. 
I understand that non-compliance with the above conditions may result in a re-evaluation of my treatment plan and 
discontinuation of benzodiazepine therapy. I may be gradually taken off these medications, or even discharged from 
the clinic.
I ______________________________________________ have read the above information or it has been read to me and 
all my questions regarding treatment with benzodiazepines have been answered to my satisfaction. I hereby give my 
consent to participate in trial benzodiazepine therapy and acknowledge receipt of this document.
Patient’s signature ______________________________________ Date_______________________
Doctor’s signature_____________________________________  Date_________________________
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Resource F. Drug and alcohol assessment tool
Alcohol Use Disorders Identification Test
AUDIT questionnaire: Screen for alcohol misuse 
The Alcohol Use Disorders Identification Test (AUDIT) was developed by the World Health Organization as a 
questionnaire to identify persons whose alcohol consumption has become hazardous or harmful to their health. 
The AUDIT tool and its Guidelines for use in primary care are available at www.who.int/substance_abuse/
activities/sbi/en
The Department of Veterans Affairs has an easy-to-use AUDIT tool that can be printed to work through with 
your patients. It is available at http://at-ease.dva.gov.au/therightmix/resources/for-health-professionals
The AUDIT-C tool is a modified version of the 10-question AUDIT instrument. It is printed below and is available 
at www.racgp.org.au/your-practice/guidelines/redbook/appendices/appendix-3-audit-c
Each AUDIT-C question has a choice of five answers. It is scored on a scale of 0–12.
In men, a score of 4 or more, and in women, a score of 3 or more, is considered positive, optimal for identifying 
hazardous drinking or active alcohol use disorders. However, when the points are all from Question 1 alone 
(questions 2 and 3 are zero), it can be assumed that the patient is drinking below recommended limits and it is 
suggested the provider review the patient’s alcohol intake over recent months to confirm accuracy.* Generally, 
the higher the score, the more likely it is that the patient’s drinking is affecting their safety.
* Bradley KA, Bush KR, Epler AJ, et al. Two brief alcohol-screening tests From the Alcohol Use Disorders Identification Test (AUDIT): 
validation in a female Veterans Affairs patient population. Arch Intern Med 2003;163(7):821–9.
Audit-C questionnaire
Patient name:  Date of visit:
1. How often do you have a drink containing alcohol?
a. Never
b. Monthly or less
c. 2–4 times a month
d. 2–3 times a week
e. 4 or more times a week
2. How many standard drinks containing alcohol do you have on a typical day?
a. 1 or 2
b. 3 or 4
c. 5 or 6
d. 7 to 9
e. 10 or more
3. How often do you have six or more drinks on one occasion?
a. Never
b. Less than monthly
c. Monthly
d. Weekly
e. Daily or almost daily
a = 0 points; b = 1 point; c = 2 points; d = 3 points; e = 4 points
AUDIT-C is based on The Alcohol Use Disorders Identification Test. Reproduced, with the permission of the publisher, from 
The Alcohol Use Disorders Identification Test: guidelines for use in primary care, AUDIT, second edition. Geneva: World Health 
Organization; 2000. P 17. Available at http://whqlibdoc.who.int/hq/2001/WHO_MSD_MSB_01.6a.pdf [Accessed 22 January 2015].
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Resource G. GP guide to behavioural therapy for 
insomnia 
Behavioural therapy for insomnia – Information for GPs
Behavioural therapies for insomnia include sleep hygiene education, stimulus control, relaxation and sleep 
restriction therapy.108
Sleep hygiene 
Sleep hygiene refers to actions that tend to improve and maintain good sleep.108,195,196
• Sleep as long as necessary to feel rested (usually 7–8 hours for adults), then get out of bed.
• Maintain a regular sleep schedule.
• Try not to force sleep.
• Avoid caffeinated beverages after lunch.
• Avoid alcohol near bedtime (late afternoon and evening).
• Avoid smoking or other nicotine intake, particularly during the evening.
• Adjust the bedroom environment as needed to decrease stimuli (eg reduce ambient light, turn off the 
television or radio).
• Resolve concerns or worries before bedtime
• Exercise regularly for at least 20 minutes, preferably more than 4–5 hours prior to bedtime.
• Avoid daytime naps, especially if they are longer than 20–30 minutes or occur late in the day.
• Avoid going to bed until you are drowsy and ready to sleep.
• If you are not asleep within 15–20 minutes, get out of bed and return only when drowsy. 
Stimulus control
Patients with insomnia may associate their bed and bedroom with the fear of not sleeping or other arousing 
events, rather than the more pleasurable anticipation of sleep. The longer you stay in bed trying to sleep, 
the stronger the association becomes. This perpetuates the difficulty of falling asleep.108
Stimulus control therapy is designed is to disrupt this association by enhancing the likelihood of sleep.197 
Patients should not go to bed until they are sleepy and should use the bed primarily for sleep (and not 
for reading, watching television, eating or worrying). They should not spend more than 20 minutes in bed 
awake. If they are awake after 20 minutes, they should leave the bedroom and engage in a relaxing activity, 
such as reading or listening to soothing music. Patients should not engage in activities that stimulate them 
or reward them for being awake in the middle of the night, such as eating or watching television. In addition, 
they should not return to bed until they are tired and feel ready to sleep. If they return to bed and still cannot 
sleep within 20 minutes, the process should be repeated. An alarm clock should be set to wake the patient 
at the same time every morning, including weekends. Daytime naps are not allowed. Patients may not 
improve immediately. However, accumulating sleepiness will facilitate sleep during successive nights.108
Stimulus control instructions
• Go to bed only when sleepy.
• Get out of bed if unable to sleep after 15–20 minutes, leave the bedroom and do something relaxing (eg 
reading or listening to soothing music). Avoid stimulating activities such as eating or watching TV. Return 
to bed only when sleepy. (Repeat as necessary.)
• Use the bed/bedroom only for sleep (not reading, watching TV or worrying).
• Arise at the same time each day (including weekends).
• Do not take naps during the day.108
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Sleep restriction therapy 
Some patients with insomnia stay in bed longer to try to make up for lost sleep. This causes a circadian 
shift and a reduction in the homeostatic drive that makes sleep onset the following night more difficult and 
results in the need to stay in bed even longer.108 
Sleep restriction therapy counteracts this tendency by limiting the total time allowed in bed, including naps 
and other sleep periods outside of bed, in order to increase the drive to sleep.198 This consolidates sleep 
and improves sleep efficiency (the percentage of time in bed that the patient is asleep).108
Sleep restriction therapy begins by decreasing the time spent in bed to the same amount of time that the 
patient reports sleeping (usually determined from sleep diaries or logs completed by the patient), but not 
less than 5 hours per night. On a daily basis, the patient reports the amount of sleep obtained the previous 
night and the amount of time spent in bed. The clinician then computes the sleep efficiency, which is the 
reported time asleep divided by the time in bed. The time in bed is increased by 15–30 minutes once the 
sleep efficiency exceeds 85%. This process is repeated until the patient reports improved sleep without 
residual daytime sleepiness.108
Naps are not permitted.
To improve compliance, the rationale for the therapy needs to be carefully explained to patients. Some care 
needs to be used to determine and schedule the time in bed in a manner that maximises the ability to sleep 
that is acceptable to the patient. Older patients tend to have more difficulty maintaining sleep even when 
restricted; therefore, they are given more lenient criteria.108
Relaxation
Relaxation therapy may be implemented before each sleep period. There are two common techniques for 
relaxation therapy: progressive muscle relaxation and the relaxation response.108
Progressive relaxation is based on the theory that an individual can learn to relax one muscle at a time until 
the entire body is relaxed. Beginning with the muscles in the face, the patient contracts the muscles gently for 
1–2 seconds and then relaxes. This is repeated several times. The same technique is used for other muscle 
groups, usually in the following sequence: jaw and neck, upper arms, lower arms, fingers, chest, abdomen, 
buttocks, thighs, calves and then feet. This cycle is repeated for approximately 45 minutes, if necessary.108
The relaxation response begins by lying or sitting comfortably. The eyes are closed and relaxation is allowed to 
spread throughout the body. A relaxed, abdominal breathing pattern is established. Thoughts are redirected 
away from everyday thoughts and toward a neutral mental focusing device, such as a peaceful word or image.108
Cognitive therapies 
Patients who are awake at night commonly become concerned that they will perform poorly the next day 
if they do not obtain adequate sleep. This worry can exacerbate their difficulty falling asleep, creating a 
vicious cycle of wakefulness and concern. A person may begin to blame all negative events in their life on 
poor sleep. During cognitive therapy, a person works with a therapist to deal with anxiety and catastrophic 
thinking, while establishing realistic expectations related to insomnia and the need for sleep.108
Cognitive behavioural therapy (CBT) is a strategy that combines several of the previously described 
approaches over several weeks.199 A sample, 8-session CBT program may include an introductory sleep 
education session, followed by two sessions that focus on stimulus control and sleep restriction. These may 
be followed by two sessions that focus on cognitive therapy and then a session on sleep hygiene. Finally, 
there may be a session that reviews and integrates the previous session and a session that addresses 
future problems, such as stress and relapse.200 
Patients are encouraged to complete sleep logs as they learn and apply the various strategies. This allows 
improvement to be measured. The advantage of the educational nature of CBT is that it provides patients 
with the tools to apply it in the future. Disadvantages of CBT include the duration of therapy, and the 
relatively few clinicians who are skilled at all of its components.108
The benefit of CBT may be reduced when it is administered by less experienced clinicians.108,201
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Appendix A. Key terms and definitions
A.1 Drugs of addiction and drugs of dependence
Legal definitions of drugs of dependence and drugs of addiction vary between states/territories. Refer to 
RACGP’s Prescribing drugs of dependence in general practice, Part A – Clinical governance framework.
This guide uses the following definitions:
Drugs of addiction refer to all Schedule 8 (S8) drugs. These have strict legislative controls regarding 
their manufacture, supply, distribution, possession and use to reduce abuse, misuse, and physical and 
psychological dependence. Examples of S8 drugs include morphine, oxycodone, dexamphetamine, 
flunitrazepam (Rohypnol) and, as of February 2014, alprazolam.*
Drugs of dependence describe all S8 drugs plus specified Schedule 4 (S4) drugs that are subject to 
misuse, abuse and trafficking. All S4 drugs are restricted substances, but only some (eg benzodiazepines) 
can form dependence (these are called S4D drugs in New South Wales). Some others drugs, like anabolic 
steroids and amphetamines, are restricted and can only be prescribed by authority. 
Each state and territory has its own legislative requirements. Refer to RACGP’s Prescribing drugs of 
dependence in general practice, Part A – Clinical governance framework.
*Xanax (Pfizer) has been withdrawn from the Australian market, however generic alprazolam is still currently available.
A.2 Tolerance, dependence, substance use 
disorder and withdrawal
The two commonly used classification systems for data collection are the International Statistical 
Classification of Diseases and Related Health Problems, 10th revision, (ICD-10) and the Diagnostic and 
Statistical Manual of Mental Disorders, 5th edition, (DSM-5). Some of the terminology adapts poorly to the 
situation where prescription drugs are used to treat conditions, such as chronic non-malignant pain. 
Tolerance is a decrease in response to a drug dose. It occurs with all chronically used drugs of 
dependence, including opioids and benzodiazepines. Increased doses are required to achieve the effects 
originally produced by lower doses.31
Dependence, in strict pharmacological terms, is a state that develops during chronic drug treatment in 
which drug cessation elicits an abstinence reaction (withdrawal).
Dependence can be associated associated with a whole range of psychoactive drugs or chemicals (eg 
caffeine, alcohol, opioid, cannabis or stimulant dependence). As awareness of problematic drug use grew, 
the definition of dependence changed to include addiction and abuse. Various definitions of dependence 
evolved with DSM-4, ICD-10, World Health Organization (WHO) and leading authors describing it as a 
cluster of behavioural, cognitive and physiological phenomena that may develop after repeated substance 
use. Now people link dependence with ‘addiction’ when in fact dependence can be a normal body 
response to a substance. While drug dependence can be part of addiction, is not the same thing.
To reduce confusion, the new DSM-5 (2013) criteria has replaced drug dependence with DSM-5 substance 
use disorder measured on a continuum from mild to severe. Refer to Appendix A.3 Misuse, non-medical 
use and abuse.
Note: There are legal implications involving the term dependence (eg restrictions around prescribing to 
drug-dependent persons). Characteristics of person who is drug dependent include having a history of 
substance misuse and being identified as a ‘doctor shopper’ or ‘prescription shopper’.202 Refer to Appendix 
A.4, Drug-seeking behaviour.
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Substance use disorder has been introduced in DSM-540 to replace dependence (or dependence 
syndrome) as used to refer to complex symptoms beyond tolerance and withdrawal. The essential feature 
of SUD is a cluster of cognitive, behavioral and physiological symptoms indicating the individual continues 
using the substance despite significant substance-related problems.40 Diagnosis of SUD requires the 
presence of at least two of 11 criteria, across four categories: impaired control, social impairment, risky use 
and pharmacology.
Note: In DSM-5, substance dependence and substance abuse have been combined into a single 
category of SUDs (eg ‘benzodiazepines dependence’ would be included within sedative, hypnotic, or 
anxiolytic use disorder).40 Each SUD is divided into mild, moderate and severe subtypes, with the number 
of criteria present determining the severity. (Refer to Table 3 for DSM-5 criteria and Table A.1 for ICD-10 
criteria.)
Withdrawal or withdrawal syndrome is a group of symptoms of variable clustering and degree of severity 
which occur on cessation or reduction of use of a psychoactive substance that has been taken repeatedly, 
usually for a prolonged period and/or in high doses. Signs of physiological disturbance may accompany the 
syndrome. A withdrawal syndrome is one of the indicators of a dependence syndrome.31
Table A.1. ICD-10 criteria for diagnosing benzodiazepine dependence*
Drug related criteria • Compulsion/craving to take benzodiazepine
• Difficulties in controlling benzodiazepine use
Consequences of use criteria • Progressive neglect of alternative pleasures/interests due to 
benzodiazepine use
• Persistent benzodiazepine use despite harmful consequences
Physiological criteria • Characteristic benzodiazepine withdrawal state
• Evidence of tolerance to benzodiazepines
Notes: A diagnosis of dependence is made if three of six criteria listed above have been met in the last 12 months.
* World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders – ICD-10 criteria for diagnosing benzodiazepine 
dependence. Geneva: WHO; 2010. Available at http://www.who.int/substance_abuse/terminology/icd_10/en/ [Accessed 12 June 2015].
A.3 Misuse, non-medical use and abuse
Misuse refers to use of a substance for a purpose that is not consistent with legal or medical guidelines, 
and includes the non-medical use of prescription medication. Patients may inadvertently misuse 
prescription medication by taking them as prescribed but in response to inappropriate prescribing practices. 
Patients may deliberately misuse medication for non-medical purposes.31
Non-medical use describes use of a prescription drug, whether obtained by prescription or otherwise, for 
any purposes other than in the manner or for the time period prescribed, or by a person for whom the drug 
was not prescribed (ie diversion). Non-medical use occurs for a variety of reasons such as enjoyment of 
effects (especially when binge dosed), to enhance the effects of other drugs (eg benzodiazepines taken with 
opiates), to decrease withdrawal symptoms, to enhance confidence, to feel normal and to facilitate sexual 
assault (eg flunitrazepam used as ‘date rape’ drug).31
Abuse is a commonly used term with a variety of meanings. It is sometimes used disapprovingly to refer 
to any use at all, particularly of illicit drugs, while in other contexts abuse has referred to non-medical or 
unsanctioned patterns of use, irrespective of consequences.31
Problematic drug use may be a wider, yet clearer, more descriptive and less judgemental term than 
misuse or abuse.31
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A.4 Drug-seeking behaviour
Drug-seeking behaviour is a poorly defined term that describes a range of activities directed towards 
attainment of sought after medications. The most common medications sought are opioids and 
benzodiazepines. Behaviours include attending multiple practitioners (prescription or doctor shopping) and 
employing manipulating tactics.203
A comprehensive list of tactics and behaviours used to obtain medication is available in RACGP’s 
Prescribing drugs of dependence in general practice, Part A – Clinical governance framework.
Prescription or doctor shopping is when patients unknowingly or deliberately obtain more medicines 
than is medically needed. This is often done by visiting many doctors, without telling them about their 
other consultations.204 The Medicare Australia Prescription Shopping Information Service (PSIS) defines 
prescription shoppers as anyone, within any 3-month period, that has been supplied with PBS items 
prescribed by six or more different prescribers (including nurse practitioners and midwives, but excluding 
specialists and consultant physicians), and/or a total of 25 or more target PBS items, and/or a total of 50 or 
more items.204 Target items are analgesics, anti-epileptics, anti-parkinson medicine, psycholeptics (including 
antidepressants), and all other nervous system medicine.
A.5 Prescriber behaviour
Appropriate prescriber behaviour refers to prescription decisions based on evidence at the time of 
assessment and taking into account the patient’s perspective. This is related to the term accountable 
prescribing.
Accountable prescribing is defined as a commitment to evidence-based practice, the use of medicines 
with proven effectiveness and the avoidance of medicines when they do not help or cause harm.205
Inappropriate prescriber behaviour refers to persistent prescribing of drugs of dependence despite 
absence of sustained improvement in function, deterioration of function and/or the development of 
unacceptable side effects.206 
A.6 Staged supply
Staged supply is the process by which pharmacists supply medicine to a patient in periodic instalments 
of less than the originally prescribed quantity, at agreed time intervals. The balance of the medicine is 
held by the pharmacy to fulfil subsequent instalments. This service can be initiated by the pharmacist, the 
prescriber, the patient (or their carer) or another health professional involved in the patient’s care.207
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Appendix B. Recommendations  
and grading
B.1 Evidence-based statements and 
recommendations – Insomnia
Number Recommendations Grading and source of grade
Rec 1 Cognitive behavioural 
therapy based treatment 
packages for chronic 
insomnia including sleep 
restriction and stimulus 
control are effective and 
should therefore be offered 
to patients as a first-line 
treatment
Grade A recommendation
Source: 
Wilson SJ, Nutt DJ, Alford C, et al. British Association for Psychopharmacology 
consensus statement on evidence-based treatment of insomnia, parasomnias and 
circadian rhythm disorders. J Psychopharmacol 2010;24(11):1577–601. 
Supported by:* 
Bloom HG, Ahmed I, Alessi CA, et al. Evidence-based recommendations for the 
assessment and management of sleep disorders in older persons. J Am Geriat Soc 
2009;57(5):761–89. 
Bonnet MH, Arand DL. Treatment of insomnia. In UpToDate, Benca R (ed). UpToDate, 
Waltham, MA 2014. Available at www.uptodate.com/contents/treatment-of-insomnia 
[Accessed October 2014].
Guideline Development Group for the management of patients with insomnia in 
primary care. Clinical Practice Guidelines for the management of patients with 
Insomnia in Primary Care. UETS No 2007/5-1. Madrid: Ministry of Health and Social 
Policy; 2009. 
Schutte-Rodin S, Broch L, Buysse D, Dorsey C, Sateia M. Clinical guideline for 
the evaluation and management of chronic insomnia in adults. J Clin Sleep Med 
2008;4(5):487–504. 
RACGP Handbook of non-drug interventions (HANDI). Brief behavioural therapy: 
Insomnia in adults. Available at www.racgp.org.au/your-practice/guidelines/handi/
interventions/mental-health/brief-behavioural-therapy-for-insomnia-in-adults 
[Accessed October 2014].
Riemann D, Perlis ML. The treatments of chronic insomnia: a review of 
benzodiazepine receptor agonists and psychological and behavioral therapies. Sleep 
Med Rev 2009;13(3):205–14. 
Rec 2 Z drugs and short-acting 
benzodiazepines are 
efficacious for insomnia
Grade A recommendation
Source: 
Wilson SJ, Nutt DJ, et al. British Association for Psychopharmacology consensus 
statement on evidence-based treatment of insomnia, parasomnias and circadian 
rhythm disorders. J Psychopharmacol 2010;24(11):1577–601. 
Supported by:*
Guideline Development Group for the management of patients with insomnia in primary 
care. Clinical Practice Guidelines for the management of patients with Insomnia in 
Primary Care. UETS No 2007/5-1. Madrid: Ministry of Health and Social Policy; 2009. 
Riemann D, Perlis ML. The treatments of chronic insomnia: a review of 
benzodiazepine receptor agonists and psychological and behavioral therapies. Sleep 
Med Rev 2009;13(3):205–14. 
Rec 3 Prescription of zolpidem and 
zopiclone should be treated 
with the same cautions as 
benzodiazepines
Grade A recommendation
Source: 
Ministry of Health Singapore. Prescribing of Benzodiazepines: MOH Clinical Practice 
Guidelines 2/2008. Singapore: MOH; 2008. 
Supported by:*
Riemann D, Perlis ML. The treatments of chronic insomnia: a review of 
benzodiazepine receptor agonists and psychological and behavioural therapies. Sleep 
Med Rev 2009;13(3):205–14. 
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Number Recommendations Grading and source of grade
Rec 4 Intermittent dosing may 
further reduce the risk of 
tolerance and dependence
Grade B recommendation
Source: 
Wilson SJ, Nutt DJ, Alford C, et al. British Association for Psychopharmacology 
consensus statement on evidence-based treatment of insomnia, parasomnias and 
circadian rhythm disorders. J Psychopharmacol 2010;24(11):1577–601 
Rec 5 If hypnotics are to be used 
for treating insomnia, it 
is recommended that 
treatment is short term (ie 
not more than 4 weeks) and 
at the lowest possible dose
Grade B recommendation
Source: 
Guideline Development Group for the management of patients with insomnia in 
primary care. Clinical Practice Guidelines for the management of patients with 
Insomnia in Primary Care. UETS No 2007/5-1. Madrid: Ministry of Health and Social 
Policy; 2009. 
*Recommendation supported, however gradings (where given) may be different from source.
B.2 Evidence-based statements and 
recommendations – Anxiety
Number Recommendations Grading and source of grade
Rec 6 Cognitive behavioural 
therapy is recommended 
as one of the treatments 
of choice for generalised 
anxiety disorder, panic 
disorder, and panic 
attacks due to its 
effectiveness at reducing 
the symptoms of anxiety 
in the short and long 
term, although patient 
preference must be taken 
into consideration
Grade A recommendation
Source: Guideline Working Group for the Treatment of Patients with 
Anxiety Disorders in Primary Care. Clinical Practice Guideline for 
Treatment of Patients with Anxiety Disorders in Primary Care. UETS no 
2006/10 ed. Madrid: Ministry of Health and Social Policy; 2008. 
Supported by:*
Agency for Healthcare Research and Quality (AHRQ). Guideline Summary NGC – 7124: 
Practice guideline for the treatment of patients with panic disorder. Derived from: 
American Psychiatric Association (APA). Practice guideline for the treatment of patients 
with panic disorder. 2nd ed. Washington, DC: APA; 2009. 
Agency for Healthcare Research and Quality (AHRQ). Guideline Summary NGC –8660: 
Generalised anxiety disorder and Panic Disorder (with or without agorophobia) in adults. 
Management in primary, secondary and community care.208 Derived from: National 
Collaborating Centre for Mental Health, National Collaborating Centre for Primary Care. 
Generalised anxiety disorder and panic disorder (with or without agorophobia) in adults. 
Management in primary, secondary and community care (Clinical guide no 113). London: 
National Institute for Health and Clinical Excellence (NICE); 2011. 
Rec 7 Consider an selective 
serotonin reuptake 
inhibitor (SSRI) for first-
line treatment, as SSRI 
are effective across 
the anxiety and related 
disorders, in both the 
short term and long term, 
and are generally well 
tolerated
Grade A recommendation
Source: Baldwin DS, Anderson IM, Nutt DJ, et al. Evidence-based 
pharmacological treatment of anxiety disorders, post-traumatic stress 
disorder and obsessive-compulsive disorder: A revision of the 2005 
guidelines from the British Association for Psychopharmacology. J 
Psychopharmacol 2014;28(5):403–39. 
Supported by:*
Agency for Healthcare Research and Quality (AHRQ). Guideline Summary NGC – 7124: 
Practice guideline for the treatment of patients with panic disorder. Derived from: 
American Psychiatric Association (APA). Practice guideline for the treatment of patients 
with panic disorder. 2nd ed. Washington, DC: APA; 2009. 
Agency for Healthcare Research and Quality (AHRQ). Guideline Summary NGC –8660: 
Generalised anxiety disorder and Panic Disorder (with or without agorophobia) in 
adults. Management in primary, secondary and community care. Derived from: National 
Collaborating Centre for Mental Health, National Collaborating Centre for Primary Care. 
Generalised anxiety disorder and panic disorder (with or without agorophobia) in adults. 
Management in primary, secondary and community care (Clinical guide no 113). London: 
National Institute for Health and Clinical Excellence (NICE); 2011. 
Guideline Working Group for the Treatment of Patients with Anxiety Disorders in Primary 
Care. Clinical Practice Guideline for Treatment of Patients with Anxiety Disorders in 
Primary Care. UETS no 2006/10 ed. Madrid: Ministry of Health and Social Policy; 2008. 
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Number Recommendations Grading and source of grade
Rec 8 Benzodiazepines have 
evidence of benefit in 
generalised anxiety 
disorder, social anxiety 
disorder and panic 
disorder, but not 
obsessive compulsive 
disorder or post-traumatic 
stress disorder
Grade A/B recommendation
Source: Bandelow B, Sher L, Bunevicius R, et al. Guidelines for the 
pharmacological treatment of anxiety disorders, obsessive-compulsive 
disorder and posttraumatic stress disorder in primary care. Int J 
Psychiatry Clin Pract 2012;16(2):77–84. 
Supported by:*
Agency for Healthcare Research and Quality (AHRQ). Guideline Summary NGC – 7124: 
Practice guideline for the treatment of patients with panic disorder. Derived from: 
American Psychiatric Association (APA). Practice guideline for the treatment of patients 
with panic disorder. 2nd ed. Washington, DC: APA; 2009. 
Baldwin DS, Anderson IM, Nutt DJ, et al. Evidence-based pharmacological treatment of 
anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: A 
revision of the 2005 guidelines from the British Association for Psychopharmacology. J 
Psychopharmacol 2014;28(5):403–39.
Bandelow B, Boerner JR, Kasper S, Linden M, Wittchen HU, Moller HJ. The diagnosis 
and treatment of generalized anxiety disorder. Dtsch Arztebl Int 2013;110(17):300–9.
Bandelow B, Zohar J, Hollander E, Kasper S, Moller HJ, WFSBP Task Force on 
Treatment Guidelines for Anxiety Obsessive-Compulsive Post-Traumatic Stress 
Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines 
for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic 
stress disorders – first revision. World J Biol Psychiatry 2008;9(4):248–312.
Canadian Agency for Drugs and Technologies in Health (CADTH). Short- and Long-Term 
Use of Benzodiazepines in Patients with Generalized Anxiety Disorder: A Review of 
Guidelines. Ottawa: CADTH; 2014.
Davidson JR, Feltner DE, Dugar A. Management of generalized anxiety disorder in 
primary care: identifying the challenges and unmet needs. Prim Care Companion J Clin 
Psychiatry 2010;12(2).
Dell’osso B, Lader M. Do benzodiazepines still deserve a major role in the treatment 
of psychiatric disorders? A critical reappraisal. European psychiatry: J Assoc Europ 
Psychiat 2013;28(1):7–20. 
Guideline Working Group for the Treatment of Patients with Anxiety Disorders in Primary 
Care. Clinical Practice Guideline for Treatment of Patients with Anxiety Disorders in 
Primary Care. UETS no 2006/10 ed. Madrid: Ministry of Health and Social Policy; 2008. 
Katzman MA, Bleau P, Blier P, et al. Canadian clinical practice guidelines for the 
management of anxiety, posttraumatic stress and obsessive-compulsive disorders. BMC 
Psychiatry 2014;14 Suppl 1:S1
*Recommendation supported, however gradings (where given) may be different from source.
B.3 Evidence-based statements and 
recommendations – Alcohol withdrawal
Number Recommendations Grade and source of grading
Rec 9 Benzodiazepines (eg diazepam, oxazepam) 
are the drugs of choice for treatment of acute 
alcohol withdrawal (including alcohol withdrawal 
delirium), but for a maximum of 7 days
Grade A recommendation
Source: Scottish Intercollegiate Guideline 
Network. The Management of Harmful 
Drinking and Alcohol Dependence in 
Primary Care. Guideline No 74. Edinburgh: 
SIGN; 2004 
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Appendix C. Process of development
This guide was developed in response to calls for a resource for GPs and general practice teams to 
manage benzodiazepine prescribing. It represents a synthesis of current scientific knowledge and rational 
clinical practice regarding treatment with benzodiazepines. The content broadly conforms to the highest 
evidence-based standards according to the principles underlying the Appraisal of Guidelines Research and 
Evaluation (AGREE) Instrument. It strives to be as free as possible of bias toward any theoretical approach 
to treatment.
The RACGP convened a GP-led advisory group, comprising GP members with expertise and experience 
in drugs of dependence and guideline development. A literature search was conducted and key resources 
were identified. 
A limited literature search was conducted, using key resources including PubMed, The Cochrane Library, 
University of York Centre for Reviews and Dissemination (CRD) databases, international health technology 
agencies, in addition to a focused Internet search. Filters were applied to limit retrieval to articles in English, 
health technology assessments, systematic reviews, meta-analyses and guidelines. In the first level of 
screening, titles and abstracts were reviewed and potentially relevant articles were retrieved based on:
• national and international benzodiazepine prescribing guidelines
• national and international guidelines of specific disease state management (eg insomnia, anxiety)
• high-quality systematic reviews on benzodiazepine prescribing
• high-quality publications that address key issues with benzodiazepine pharmacology, dependence, 
tolerance and adverse effects.
An in-depth critical analysis of the publications was not undertaken.
This guide provides recommendations based on current evidence-based guidelines, including the Scottish 
Intercollegiate Guidelines Network (SIGN), the British Association of Psychopharmacology, and the Health 
Technology Assessment Unit of the Spanish Ministry of Health and Social Policy. 
In cases where guideline recommendations specific to the indication were not available, other sources, such 
as systematic reviews, have been used to inform the recommendations.
The advisory group did not attempt to re-evaluate the evidence behind these recommendations or 
convert the recommendation grades to the Australian National Health and Medical Research Council 
(NHMRC) grading levels. Therefore, the recommendations tables include the reference and sources of 
recommendations, the recommendation grade and links to further information on the evidence grade where 
available (refer to Appendix B). For some recommendations, an evidence grade was not available; therefore, 
these recommendations should be treated as expert opinion
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